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Abstract 
Traumatic Brain Injury (TBI) is a recognized cause of long-term disability worldwide 
with mild TBI accounting for 80% of all head traumas. Growing evidence links mTBI, and 
particularly repetitive mTBI (r-mTBI), with long lasting pathological and cognitive deficits that 
can serve as a risk factor for neurodegenerative disorders such as Alzheimer’s Disease, 
Parkinson’s Disease, Chronic Traumatic Encephalopathy and others. So far, there is no FDA-
approved treatment to mitigate the consequences of r-mTBI, mainly due to the lack of an 
effective therapeutic target and a poor translatability of existing preclinical studies, which fail to 
mimic heterogeneous nature of TBI. In the current thesis, I used a mouse model of r-mTBI which 
was treated with two different drugs, nilvadipine and anatabine, that have been previously shown 
to decrease inflammation and neurodegenerative mechanisms and improve cognition. To address 
the heterogenous nature of r-mTBI, I used several cohorts of mice which vary in age at injury 
(young vs old), number of hits (5 vs 24), acute or chronic duration of treatment, and the time of 
the first treatment intervention post injury (immediate vs delayed). I have found that both 
nilvadipine and anatabine, in their respective treatment paradigms, improved cognitive deficits, 
decreased neuroinflammation, and reduced tau pathology. Moreover, nilvadipine was equally 
effective in both young and old 5-hit r-mTBI mice during the acute treatment. Anatabine was 
shown to be effective as a delayed treatment starting at 3 months after the last injury in r-mTBI 
mice with both 5 and 24 hits. We further conducted a phosphoproteome analysis to identify 
common alterations in response to r-mTBI and tested therapeutics. Despite a high heterogeneity 
of the phosphoproteome profile between the analyzed cohorts, our data identified several 
molecules (ARPP21, Syt-1) which were equally altered in response to treatment in all r-mTBI 
cohorts and may represent potential therapeutic targets that are effective across different models 
of r-mTBI. Future studies will focus on the total proteome analysis and a subsequent validation 
of these potential targets. 
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Chapter 1 – General Introduction 
1.1 Traumatic Brain Injury Epidemiology and Statistics 
Globally, 61 million individuals are estimated to sustain Traumatic Brain Injury (TBI) 
each year (Dewan et al. 2019). In the United Kingdom (UK) alone, TBI-related hospital visits 
account for 1.4 million cases annually (Lawrence et al. 2016), whereas in the United States (US) 
TBI affects over  2.5 million people per year and accounts for more than 13 million cases of 
long-term disability to date (Taylor et al. 2017). The highest incidence of TBI per 100,000 
people is recorded in North America (1299 cases)  and Europe (1012) (Dewan et al. 2019).  
These data, however, underestimate the real number of TBI cases because many victims do not 
seek medical attention, especially in cases of mild forms of TBI (mTBI) when no obvious 
symptoms are present during the acute and subacute period post injury. For instance, all TBI-
related hospital visits between 2014 and 2015 in England and Wales were dominated by mild 
injuries (68%) while more severe forms of TBI accounted for the remainder (Lawrence et al. 
2016). Worldwide, according to the meta-analysis of 121 incidence studies between 1980 and 
2000, 42 million people sustain mTBI occupying the majority of all TBI cases (Cassidy et al. 
2004).  According to the Centers for Disease Control (CDC), the rates of TBI-related Emergency 
Department (ED) visits increased from 521.0 to 823.7 per 100,000 in the decade between 2001 
and 2010 (CDC. Injury prevention & control: traumatic brain injury & concussion 
https://www.cdc.gov/traumaticbraininjury/data/rates.html).  Meanwhile, the rates of deaths 
caused by TBI recorded for the same period decreased from 18.5 to 17.1 per 100,000, likely in 
part to an increased awareness and medical advancements. Worldwide, TBI is most prevalent in 
infants (0-4 years), younger adults (15-24 years) and the elderly (> 65 years) (Sarmiento et al. 
2019; Centers for Disease Control and Prevention 2011; Flanagan et al. 2006; Nguyen et al. 
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2016). The most common causes of acquired brain injury include sport-related injuries, motor 
vehicle accidents, falls and assaults (Rutland-Brown et al. 2006; Lajoie and Gallagher 2004). In 
the US, the highest incidence of TBI and repetitive TBI is recorded in professional athletes. In 
the years 2001-2012, sport-related injuries contributed to over 3 million ED visits (Coronado et 
al. 2015). The number of ED visits was increased for both males and females, with males having 
twice higher rates of TBI incidence each year. In the survey conducted by Coronado et al., 
around 90% of all TBI patients were released within days, indicating that milder forms of TBI 
were the most prevalent (Coronado et al. 2015). Military personnel represent another population 
group that is associated with high incidence of TBI worldwide. In the US, The Department of 
Defense (DoD) reported more than 380,000 of the US service members diagnosed with TBI 
between years 2000 and 2018 (Defense and Veterans Brain Injury Center 2018). Among them, 
nearly 316,000 (82.3%) individuals had mild form of TBI as assessed by GCS (12-15). In a 
recent study that evaluated the incidence of TBI in the service members of the Iraq and 
Afghanistan conflicts (VA TBI Veterans Health Registry 2001-2013), mTBI constituted 87.3% 
of all brain traumas with blast waves (33.1%) and objects hitting the head (31.7%) being among 
the most reported reasons (Lindquist et al. 2017). TBI has also been recognized as a signature 
wound of Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF) and Operation 
New Dawn (OND) where out of 185,437 veterans, who completed the survey, 78% reported 
exposure to a traumatic event associated with alteration of consciousness. Similarly, 81% of 
these veterans experienced mTBI with 77% arising from blast injuries (Whiteneck et al. 2015). 
In the UK armed forces, between 2003 and 2011, 19% of all casualties in Iraq and Afghanistan 
wars suffered a TBI (Hawley et al. 2015).  
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1.2 Classification of Traumatic Brain Injury 
TBI describes a spectrum of head traumas that can be classified into several types 
depending on the severity, mechanism, location on the head and other factors (Saatman et al. 
2008). The most common tool for classification is the Glasgow Coma Scale (GCS), which is 
used for clinical diagnoses (Green et al. 2017). It is based on the acute neurological assessment 
that measures eye, verbal and motor responses. Each parameter is scored individually according 
to its severity (1-4, 1-5 and 1-6 respectively) with the most severe presentation in each category 
(e.g. no eye opening, no sounds or no response respectively) having the lowest score of 1; these 
three scores are then combined in a 3-15 point scale. The 15-point GCS system classifies mild 
(13-15), moderate (9-12) and severe (3-8) TBI (Johnson et al. 2017).  Moderate and severe head 
injuries are associated with higher hospitalization rates, gross brain pathology and increased 
mortality. These usually result from a penetrative focal injury that involves skull fracture and 
brain tissue damage. Such injuries often arise from assaults or accidents. Conversely, mTBI does 
not lead to gross pathology or strong neurological dysfunctions at the acute hospitalization 
period. Mild TBI patients may experience short loss of consciousness (LOC) <30 min and brief 
post-traumatic amnesia (PTA) <24h (Carroll et al. 2004; Eme 2017; Pavlovic et al. 2019). Such 
injuries include non-penetrative blunt impacts that result in diffuse cellular injury rather than 
focal tissue loss. Most mTBI result from concussions, falls, blast waves and mild accidents. 
Assessment by GCS, LOC and PTA is, however, being criticized by the scientific community as 
insufficient to accurately determine the severity of an injury  (Braine and Cook 2017). To 
overcome this uncertainty, additional tools, including imaging techniques, have been used to 
differentiate mTBI pathology. Traditionally, computer tomography (CT) scan could not diagnose 
mTBI due to its low sensitivity (Eme 2017). However, emerging advances in functional 
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magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) provide the ability to 
distinguish subtle neuropathological processes such as axonal and vascular injury (Pavlovic et al. 
2019).  
 
1.3 Mild TBI and repeated mild TBI in humans.  
1.3.1 Mild TBI Clinical Presentation 
The immediate response to mTBI includes headaches, dizziness, fatigue and sleep 
disturbances, and they usually resolve within several days or weeks (more rarely, within couple 
months) (Katz et al., 2015; Prince and Bruhns 2017). If unresolved, these symptoms may evolve 
into prolonged neurological problems lasting for months and years post-trauma. For example, 
memory problems are among the most common deficits reported after mTBI in both acute and 
chronic periods. Within the first 24 hours post mTBI, patients may have impaired consolidation 
processes leading to difficulties in memorizing new information, known as post-traumatic 
amnesia (PTA) (Flynn 2010). Later, within months after mTBI, if memory problems are 
sustained, they are expressed as difficulties in memory retrieval, impaired working memory and 
slow speed of processing. However, a comprehensive analysis of neurological deficits should 
include combinatory and not individual effects of lasting symptoms. For example, mTBI-induced 
sleep disturbances and insomnia are strongly correlated with memory deficits  (Mantua et al. 
2017). Adolescents with sport-related concussions report sleep disturbances and demonstrate 
impaired verbal and visual memory compared to patients who recover regular sleep behavior 
(Beebe et al. 2018; Kostyun et al. 2015).  
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Early studies in boxers who sustained multiple concussions throughout their career 
reported balance problems, memory deficits, personality change, aggressive behavior, mood 
disorder, depression, suicidal behavior and other neuropsychiatric impairments (Martland 1928; 
Millspaugh 1937; Critchley 1957). Such clinical presentation of chronic consequences of r-mTBI 
was referred as ‘punch drunk’ syndrome. Later, similar behavioral outcomes were recorded in 
former National Football League (NFL) players (“American Football”) who sustained repetitive 
concussions throughout their career in sport. Omalu and colleagues first described this condition 
as Chronic Traumatic Encephalopathy (CTE), where former football players experienced chronic 
depression, suicide attempts, paranoia, insomnia and mood changes at up to 12 years after their 
retirement (Omalu et al. 2005, 2006, 2010).  A more recent review summarized 51 cases of CTE 
among which 46 occurred in boxers and football players (McKee et al. 2009).  Common clinical 
symptoms included irritability, memory loss, aggressive behavior, gait abnormalities, slurred 
speech and Parkinsonism. Nearly 50% of described individuals were symptomatic within 4 years 
after they stopped playing. In recent years, CTE has become a subject of intense media scrutiny 
raising legal and societal implications (Korngold et al. 2013). Despite increased attention to, and 
recognition of, the chronic effects and negative sequelae of mTBI, CTE has temporarily 
subverted TBI field into the belief that all mTBI are equivalent to CTE. Thus far, CTE has been 
assessed in former athletes with the history of r-mTBI, however, whether sport-related 
concussions are the definitive cause of CTE remains unclear.  
1.3.2 Mild TBI Pathology in humans 
Clinical symptoms are essential to distinguishing mTBI from more severe forms of injury 
at the acute phase, however, they do not provide a comprehensive picture of injury-induced brain 
pathophysiology. Neuropathological changes in the mTBI brain are responsible for long-lasting 
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cognitive deteriorations and thus require special attention. There are 3 ways to measure cellular 
and molecular changes in the brain: live imaging, biomarkers and post-mortem analysis.  
Live imaging uses multiple techniques such as CT, MRI, DTI and positron emission 
tomography (PET) that are able to capture certain morphological and physiological changes, 
depending on the sensitivity of the technique employed.  Due to the mild nature of concussions, 
most live-imaging techniques fail to detect brain microscopic abnormalities after mTBI (Bigler 
2015). For instance, CT and MRI can only detect gross pathology such as skull fracture, 
bleeding, and edema, none of which are typically present in mTBI (Bigler 2015). Conversely, 
diffuse imaging techniques such as DTI have higher sensitivity and are able to detect changes in 
large fiber tracts in white matter such as diffuse axonal injury (DAI) (Bigler 2015; Toth 2015). 
Although DTI limitations include low specificity to injury-induced vs nonpathological changes 
of cell integrity, recent advancements have made DTI an attractive technique for mTBI 
diagnosis. Nevertheless, structural imaging alone does not provide enough information about 
mTBI pathology (Shin et al. 2017). Instead, functional imaging techniques which measure 
metabolic changes are more advantageous. For instance, PET imaging can measure glucose 
uptake which is known to be altered after mTBI. Byrnes and colleagues summarized clinical 
PET studies for mTBI in their review and highlighted important temporal changes in glucose 
levels (Byrnes et al. 2014). Several studies confirmed glucose uptake reduction in different 
regions at both acute and chronic time points after mTBI. For example, veterans with blast-
induced concussions showed a decrease of glucose metabolism at 2 years post-TBI in regions 
varying from frontal and temporal cortex to brainstem and cerebellum (Mendez et al. 2013; 
Petrie et al. 2014). These findings were confirmed by PET imaging in animal studies where rats 
were exposed to experimental mild TBI (Selwyn et al. 2013, 2015). Functional MRI (fMRI) is 
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another imaging approach with high enough sensitivity to detect network connectivity changes in 
the brain. fMRI scans showed reduced functional connectivity between different brain regions at 
90 days post-mTBI in veterans, and decreased interhemispheric connectivity at 10 days post-TBI 
in athletes (Han et al. 2014; Slobounov et al. 2011).  
Peripheral biomarkers have proven to be another promising tool to determine TBI 
occurrence and severity and propose an ongoing pathology. Brain injury leads to the disruption 
of blood-brain barrier (BBB) and astrocytic/neuronal integrity, which trigger the release of 
intracellular molecules into the blood stream.  Several neuron-specific proteins, such as UCHL1 
(Ubiquitin C-Terminal Hydrolase 1), NSE (neuron-specific enolase), NF (neurofilament), and 
tau, have been recorded to enter the circulation if the BBB integrity is compromised (Kim et al. 
2018; Papa et al. 2015; Zetterberg et al. 2013). However, few candidate biomarkers have 
demonstrated the ability to differentiate mTBI from more severe injuries. For example, elevated 
levels of phosphorylated tau (p-tau), total tau (t-tau) and the p-tau/t-tau ratio have been found in 
the plasma of patients with acute and chronic TBI across different severities (Rubenstein et al. 
2017). In fact, in this study, the concentration of plasma tau was associated with TBI severity, 
allowing differentiation of mTBI from more severe injuries. Conversely, some clinical studies 
suggest that increased tau is only seen in moderate and severe TBI (Lippa et al. 2019). Further, in 
the study of American football and ice hockey players, plasma tau in athletes with r-mTBI was 
not increased at 6 days post-injury suggesting specificity of tau as a chronic biomarker (Wallace 
et al. 2018). Another biomarker, neuronal cytoplasmic protein UCHL1, plays an important role 
in removing abnormal proteins through the ubiquitin-proteasome pathway and autophagy (Liu et 
al. 2019).  Increased levels of UCHL1 were found in the serum of mild and moderate TBI cases 
within one hour post-injury, and was correlated with CT signal and GCS score (Papa et al. 2012; 
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Ramezani et al. 2018).  Neurofilaments, which are found in axons, have also been found in the 
serum of mTBI patients within 1 hour and 3 days after the injury corroborated by a negative CT 
signal, confirming the inability of CT to differentiate between mTBI and controls (Gatson et al. 
2014).   
In addition to neuronal biomarkers, astrocyte-derived Glial Fibrillary Acidic Protein 
(GFAP) has also been detected to be elevated for up to 90 days post injury in the blood of mTBI 
patients (Bogoslovsky et al. 2017). In fact, a combination of GFAP and UCHL1 has been 
recently approved by the Food and Drug Administration (FDA) as the first biomarker for acute-
phase TBI (Bazarian et al. 2018). Studies showed that serum concentrations of GFAP and 
UCHL1 had a high sensitivity and Negative Predictive Value (NPV) for the detection of 
intracranial injuries on CT scans, thus allowing avoidance of unnecessary CT imaging for 
patients with mTBI with GCS 14-15 (Bazarian et al. 2018; Posti et al. 2016). Measurement of 
GFAP and UCHL1 however provides only an exclusionary biomarker for mTBI, not a diagnostic 
biomarker. Since very few mTBI victims seek medical attention at acute times, there remains a 
need for diagnostic biomarkers of mTBI that persist at a chronic period post injury. Several 
studies of military personnel with a history of mTBI also showed elevated levels of inflammatory 
cytokines IL-6, IL-10 and TNFα in plasma at 3 - 18 months post injury, suggesting an ongoing 
inflammation in a concussed brain (Kanefsky et al. 2019; Gill et al. 2018). The use of biomarkers 
helps to detect distinct pathophysiology after mTBI associated with BBB disruption and neuronal 
damage, however, they do not allow identification of brain-specific mechanisms that are not 
associated with BBB damage and resulting leakage into the periphery.  
Post-mortem analysis allows for the identification of macroscopic and microscopic 
changes in different brain regions and thus provides a comprehensive picture of mTBI pathology. 
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Unfortunately, pathological studies of acute mTBI are rare and usually include more severe 
injuries. Of the few cases available of early post injury examination of mTBI brains, some reveal 
normal brain appearance without gross morphological changes after a concussion (Bigler 2004; 
Blumbergs et al. 1994). On the microscopic level, one study of 5 mTBI victims, who died within 
2-99 days post injury from other causes, found consistent axonal injury in the white matter 
hemispheres, corpus callosum and fornices, which are involved in memory, as assessed by 
amyloid precursor protein (APP) staining (Blumbergs et al. 1994). Another study of mTBI brains 
analyzed at couple days to several weeks post-injury demonstrated axonal injury and microglial 
clustering in the perivascular regions (Oppenheimer 1968). In young (14-28 years old) athletes 
across different sports who died within 6 months after a reported mTBI, pathological 
examination showed axonal injury in white matter, perivascular microgliosis and astrogliosis, 
and focal accumulations of p-tau (PHF) (McKee et al. 2014). To our knowledge, these are the 
only studies that performed acute pathological analysis after mTBI, which is likely due to very 
few cases of immediate death after mild head injury. Indeed, most autopsy examinations are 
performed at chronic timepoints after mTBI, especially in cases when multiple concussions are 
associated with neurodegenerative disorders.  
  1.3.3 Chronic Outcomes of mTBI and related disorders 
The first evidence of the chronic effects of r-mTBI was recorded by Dr. Martland when 
he described ‘punch drunk’ syndrome in boxers with the history of multiple concussions who 
developed long-lasting motor, cognitive, and behavior abnormalities (Martland 1928).  In 1937, 
Millspaugh introduced the term ‘dementia pugilistica’ by commenting on Martland’s findings, 
suggesting the possibility for microscopic changes in these brains, which were later confirmed by 
Corsellis (Millspaugh 1937, Corsellis et al., 1973).  Next, Dr. Bennet Omalu described CTE 
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when he analyzed the brains of former NFL players who died at the age of 45 or 50, 12 years 
after their retirement from professional football that involved multiple concussions (Omalu et al. 
2005, 2006). Post-mortem analysis revealed the presence of neurofibrillary tangles (NFTs) in the 
neocortical areas of both cases, whereas the first case (Omalu et al. 2005) was also characterized 
by the presence of diffuse amyloid plaques. Later, Dr. Omalu presented the third case of CTE in 
a former NFL player who died at the age of 44, 11 years after his retirement from professional 
sport, and exhibited NFTs but no amyloidopathy (Omalu et al. 2010).  Medical records from all 3 
cases reported neuropsychiatric history and major depressive disorders between the end of their 
career and death. Additional studies later confirmed that CTE patients share common symptoms 
such as irritability, memory loss, confusion, mood disturbances, gait abnormalities and speech 
problems (McKee et al. 2009).  
Neuropathologically, CTE was characterized by atrophy of cerebral hemispheres, 
thalamus, brainstem and medial temporal lobe, dilation of ventricles and fenestration of the 
cavum septum pellucidum (McKee et al. 2009). On the microscopic level, multiple autopsy 
analyses demonstrated presence of tau pathology, neurofibrillary threads, endoplasmic reticulum 
stress, inflammation and cerebrovascular damage (Lucke-Wold et al. 2015; McKee et al. 2009; 
Omalu et al. 2011).   A broad spectrum of pathophysiological outcomes in CTE cases and its 
overlap with other neurodegenerative disorders undermines the diagnostic accuracy. A consensus 
panel comprised of independent neuropathologists defined the criteria for CTE diagnosis based 
on 25 tauopathy cases and included abnormal accumulation of hyperphosphorylated tau around 
blood vessels and in the depth of cortical sulci as the main symptoms (McKee et al. 2016). 
However, an early diagnosis of CTE is based solely on clinical examination by assessing 
cognitive abnormalities associated with mood and behavior dysfunctions (Montenigro et al. 
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2014). Although advancements have been made in identifying CTE, the idea of defining CTE as 
a distinct disease remains debatable. A recent study showed that not all athletes who received 
repetitive concussions develop CTE, despite a positive neurological assessment (Lee et al. 2019). 
Lee and colleagues suggest that CTE often develops as a co-morbidity to other diseases and not 
as a primary dementia. One study also presented a case of CTE-like pathology in a 45-year old 
man with 7-year history of ALS and no known records of TBI (Gao 2017). Postmortem 
examination demonstrated NFTs in the superficial layers of neocortex, areas surrounding blood 
vessels and in the depth of sulci in the frontal and temporal lobes as well as glial tau tangles and 
diffuse amyloid plaques.  
In brains with chronic TBI, astroglia have been shown to surround tau oligomers 
suggesting a strong link between inflammation and tau pathology. Hyperphosphorylated 
astrocytic tau impairs normal astroglial functions, leading to BBB disruption, decreased 
glutamate re-uptake and increased inflammation (Kahlson and Colodner 2015). A spectrum of 
astroglial tau pathology in neurodegenerative disorders has been named Aging-Related Tau 
Astrogliopathy (ARTAG) and is mainly detected in the elderly (Kovacs et al. 2016). ARTAG 
astrocytes are usually thorn-shaped and have fine granular immunoreactivity in the astrocytic 
processes, which distinguish them from the primary tauopathies. Although more research is 
necessary, ARTAG has been found in 455 of 687 cases across different neurodegenerative 
disorders including frontotemporal lobar degeneration (FTLD), Pick’s disease, Lewy body 
disease, AD and others (Kovacs et al. 2018). To date, there are no studies linking ARTAG and 
mTBI, however neuropathological similarities between the two warrant further investigation. 
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1.4 Animal models of mild TBI 
1.4.1 Review of preclinical injury models 
Preclinical studies are crucial in understanding cellular aspects of mTBI neuropathology, 
assessing potential therapeutic targets and testing prospective drugs prior to clinical trials. 
Numerous animal models of brain injuries have been developed in flies, fish, pigs, rodents, 
ferrets, sheep and non-human primates (Bolouri and Zetterberg 2015; Sorby-Adams et al., 2018).  
Although large animals, such as pigs, sheep and non-human primates, may seem to be a better 
model because they have gyrencephalic brains (as do humans), most mTBI (and r-mTBI) studies 
use rodents due to their availability, low cost, high reproducibility and easy manipulation. These 
models have been proven to closely replicate many aspects of human mTBI pathobiology such as 
axonal injury, inflammation, tauopathy, oxidative stress, BBB disruption and cognitive deficits 
such as memory loss, anxiety, social interaction, stress and motor impairments (Bolouri and 
Zetterberg 2015).  
Table 1 summarizes rodent models of mTBI that are commonly used in pre-clinical 
research (for review see Bolouri and Zetterberg 2015 and Bolton-Hall et al. 2019). All these 
models can be divided into closed-head or open-skull injuries. Open-skull injuries include 
controlled cortical impact (CCI) and fluid percussion injury (FPI), both of which require 
craniectomy prior to the mechanical impact (Morganti-Kossmann et al. 2010). CCI uses an 
impactor device with pre-determined velocity and depth of penetration. It results in a focal 
injury, usually affecting a single hemisphere and causing loss of tissue (Romine et al. 2014). 
Although multiple studies refer to their CCI models as mTBI, sham mice for such models are 
themselves experiencing a mild TBI through the craniectomy. Therefore, mice receiving a CCI 
injury are more likely to replicate moderate and severe TBI and thus such data should be viewed 
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in that regard (Lagraoui et al. 2012, Ferguson et al. pers comm). A benefit of using the FPI model 
is its ability to cause diffuse injury by applying a high-pressure pulse of fluid onto the intact 
brain through the craniectomy window. FPI is a widely-accepted model for mTBI that does not 
cause tissue loss or gross pathological symptoms, however, again, craniectomy by itself induces 
injury-like pathology such as neuroinflammation and cerebrovascular damage in sham animals 
confounding data interpretation (Cole et al. 2011; Sargolzaei et al. 2018). Hence, alternative 
models using closed head injury (CHI) are more relevant for mimicking concussions in animals. 
One such model is a Marmarou’s weight drop model of TBI that uses a free-falling weight on the 
closed head (Marmarou et al. 1994). It triggers the anticipated mTBI pathology of axonal injury, 
inflammation and long-lasting cognitive deficits (Zohar et al. 2003; Tweedie et al. 2016; Milman 
et al. 2005). However, due to poor control of the impact driven solely by gravity force, the 
results can vary from study to study. Another limitation of the previously described models is the 
lack of information on how head movement contributes to a concussion. In humans, a vast 
number of injuries involve head rotation due to acceleration and deceleration. This rotation 
results in the movement of the brain inside the skull and consequently produces two impact 
areas. However, none of the previously described models consider free head movement. The 
most recent Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) is 
designed to address this limitation and account for biomechanical aspects of head impact 
(Namjoshi et al. 2014). This model is advantageous in mimicking repeated injuries which 
replicate human r-mTBI pathology such as diffuse axonal injury, excessive microgliosis and 
astrogliosis, and tau phosphorylation both acutely and chronically (Namjoshi et al. 2014; Cheng 
et al. 2019). CHIMERA mice also exhibit neurological, motor and cognitive deficits with 
anxiety-like behavior.  
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Injury 
model 
Benefits Drawbacks References 
CCI High reproducibility of 
the focal impact; 
controlled impact 
variables.  
Craniectomy induces mTBI-
like pathology in the sham;   
focal impact; fixed head, no 
rotation; craniectomy position 
may cause variable outcomes 
between laboratories. 
(Onyszchuk et al. 2008; 
Romine et al.2014) 
FPI/LFP High reproducibility of 
the impact; 
controlled impact 
variables; diffuse 
impact. 
Craniectomy induces mTBI-
like pathology in the sham; 
fixed head, no rotation; 
craniectomy position may cause 
variable outcomes between 
laboratories; focal cell loss is 
sometimes present. 
(Alder et al. 2011; 
Carbonell et al. 2009; 
Lyeth 2016; Thompson 
et al. 2005) 
Weight 
Drop 
Closed head injury; no 
craniectomy induced 
pathology; possibility to 
induce free movement of 
the head and body upon 
the impact (including 
falls); diffuse impact. 
Low reproducibility due to 
little control over impact 
variables (i.e. gravity force); 
inability to visualize anatomical 
landmarks of impact; poor 
comparability between the 
studies. 
(Abd-Elfattah Foda and 
Marmarou 1994; Zohar 
et al. 2003; Marmarou et 
al. 1994) 
Blast Injury Closed head injury; no 
craniectomy induced 
pathology in sham 
animals; diffuse impact; 
may trigger head 
movement upon the 
blast impact; high 
relevance to military 
blast injuries. 
High variability between and 
within models due to: different 
blast sources, variability in the 
distance between the blast 
source and the head, little 
control over the blast forces 
propagation through the air 
(Perez-Polo et al. 2015; 
Mendez et al. 2013;  
Wang et al. 2016) 
CHIMERA Closed head injury; no 
craniectomy induced 
pathology in sham 
animals; high 
reproducibility and 
comparability between 
the studies; rotational 
movement of the head 
Focal injury; inability to 
visualize anatomical landmarks 
for the impact; 
this model introduces a new 
variable - the injury tolerance 
depending on the angular plane. 
(Cheng et al. 2018, 
2019;  Namjoshi et al. 
2014, 2017) 
Closed 
Head CCI 
Closed head injury; no 
craniectomy induced 
pathology in sham 
animals; high 
reproducibility and 
comparability between 
the studies. 
Fixed head, no rotation; 
inability to visualize anatomical 
landmarks for the impact. 
 
(Mouzon et al. 2012) 
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               Table 1. Summary of experimental models of mTBI in rodents 
 
Finally, animal models have also been developed which replicate concussions in the military 
personnel resulted from explosions (Mendez et al. 2013; Perez-Polo et al. 2015). These 
experimental models use blast waves in the proximity of an animal to cause a blast 
decompressive injury. This type of injury does not produce skull fracture or gross pathology and 
replicates a typical response to mTBI. Blast injury in mice induces gliosis, axonal injury, BBB 
disruption and severity-dependent behavior deficits (Wang et al. 2016). However, limitations in 
measuring remote blasts and high variability of the distance from the blast source across different 
studies make direct comparison difficult.  In general, clinically relevant models of mild TBI 
demand the following characteristics: 1) closed head, 2) mild level of impact, 3) low to none 
mortality rate and 4) ability to cause mTBI pathology without gross symptoms (Bolouri and 
Zetterberg 2015). 
 
1.4.2 Mild TBI pathology in animal models 
Axonal Injury 
Mild TBI is a heterogeneous condition that triggers a series of pathological events lasting 
from seconds and minutes to days, months and even years. The immediate response of brain cells 
to the mechanical impact is called primary injury. At this stage, mechanical stress affects neurons 
and neuronal structures leading to either cell death or cell damage depending on the proximity of 
cells to the impact areas, propagation of stress, and individual cell characteristics.  The key 
elements of primary injury are shear and stretch forces that result from rotational 
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acceleration/deceleration and stress propagation in the brain (Siedler et al. 2014). Axonal 
structures have been shown to be the most vulnerable structures to such forces which result in 
axonal injury. Most animal models of mTBI closely replicate human axonal pathology, which is 
identified by the presence of bulbs and swellings inside the axons.  These morphological changes 
result from the microtubules mislocation and accumulation of amyloid precursor protein (APP) 
(Tang-Schomer et al. 2012; DiLeonardi et al. 2009). APP is a transmembrane protein that has 
been implicated in axonal transport by anchoring cargo proteins and vesicles to the motor protein 
associated with microtubules (Muresan et al. 2009). Historically, APP has been used as a marker 
for axonal injuries and has been demonstrated in numerous animal models of mTBI, particularly 
at acute timepoints.  Another common marker of axonal injuries is neurofilament which in in 
vitro models of mild stretch injury show a strong immunoreactivity forming ring-like structures 
with axonal swellings (Chung et al. 2005; Dunn-Meynell and Levin 1997).   Interrupted axonal 
transport serves as a signal of potential cell damage, which consequently releases a number of 
molecules in the extracellular space to activate protective mechanisms. Released molecules are 
known as Damage Associated Molecular Patterns (DAMP) and include such important 
molecules as zinc, ATP and glutamate (Loane and Kumar 2016; Russo and McGavern 2016). 
These trigger calcium influx in the surrounding cells leading to oxidative stress, activation of 
glial cells and infiltration of leukocytes and neutrophils from the periphery. Traditionally, 
excessive release of glutamate has been known as excitotoxicity, however alternative studies 
suggest that there are also glutamate-independent mechanisms of excitotoxicity triggered after 
mTBI (Tehse and Taghibiglou 2018). Excitotoxicity is a transitional step from primary to 
secondary injury, which is triggered by prior pathological events and not by the impact itself. It 
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launches a biochemical cascade that can last for months and years post trauma and contribute to 
chronic impairments.  
 
Neuroinflammation  
A key element of secondary injury is inflammation, which is regulated by activated 
resident and peripheral immune cells infiltrated from the blood. Inflammation is a natural 
response to pathogens and stress, including mechanical impact, and serves to eliminate damage-
associated molecules and restore normal balance of the environment. Resident immune cells 
include microglia and astroglia which are activated by excitotoxic molecules released during the 
primary injury. When activated, microglia undergo morphological changes from a resting 
ramified state to an amoeboid phenotype. Microglial activation is thought to have a dynamic 
temporal profile serving as a defense system in the acute phase and as neuroprotective at sub-
acute time points (H. Xu et al. 2017). A simple categorization of activated microglia phenotypes 
describes two opposing states: pro-inflammatory (M1) and anti-inflammatory (M2) (Loane and 
Kumar 2016).   M1 microglia are characterized by an upregulated expression of IL-1β, TNFα, 
iNOS, IL-6 and IL-12p40 and are linked to oxidative stress, suppressed axonal growth, reduced 
phagocytic activity and chronic inflammation. M2 microglia express anti-inflammatory 
cytokines such as IL-10, IL-4 and contribute to neuronal regeneration, angiogenesis and 
remyelination. Typically, M1 is rapidly induced after TBI followed by the activation of M2 but 
under pathological conditions, the M1 phenotype remains dominant over M2 leading to long-
lasting inflammation. For example, in mice subject to CCI, M2 microglia have been reported to 
peak at 5-7 days post injury while the increase in M1 microglia continued for 14-30 days post 
injury (Jin et al. 2012; Wang et al. 2013). Another study reported that transition from M2 to M1 
18 
 
begins at 7 days and can be found up to 1 year post-TBI (Loane et al. 2014). Prolonged 
activation of microglia results in pro-inflammatory cytokine production that suppresses 
regeneration and contribute to neuronal dysfunction (Loane and Kumar 2016; Xu et al. 2017). 
However, this dichotomic classification is considered an oversimplification and inappropriate to 
describe the complexity of microglial/macrophages responses after TBI (Loane and Kumar 2016; 
Kumar et al. 2016; H. Xu et al. 2017).  
Like microglia, astroglial cells are also key components of the secondary injury. Healthy 
astrocytes support homeostasis of the brain by regulating the BBB (Abbott et al. 2006) and 
extracellular glutamate levels. Mechanical impact leads to astroglial proliferation, hypertrophy 
and their migration to the damaged tissue (Burda and Sofroniew 2014). Astrocytes move towards 
the injury site and elongate their processes forming a mesh-like structure called a glial scar 
(Bardehle et al. 2013). Glial scars are most evident in cases of focal injury, usually associated 
with moderate and severe TBI, however some studies showed the presence of such scars in 
diffuse mTBI (Burda et al. 2016).  Glial scars segregate damaged and inflamed tissue from the 
adjacent cells and serve as a barrier that regulates spreading of the pathology (Wanner et al. 
2013). The migration of astrocytes is triggered by matrix metalloproteinase 9 (MMP9) released 
by reactive astroglia into the extracellular space (Candelario-Jalil et al. 2009) and by aquaporin 4 
(AQ4) translocating from the perivascular space to astrocytes (Ren et al. 2013).  In the proximity 
to damaged tissue, astrocytes respond to and produce cytokines, chemokines, inflammatory 
mediators and DAMPs (Burda et al. 2016). Several mouse models of mTBI/r-mTBI showed an 
acute increase of GFAP starting 24h post-injury with the peak at days 3-7 followed by  
progressive increase during chronic period (Kane et al. 2012; Mouzon et al. 2014,2018; Susarla 
et al. 2014). Typically, immunohistochemical (IHC) analysis reveals GFAP signal in cortical and 
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subcortical areas in proximity to the injury site during the acute phase, while in more chronic 
periods GFAP is prevalent in the corpus callosum and hippocampus. Due to the vital role of 
these brain areas in memory formation, chronic inflammation may be associated with memory 
loss. Neuroinflammation has been demonstrated to be the most consistent pathology in response 
to experimental mTBI as was shown in all previously described animal models of mild injury. 
 
Tau phosphorylation and oligomerization  
There is a considerable interest in the investigation of the pathobiology of tau protein in 
pre-clinical models of mTBI, given its potential role in neurodegenerative diseases and aging. 
Tau is a microtubule associated protein that is responsible for microtubule stabilization and 
axonal transport. The tau protein is primarily located in the axonal cytoskeleton but can also 
localize to the nucleus, plasma membrane and post-synaptic density. Tau is expressed by MAPT 
gene that encodes a total of 16 exons, out of which exons 2, 3 and 10 undergo alternative splicing 
(for review see Wang & Mandelkow 2016). Exons 2 and 3 contain amino terminal sequences 
while exon 10 encodes carboxyl terminal repeats that function as microtubule binding domains. 
When exon 10 is present, there are 4 microtubule repeats (4R) and when absent, there are 3 
microtubule repeats (3R) (McMillan et al. 2008). Human tau profile is represented by the total of 
6 isoforms (0N3R, 1N3R, 2N3R, 0N4R, 1N4R, 2N4R) that vary by the presence or absence of 
N-terminal (0N, 1N or 2N) and C-terminal microtubule binding repeats (3R or 4R) (Sealey et al. 
2017). In a healthy brain, the 4R:3R ratio is 1:1 while in neurodegenerative conditions, such as 
Alzheimer’s Disease (AD) and CTE, the tau profile is predominantly 4R (Chen et al. 2010; 
Goedert and Jakes 1990; Schmidt et al. 2001).  Iqbal and colleagues showed that in human brain, 
4R tau had a higher level of phosphorylation than 3R, and 4R was demonstrated to acquire a 
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more favorable conformation for self-assembly and polymerization (Iqbal et al. 2009). Mild TBI, 
especially repetitive mTBI, has been shown to promote hyperphosphorylation of tau leading to 
its conformational changes and dissociation from the cytoskeleton (Iqbal et al. 2009; Morris et al. 
2011; Fontaine et al. 2015). While tau phosphorylation is not always pathologic, in 
neurodegenerative disorders it is likely to form aggregates by binding normal tau (Alonso et al. 
1996). These intracellular aggregates translocate to soma and dendrites and negatively affect 
synaptic functions and axonal transport.  Phosphorylated tau can be released by exocytosis into 
the extracellular space (Morris et al. 2011) and spread in a prion-like behavior forming oligomers 
and tau threads that are hallmarks of AD and other forms of dementia, and are now linked to 
chronic effects of mTBI (Guo and Lee 2011; De Calignon et al. 2012).  
 Interestingly, tau pathology in wild-type rodents does not recapitulate the tau pattern in 
human brains. There are several reasons that can contribute to such differences. First, both 
human and mouse brains express 2 types of tau isoforms, 3R and 4R, however, the relative 
proportions of these isoforms vary between the species.  A mouse tau profile is mostly 
represented by 4R forms, representing 98% of all tau, while humans express an equal ratio of 
3R:4R (McMillan et al. 2008). Despite an increased 4R:3R ratio in wild-type mice, literature 
shows inconsistent results in tau behavior under pathological conditions varying from persistent 
to transient to no changes (for review see  Ojo et al. 2013). One study compared single and 
repetitive mTBI (6 hits daily for 7 days) in C57BL/6 mice and observed an increase of tau 
phosphorylation (AT8) at 1 month but not at 6 months after single TBI (Petraglia et al. 2014). In 
the r-mTBI mice, however, p-tau was observed up to 6 months post injury. Meanwhile, in our 
previous study, wild-type mice, which received 5 mTBI 48 hour apart, did not exhibit 
phosphorylation of tau at any timepoint up to 24 months post TBI (Mouzon et al. 2018). Several 
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other studies confirmed acute/subacute accumulation of tau across different models of TBI 
including FPL (Hawkins et al. 2013) and blast injury (Goldstein et al. 2012), however 
publications extending these data to chronic timepoints post injury remain scarce. Second, 
human and murine tau differ in the number of amino-acid residues (where humans express 14 
additional residues) that are crucial for protein conformation and its enzymatic activity 
(Jeganathan et al. 2008; Goedert and Jakes 1990; Andorfer et al. 2003). Taken together, the 
differences in the ratio of tau isoforms and amino acid residues can cause inconsistency between 
the mouse and human tau response to brain injury. Using transgenic mice that express 
humanized tau has been proposed (and adopted) as an approach to more closely mimic r-mTBI 
and possible CTE pathology in pre-clinical models.  
A convenient model for tauopathies is the hTau mouse that expresses all 6 isoforms of 
human nonmutated tau on a null murine tau background (Andorfer et al. 2003). These mice are 
produced by crossing tau knock-out (KO) mice, with a targeted disruption of exon 1 of MAPT, 
with 8c mice expressing human tau transgene via a P1-derived artificial chromosome (PAC) 
cloning vector (Duff et al. 2000; Tucker et al. 2001). The first generation of mice expressing 
human tau is then backcrossed with KO mice to generate a homozygous line.  hTau mice 
reproduce human-like tau pathology where tau translocates from axons to cell bodies by 3 
months of age and becomes hyperphosphorylated by 6 months (Andorfer et al. 2003), and they 
develop age-dependent memory deficits and synaptic dysfunction by 12 months of age, while no 
other health problems linked to weight, basic reflexes, anxiety and motor functions are present 
(Polydoro et al. 2009). The most common areas of pathology in hTau mice are hippocampus and 
neocortex, including subcortical regions such as medial septum and the nucleus of the diagonal 
band. Moreover, these mice demonstrate thinning of corpus callosum, ventricular enlargement, 
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and reduced cell number between 10 and 14 months of age.  This pathology is believed to be 
driven not only by the absence of mouse tau and the presence of human tau but also by a higher 
expression of 3R tau in hTau mice. Interestingly, injections of tau oligomers from mTBI (blast or 
FPI) hTau mice into healthy hTau mice cause cognitive deficits confirming a direct link between 
the pathologic tau and behavior dysfunction (Gerson et al. 2016).  At the Roskamp Institute, we 
have used hTau mice to study the effects of repetitive mTBI on chronic pathological and 
cognitive outcomes that involve modifications of tau. First, we found that 18-month old exposed 
to r-mTBI but not to single mTBI have increased levels of tau phosphorylation. These data also 
demonstrated TBI-dependent tau pathology in aged (18-month old) hTau mice where tau 
pathology was already present at the time of injury (Ojo et al. 2013). Second, the apparent 
significance of TBI-dependent p-tau in humans, typically detected at times long past the period 
of TBI exposures, encouraged us to measure tau levels at 6 months post first TBI. For this, we 
administered r-mTBI for 3-4 months (2 hits per week) and at 3 months post-last injury observed 
a long-lasting increase in total tau and mild increase in phosphorylated tau (Ojo et al. 2016).  
Given that we have not demonstrated TBI-dependent tau pathology in WT mice on our 
laboratories, these findings confirm the benefits of using hTau mice over wild-type to replicate 
human-like TBI response. 
 
1.5 Therapeutic approaches for TBI 
1.5.1 Clinical Trials for TBI 
Over the past several decades, more than 50 clinical trials have been initiated to test 
potential neuroprotective and neuroreparative pharmacological interventions for TBI (Stein et al. 
2015).  Unfortunately, all these trials failed during Phase II or Phase III and none of the tested 
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drugs have been approved for clinical application (Stein et al. 2015). Direct comparison of these 
trials is complicated due to a high variability of injury severities across patients, however, the 
main findings are worth mentioning.  
The largest trial ever conducted on head trauma, to date, was CRASH (Corticosteroid 
Randomization After Significant Head injury) which was designed to measure the effect of the 
corticosteroid methylprednisolone on neurorecovery in patients with severe TBI (Roberts 2002; 
The CRASH trial protocol (corticosteroid randomisation after significant head injury) 
[ISRCTN74459797] 2001). Prior experimental studies in animal models confirmed the ability of 
corticosteroids to decrease intracranial pressure (ICP), inhibit immune response and reduce 
neurodegeneration (Edward D. Hall 1985; Ildan et al. 1995). Previously conducted clinical trials 
of corticosteroids in head injuries were too small to confirm or refute their clinical benefits 
(Alderson and Roberts 2011). Hence, the need for a large-scale study seemed rational. The 
hypothesis stated that a high-dose (0.4 g/h)  infusion of corticosteroids for 48 hours could reduce 
mortality and disabilities in patients with severe TBI (Edwards et al. 2005). The trial aimed to 
recruit 20,000 subjects within an 8-hour post injury window and assess their outcomes at 6 
months post treatment using Glasgow Outcome Scale (GOS). However, the trial was terminated 
when 10,000 individuals had been randomized to the trial, when the group allocated with 
corticosteroids was found to demonstrate increased mortality at 14 days and 6 months following 
the treatment (Edwards et al. 2005;  Roberts et al. 2004). The increased death rates in the 
treatment groups did not differ by injury severity or time after injury.  The main flaw of the study 
was determined to be a poor understanding of the proposed mechanism of action of the 
treatment, and the lack of a specific target. The CRASH study indicated that non-specific 
immune suppression acutely after TBI can be detrimental.  
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Another set of promising clinical trials investigated the effect of progesterone in TBI, due 
to numerous pre-clinical studies having shown its significant benefits (Siddiqui et al. 2016). The 
rationale for using progesterone was based on the observations of superior cognitive performance 
in naïve (uninjured) female mice and the ability to replicate the same behavior in male mice upon 
administration with the hormone (Auger and Forbes-Lorman 2008; Frye et al. 2009). 
Progesterone was also shown to decrease inflammation, brain edema, apoptosis and axonal 
injury in animal models of TBI and ischemic injury (Guennoun et al. 2015; Chan et al. 2014; 
Chen et al. 2008; Lei et al. 2014; O’Connor et al. 2007). Two Phase II clinical trials 
demonstrated safety of progesterone injections in patients with mild to severe TBI (Wright et al. 
2007; Xiao et al. 2008). Progesterone treated groups also showed decreased mortality and better 
functional outcomes for up to 6 months after head injury. These positive results prompted two 
independent Phase III clinical trials, ProTECT III (Clinicaltrials.gov NCT00822900) and 
SyNAPSe (Clinicaltrials.gov NCT01143064), were initiated to test acute administration of 
progesterone in patients with moderate and severe TBI (Stein 2015). In the ProTECT III study, 
progesterone was administered within 4 hours post-TBI for 96 hours (0.5 mg/kg/h tapered over 
the additional 24 hours, intravenously (i.v.)) in patients with GCS < 13, and the analysis included 
GOS, Disability Rating Scale (DRS), and mortality (Wright et al. 2014).  In the SyNAPSe trial, 
patients with GCS < 8 received treatment within 8 hours post TBI for total of 120 hours (0.71 
mg/kg/h for 1 hours following 0.05 mg/kg/h for 119 hours, i.v.) and the outcomes were assessed 
using GOS. Both studies analyzed TBI outcomes 6 months after the injury. In both studies, 
progesterone treated patients exhibited the same recovery rate as the placebo group and no 
differences in outcome compared to placebo group were detected (Skolnick et al. 2014; Butler 
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2015). Further attempts to test progesterone for TBI have been withdrawn due to the failures of 
these two independent trials. 
Interestingly, some drugs that have been tested in TBI patients, but failed to show 
significant improvements, are still used as medications for brain injuries. For example, 
amantadine, a dopamine agonist, is one of the most common medications prescribed for TBI 
despite its failures in clinical trials (Hammond et al. 2015). In rats, amantadine increases 
dopamine release while reducing  dopamine reuptake and has been shown to improve TBI-
induced motor and cognitive deficits, including memory impairment and depression-like 
behavior (Tan et al. 2015; E. Y. K. Huang et al. 2014). Several clinical studies tested acute and 
sub-acute administration of amantadine in patients with severe TBI and showed accelerated pace 
of functional recovery during active treatment compared to placebo (Giacino et al. 2013; J. M. 
Meythaler et al. 2002). In the first study, patients that remained in the vegetative state (VG) or 
minimally conscious state (MCS) 4-16 weeks post TBI received amantadine (200-400 mg/day) 
for 4 weeks and the DRS score was measured at 2 weeks after the termination of treatment. 
Amantadine treated patients exhibited faster recovery during the 4 week period of active 
treatment whereas this effect disappeared during the following 2 weeks when treatment was not 
present (Giacino et al. 2013, ClinicalTrial.gov NCT00970944). In the second study, amantadine 
(200mg/day) was administered within 4-6 weeks post TBI to patients with GCS < 10 (J. M. 
Meythaler et al. 2002). The study included 2 groups each of which received either amantadine or 
placebo in the first 6 weeks and treatments were switched in the following 6 weeks. Results were 
analyzed at 6 and 12 weeks after the beginning of treatment and included GOS, Mini Mental 
State Examination (MMSE), and DRS. The study found a significant improvement in 
amantadine treated patients in both groups regardless of when the treatment was started. 
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However, when amantadine was withdrawn during the second 6 weeks and cognitive functions 
were assessed at 12 weeks, no improvement was recorded. Additional clinical studies were 
unable to replicate any significant benefits of amantadine on cognitive outcomes or functional 
recovery (Schneider et al. 1999; Hammond et al. 2018). 
Another drug that had promising pre-clinical results and underwent several clinical trials 
was erythropoietin (EPO). EPO is essential for erythropoiesis and is used as an endogenous 
neuroprotective in the ischemic brain (Mallet et al. 2017). Low levels of EPO are expressed by 
neurons and astrocytes under normal conditions and are upregulated after CNS insult. Animal 
models of TBI confirmed the neuroprotective effects of EPO through suppression of glutamate 
toxicity, apoptosis, oxidative stress and a number of proinflammatory cytokines: IL-1β, TNFα, 
ICAM1, CCL-2 (Xiong et al. 2008, 2010; Peng et al. 2014; Zhou et al. 2017). Several clinical 
trials tested acute EPO administration in patients with moderate to severe TBI and demonstrated 
no difference in outcomes (Liu et al. 2016). A clinical trial in Australia (ANZICS-CTG 
NCT00987454) that recruited 606 patients with moderate and severe TBI analyzed their 
outcomes at 6 months post injury and showed no treatment effect on mortality and neurological 
dysfunctions when treated within 24 hours post-TBI and for 3 weeks  (Nichol et al. 2015). 
Moreover, EPO did not impact plasma levels of potential TBI biomarkers NSE, S100β, UCHL-1, 
NF, nor did it improve cognitive outcomes (Nirula et al. 2010; Hellewell et al. 2018; Nichol et al. 
2015).   
A few clinical trials have “repurposed” approved drugs to target TBI outcomes such as 
depression and sleep deficits. For example, sertraline, a common mood-altering drug, has 
showed efficacy in preventing the onset of depressive disorder in patients across different TBI 
severities  (Jorge et al. 2016) while armodafinil improved sleep deficits in patients with mTBI 
27 
 
and moTBI (Menn et al. 2014). While most clinical trials recruit patients with moderate and 
severe TBI, mTBI remains greatly understudied in the human population. 
 
1.5.2 Preclinical treatment studies for mTBI 
One approach to address the problem of these many failures in TBI clinical trials is to 
have more thorough investigation of potential therapeutics in translationally relevant preclinical 
models.  In the past decades, experimental studies have investigated a large number of treatments 
strategies including target-specific and multimodal drugs; natural and synthetic compounds; 
noninvasive approaches, such as environmental enrichment and exercises, and engineered 
approaches, such as laser, sound and magnetic stimulations (Pearn et al. 2017). Most of these 
approaches have been tested in animal studies of moderate and severe TBI to model a TBI 
population with GCS < 12 who are typically enrolled in these clinical trials, with only a few to 
apply similar treatments for mTBI. 
Inflammation 
Regardless of the severity of injury, inflammation appears to be an integral part of TBI 
and hence is a popular target in preclinical treatment studies. Anti-inflammatory drugs may 
represent the largest group of therapeutics used in animal models. They include, but are not 
limited to, cytokine inhibitors, glucocorticoids, inhibitors of infiltration of the peripheral immune 
cells, and drugs with unknown anti-inflammatory mechanism such as minocycline, 
erythropoietin, resveratrol, statins and others (for review see Bergold 2016). Infiltrating 
monocytes and neutrophils are an integral part of the immune response to TBI, and their 
inhibition has been shown to suppress neuroinflammation in preclinical models  For instance, 
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blood-derived monocytes are recruited by C-C motif chemokine ligand 2 (CCL2) which binds its 
receptor CCR2 and promotes their migration to the injury site (Muessel et al. 2000). Deficiency 
in CCL2 or CCR2 has been associated with reduced inflammation and faster recovery after TBI, 
while acute administration of CCR2 antagonists in TBI models ameliorated long-term cognitive 
deficits (Semple et al. 2010; Morganti et al. 2015; Hsieh et al. 2014). Neutrophils express 
CXCR1/2 which, in a similar manner to CCR2 on monocytes, bind their respective ligand 
CXCL1/2 and migrate into the injured area of the brain. Mice deficient for CXCR1/2 show 
reduced neutrophil migration, decreased mortality and improved BBB permeability (Semple et 
al. 2010).  Minocycline, a second-generation tetracycline, has also drawn lots of attention due to 
its proven safety in humans and neuroprotective properties in several neurodegenerative 
disorders (Plane et al. 2010). In CCI models, acute and subacute administration (30min-72 h) of 
minocycline improved motor deficits, decreased lesion volume, suppressed caspase-1 activity 
and microglial activation (Sanchez Mejia et al. 2001; Vonder Haar et al. 2013). 
Fewer studies have been carried out in mTBI models, although recognition of the 
prevalence of concussive injuries in humans has begun to be reflected with more mTBI studies in 
the literature.  As some aspects of mTBI share pathological features seen in more severe models, 
drugs that have been investigated in moderate to severe TBI are now being used in mild models.  
As mentioned above, minocycline is one of these drugs that has been administered to both: 
moderate to severe TBI and mTBI.  For all TBI severity, it has shown  efficacy in damping  
microglia activation and downregulating IL-1β/ MMP-9 if administered acutely after injury (Bye 
et al. 2007; Homsi et al. 2009; Siopi et al. 2012). A prolonged 2 week treatment of mTBI rats 
with minocycline confirmed downregulation of microgliosis and amelioration of neurological 
functions but did not induce neurogenesis in the injured brain (Ng et al. 2012). Interestingly, one 
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study suggests that minocycline treatment within 9 h post TBI has prolonged positive effect on 
memory improvement up to 3 months following drug administration while other studies only 
support its acute efficacy. Another strategy that has been employed is to selectively influence the 
cytokines profile by either promoting anti-inflammatory or inhibiting pro-inflammatory 
cytokines. For instance, administration of anti-inflammatory cytokine IL-10 increases 
neurological recovery and suppresses pro-inflammatory response in FPI animal model (Knoblach 
and Faden 1998) while inhibition of TNFα in the same model decreases inflammation and 
promotes neurological recovery (Rowe et al. 2018). 
Neurogenesis  
Multiple mTBI models have reported that excitotoxicity leads to apoptosis and a decrease 
in newly proliferating cells which are usually compensated by the activation of neurogenesis and 
active cell proliferation. The use of neural stem cells (NSCs) in treatment of TBI has gain 
enormous interest over the last decade. NSCs are attractive candidates for contributing to 
restoration of brain function through repair (neuroprotection) or reconstruction (cell replacement) 
after brain trauma. The working principle is that NSCs, through their intrinsic migration to sites 
of brain inflammation, will promote an environment that fosters cellular regeneration by 
mechanisms such as delivery of growth factors, suppressing inflammation, reducing axonal 
injury, and/or by differentiating into mature neural-lineage brain cells. Pre-clinical studies 
suggest that administration of NSCs and mesenchymal (MSCs) stem cells have a positive effect 
on neurogenesis in TBI models (Hasan et al. 2017). In rats exposed to TBI, NSCs administration 
decreased apoptosis, increased expression of synaptic proteins and ameliorated neurological 
functions acutely after the injury (Pang et al. 2017; Ma et al. 2011). Interestingly, a cell-free 
secretome from human MSCs also decreased apoptosis and promoted vascular endothelial 
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growth factor (VEGF) production when administered in TBI rats (Chuang et al. 2012, 2013).  
Due to less severe neuronal loss in models of mild injury, stem cells therapies are poorly 
described in mTBI animals. One study showed that NCSs administered after mTBI express 
higher levels of survival and proliferation that in mice with severe TBI (Shindo et al. 2006). 
These mTBI mice exhibit greater expression of neurotrophic factors and lower levels of GFAP 
signal than mTBI untreated or severe TBI treated groups. Moreover, transplantation of MSCs in 
mTBI rats for 14 days results in an increased number of newly formed neurons and astrocytes 
and improved neurological functions (Anbari et al. 2014).  
Described therapeutics represent a small fraction of treatments tested in mTBI models, 
but it is worth mentioning that only few of them proceeded to the clinical trials and none, so far, 
showed successful clinical translation.  
 
1.5.3 Problems of translation 
Although an expanding number of animal studies suggest beneficial effects of multiple 
therapeutics in TBI models, clinical trials have failed to replicate these results.  So far, there is no 
available drug to treat post-TBI outcomes.  In addition to the complicated pathophysiology of the 
injured brain, significant obstacles arise from the translation of preclinical findings into clinical 
practice. Recent failures in TBI clinical trials drew lots of attention to the possible reasons 
behind these failures. They include choosing irrelevant pre-clinical models, poor experiment 
design, unjustified selection of dose/time window, low sample size and other factors. 
A lack of depth and detail in preclinical studies has been cited as a leading reason for the 
failure in clinical translation (Diaz-Arrastia et al. 2013).  There has been insufficient 
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investigation of injury heterogeneity, drug mechanism of action, target engagement, 
pharmacokinetics and pharmacodynamics, bioavailability, dosing and administration paradigms. 
One of the main criticisms is large differences in the neuroanatomical structure of small animals 
compared to humans. The most common animals used for TBI research are rodents, which are 
popular due to their availability, low cost, easy manipulation and short life-span. Rats and mice 
represent 90% of all experimental TBI research. Rodents express many human-like pathological 
patterns after TBI including acute transient primary injury and long-lasting heterogeneous 
secondary injury. Similar pathophysiology makes them an attractive model for studying 
molecular mechanisms of TBI and its correlation with cognitive performance. However, strong 
anatomical differences between rodent and human brains may lead to inaccurate replication of 
injury mechanisms. The gyrencephalic human brain contains numerous cortical folds - gyri and 
sulci. Evolutionarily, gyrification has been linked to an increased surface area to total mass ratio 
and an increased number of neurons (Sorby-Adams etal. 2018). It plays an important role in 
structural organization and functioning. Gyrencephalic brains also have a higher ratio of 
subcortical white to grey matter (Dubois et al. 2008). In cases of mTBI, the involvement of white 
matter in the injury-induced pathology is high. Particularly, the white matter is comprised of 
myelinated axons which are extremely vulnerable to mechanical impact and result in DAI. 
Moreover, mathematical models of brain heterogeneities (i.e. gyri and sulci) showed increased 
levels of the equivalent stress under loading conditions compared to homogeneous models 
(Cloots et al. 2008). In another words, gyri and sulci may lead to the stronger tissue deformation 
in gyrencephalic brain than in a lissencephalic brain. Meanwhile, the presence of the sulci 
focuses mechanical stress away from the cortical surface into the base of sulci while in a rodent 
brain stress propagates uniformly across the cortical superficial layers (Ho and Kleiven 2009). 
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Such redirection of stress is believed to be protective for the surface of cortex but increases 
abnormal pathology in the depths of the sulci. Indeed, in a CTE brain, accumulation of NFTs is 
often found in sulci , a pathology that we are unable to demonstrate in lissencephalic brain 
(McKee et al. 2009; Sorby-Adams et al. 2018). 
Another explanation of the many failures in human clinical trials is that they were based 
on preclinical studies that had poor translational relevance. In other words, the many variables 
listed above (e.g. dose, administration, paradigm, PK/PD, bioavailability, target engagement, 
outcomes and of course the potential efficacy of the treatment in question) were insufficiently 
characterized in the animal model to enable successful translation to more complex and 
heterogeneous human patient populations (Schwamm 2014). For example, the CRASH trial (the 
first large-scale human TBI trial) was based on preclinical studies that did not resemble the final 
clinical trial design. In the clinical trial, TBI patients (GCS < 14) were treated for 48 hours 
starting within 8 hours post-TBI, and their outcomes were analyzed at 6  months (Ian Roberts 
2002). Prior preclinical studies, however, had administered corticosteroid treatment immediately 
after the experimental injury (within 5 min) and analyzed neurorecovery within 1 hour (Ildan et 
al. 1995; Hall 1985).  The two unsuccessful progesterone trials again provide a good example of 
how experiment design including dosing, treatment window, and prior optimization can 
influence the final outcomes. Both Phase III progesterone trials (ProTECT III and SyNAPse) 
were based on multiple pre-clinical studies that showed only modest improvement in cognitive 
functions in TBI animals treated with the hormone (Stein 2015; Schwamm 2014). The earlier 
stage Phase II clinical studies also did not show strong therapeutic effect in the human 
population. In fact, the ProTECT Phase II trial, which treated TBI patients in the first 3 days post 
injury and evaluated their cognitive symptoms at 30 days, found that both treated and non-treated 
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patients had poor neurological outcomes (Wright et al. 2007). Similarly, a Chinese Phase II trial 
showed only modest cognitive improvements in TBI patients treated with progesterone (Xiao et 
al. 2008). Phase II data weren’t strong enough to bolster moving forward with the Phase III, but 
with no treatments available, the pressure to advance to Phase II prevailed over scientific 
method. Observations also demonstrated that 50% of placebo patients had favorable outcomes by 
the end of the trial, indicating the overall beneficial effect of medical care and attention in all 
tested subjects, which undermines the ability to separate progesterone-dependent effects (Xiao et 
al. 2008).  Although one of the aims of a Phase II trial is to identify the optimal treatment dose, 
this was not sufficiently investigated in the progesterone Phase II studies (Stein 2015).  The 
Phase II  trials varied in several parameters including dosing (0.71→0.5 mg/kg/h vs 
1→2mg/kg/day), administration routes (i.v. vs intramuscular (i.m.)) and vehicles (Intralipi vs 
camellia oil) (Schwamm 2014; Stein 2015). No consensus was formed on the optimal drug 
concentration to be used in the following trials. Consequently, instead of first optimizing the 
dosing, the Phase III trials chose the highest dose expecting to reach the maximum therapeutic 
effect. This strategy failed to demonstrate positive impact on cognition in TBI patients.  The 
problem, however, began with inappropriate translation from the preclinical studies wherein a U-
shaped dose response to progesterone was observed, with higher doses demonstrating lower 
efficacy (Goss et al.2003; Wali et al. 2014). In both studies, TBI rats underwent acute treatment 
with progesterone using three different doses - 8, 16 or 32 mg/kg.  During the behavior 
assessment, only moderate doses, 8 and 16 mg/kg, were associated with cognitive improvement 
while the highest dose did not show similar therapeutic effect.  These findings prove the lack of 
direct dose-effect correlation for individual drugs and must be accounted for when designing 
clinical trials. Another flaw of the progesterone trials was the inconsistency of the therapeutic 
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time window when compared to prior animal studies. In preclinical studies, the drug is usually 
given right after injury while in humans by necessity it will typically be delayed by at least a few 
hours (Diaz-Arrastia et al. 2013). This design fails to account for the interim period after the 
injury and before the patient seeks medical care. In fact, both progesterone trials administered the 
drug within the first 4-8 hours post TBI. This is an even greater translational problem in the case 
of mTBI as patients do not typically seek medical attention immediately after the injury due to 
the lack of gross symptoms.  
According to medical records, only 10% of all TBI victims admitted to the ER in the US 
are diagnosed with mild forms of brain trauma (Laskowitz and Grant 2016). Taking into account 
that mTBI accounts for 70-90% of all brain injuries worldwide, such rates appear to be extremely 
low (Cassidy et al. 2004).  Similarly, patients who get admitted to the ER are frequently 
misdiagnosed due to a general underestimation of mTBI by medical professionals. The GCS, 
which is the most popular assessment system, is a useful tool for differentiating moderate and 
severe forms of brain injury but is less helpful for distinguishing mTBI from non-concussed 
patients (Cappa et al. 2011).  In fact, underestimation of mTBI, both by patients and medical 
attendees, creates a void in the literature by not including a large number of mTBI cases in the 
epidemiological and clinical studies (Laskowitz and Grant 2016). One population-based study 
performed in New Zealand was aimed to identify the annual incidence of TBI nationwide and 
showed higher rates of mTBI admissions in NZ (790 per 100,000 per year) than similar studies 
from other high income regions (Europe 47-453 per 100,000 per year; North America 51-818 per 
100,000 per year) (Feigin et al. 2013). They reported that the advantage of their study was a 
thorough investigation of the overlooked diagnoses of less severe forms of injuries.  
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Due to the long-lasting consequences of TBI, the evolving pathobiology and competing 
mechanisms of neurodegeneration and neurorepair, and the heterogeneity of timing of first 
treatment, drugs that are effective in the acute phase may lose their therapeutic potential if 
administered at a delayed timepoint. A transition from primary to secondary injury results in the 
appearance and disappearance of potential drug targets. For example, glutamate release 
following primary injury leads to rapid activation of NMDA receptors and calcium overload 
whereas ongoing secondary injury produces downregulation of NMDA receptor expression  
(Guerriero et al. 2015; Mohamadpour et al. 2019). In the TBI models, NMDA antagonists were 
able to prevent calcium overload when administered within 24-72 hours post TBI (Shohami and 
Biegon 2014) while treatment with NMDA agonists at acute timepoints (8 and 16 hours post 
TBI) was not effective. Later administration of these agonists, however, improved synaptic 
plasticity and neurological functions (for review see Mohamadpour et al. 2019). A calcium 
channel blocker (CCB) ziconotide, administered in rats 15 min after TBI, improved 
mitochondrial functions while administration at 1 and 10h post TBI had no effect (Weber 2012). 
The anti-inflammatory drug minocycline also showed heterogeneous temporal effects in TBI 
models: it increased myelin content and improved spatial memory in CHI rats when administered 
at 12h and 24 h but not 72h after injury (Sangobowale et al. 2017, 2018). A recent review 
summarized 27 preclinical studies of different TBI models where treatment was administered no 
earlier than 12 hours after the injury (Mohamadpour et al. 2019). In 25 of them, the latest time of 
the initiation of treatment was 24 hours with only two extending their window up to 72 h or one 
month post-TBI. This intervention time may still not translate well to the   many human cases 
where cognitive outcomes manifest starting several months or years after TBI. Attempts to relate 
timelines seen in humans to those used in animal models is crucial for successful translation.  
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1.6 Potential therapeutics developed by The Roskamp Institute 
Identification of effective therapeutics for TBI remains a key challenge in the TBI 
research field. Despite existing attempts to suppress pathological mechanisms, none of the 
clinically tested treatments can effectively mitigate both metabolic and clinical deficits. In the 
Roskamp Institute, we have developed and characterized different mouse models of r-mTBI in 
collaboration with clinical consultants, in order to ensure that our models have translational 
relevance (described in Materials and Methods). To address the heterogeneity of human mTBI, 
we used different paradigms that varied in injury repetitiveness, age of mice and therapeutic time 
window. Through our work on AD and neuroinflammation we have characterized two drugs - 
nilvadipine and anatabine - both preclinically and clinically, which have relevance for TBI 
pathophysiology in terms of their effect on neuroinflammation, amyloid and tau. Although they 
appear to have different molecular targets, their multimodal actions on these pathobiologies have 
therefore suggested both drugs as candidate therapeutics for TBI. 
                  1.7 Hypothesis 
 
Given the current lack of any effective therapies for TBI, and the relative lack of 
investigation of any therapeutic approaches for mild TBI, my goal was to test the potential 
efficacy of two drugs previously tested at the RI: nilvadipine and anatabine. The obstacles to 
developing treatments for r-mTBI arise from the complexity of pathological mechanisms 
including their high heterogeneity and time-dependent changes. Previous studies have focused on 
targeting individual molecules involved in the pathogenesis of r-mTBI. We hypothesized that 
using drugs that influence several aspects of TBI pathobiology may reduce neurodegeneration 
and/or increase neurorepair. Therefore, in this thesis, I addressed the following aims:  1) To 
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replicate heterogeneity of human concussions by using two mouse models of r-mTBI; 2) To 
compare the effect of young vs old age in mice at the time of injury on the extent of TBI 
pathology and cognitive deficits; 3) To test two potential TBI therapeutics - nilvadipine and 
anatabine - that have demonstrated safety in humans; 4) To address the long-term consequences 
of mTBI by exploring delayed and chronic treatment paradigms; and 5) To investigate common 
therapeutic responses across these multiple approaches in order to identify viable, translational 
targets for further investigation. 
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  Chapter 2 – Investigation of the effect of acute treatment with nilvadipine in    
                       the aged hTau mice following r-mTBI 
 
2.1 Introduction 
2.1.1 Nilvadipine is a potential treatment for mTBI 
The human neuropathology of r-mTBI has many facets, which are presumed to share 
common mechanisms with neurodegenerative diseases. For example, repetitive mild TBI (r-
mTBI) and Alzheimer’s Disease (AD) share similar pathological features such as the presence of 
neurofibrillary tangles (NFTs), a marked neuroinflammatory response, and to a lesser extent, the 
presence of amyloid-β (Aβ) pathology (Tateno et al. 2015). There are currently no FDA-
approved drugs for the treatment of TBI, however the shared pathology may indicate that 
treatments tested for AD could be effective at treating the consequences of mTBI by reducing tau 
hyperphosphorylation and neuroinflammation. Unfortunately, there are no disease modifying 
treatments for AD and most strategies are targeted toward symptomatic therapy, but medical 
advancements in targeting AD pathology provide a wide range of potential therapeutic 
candidates (Weller and Budson 2018).  Our scientists have previously shown that the anti-
hypertensive drug nilvadipine can enhance Aβ clearance, decrease tau phosphorylation and 
reduce inflammation in a mouse model of AD (Paris et al. 2014).  Nilvadipine is a 
dihydropyridine (DHP) class molecule that blocks L-type calcium channels and exhibits anti-
hypertensive properties (Brogden and McTavish 1995). In preclinical studies, nilvadipine was 
first demonstrated to have neuroprotective properties in ischemic rats (Kawamura et al. 2005; 
Takakura et al. 1994). In addition to reduced apoptosis, it also improved spatial memory in 
stroke animal models (Iwasaki et al. 2003).  When tested in AD models, nilvadipine decreased 
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Aβ  production, increased Aβ clearance across the BBB and improved cognitive functions, 
whereas other DHPs such as nitrendipine and cilnidipine were less effective in reducing AD 
pathology, indicating that it is not a common class effect of the DHPs (Paris et al. 2011; 
Bachmeier et al. 2011).  Additional studies proposed an alternative target for nilvadipine action – 
through inhibition of spleen tyrosine kinase (syk) (Paris et al. 2014). In the P301S transgenic 
mice, which develop filamentous tau lesions by 6 months and neurofibrillary tangles by 9-12 
months, nilvadipine treatment resulted in the suppression of syk phosphorylation and reduced tau 
pathology (Paris et al. 2014). Further, a decrease of amyloid and tau pathology was also shown 
in P301S mice when they were treated with selective syk inhibitors (Paris et al. 2014). In two 
independent, small clinical trials, nilvadipine demonstrated therapeutic effect on cognitive 
function in hypertensive patients with mild cognitive impairment (MCI) (Hanyu et al. 2007, 
2007(2)). In the first trial, 12 amnesic MCI patients with hypertension were randomly assigned to 
either amlodipine (6) or nilvadipine (6) for 12-16 week followed by cognitive evaluation and 
SPECT imaging (Hanyu et al. 2007). Nilvadipine, but not amlodipine, improved CBF in the 
frontal lobe and ameliorated working memory. Stronger therapeutic effects of nilvadipine were 
attributed to its ability to easily cross BBB compared to amlodipine and to its alternative anti-
degenerative mechanisms. In the second study, a 20-month assessment conducted in 15 subjects 
with MCI (12 subjects from the previous study) treated with either nilvadipine or amlodipine 
showed that nilvadipine delayed clinical a progression of MCI to AD, with only 1 patient (out of 
8) been converted to AD in the nilvadipine group while 5 (out of 7) were converted in the 
amlodipine group (Hanyu et al. 2007) . 
 Given the promising preclinical data from our laboratories, and independent supporting 
clinical data, we conducted an open label Phase I/IIa clinical study (in Europe, where the drug 
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was available on prescription for hypertension) to determine the feasibility of treating AD 
patients, and we showed safety and tolerability of nilvadipine in the AD patients and no adverse 
effects on blood pressure  (Kennelly et al. 2011).  We then investigated nilvadipine in a Phase III 
randomized controlled clinical trial for AD in Europe (NILVAD) that recruited 510 mild to 
moderate AD patients for treatment with nilvadipine or placebo (Lawlor et al. 2014). After 78 
weeks of daily drug administration no differences in cognitive outcome measures were observed 
between treated and placebo groups for the entire cohort; however, when stratified according to 
baseline MMSE scores, the very mild AD cases (>=25, N=80), demonstrated a significant 
reduction in cognitive decline following treatment with nilvadipine compared to placebo (Lawlor 
et al. 2018; Abdullah et al. 2019). These encouraging data, together with our preclinical data 
demonstrating the ability of nilvadipine to suppress inflammation, amyloid and tauopathy, 
pathologies common for both AD and TBI, encouraged us to test this drug in our models of r-
mTBI. Moreover, proven safety and tolerability of nilvadipine makes it a promising candidate 
for successful translation to future TBI clinical trials. 
 
2.1.2 Rationale for using aged mice of r-mTBI 
We initially investigated the therapeutic efficacy of nilvadipine in our model of 5r-mTBI 
(5 hits, 48 h inter-concussion intervals) in aged mice that were 24-26 months old at the time of 
injury. The rationale for using very aged mice is the high incidence of mTBI in the elderly 
human population and the lack of preclinical work addressing this population. In the USA, TBI 
patients aged 65 and older have double the rate of hospitalizations compared to younger patients 
(<65yrs: 60.6 per 100,000; >65yrs: 155.9 per 100,000 (Coronado et al. 2005)), with ground falls 
and motor vehicle accidents (MVAs) as primary causes of brain trauma (Mak et al. 2012; 
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Thompson et al.  2006). Age alone is known to be associated with cognitive decline and 
dementia, but also significantly worsens mTBI-related outcomes (Bartrés-Faz et al. 2001; 
LeBlanc et al. 2006; Lee et al. 2013; Mak et al. 2012; Onyszchuk et al. 2008; Thompson et al., 
2006). Growing evidence links mTBI, and particularly r-mTBI, with neurodegenerative diseases 
such as AD (Lee et al. 2013; Tateno et al. 2015), PD (Jafari et al. 2013), ALS (McKee et al. 
2010) and CTE (Gardner and Yaffe 2015; McKee et al. 2013). Persons aged 65 and older have a 
higher probability of developing these disabilities following mTBI due to pre-existing medical 
conditions, worsened functional recovery, and excessive pathological response (Mak et al. 2012). 
Additionally, the aged population is highly susceptible to repetitive brain injuries due to age-
related deficits in motor functions, particularly balance (Lajoie and Gallagher 2004; Flanagan et 
al. 2006; Langlois et al. 2003). A single mTBI increases the probability of future falls, leading to 
repetitive concussions; and the cumulative injury effect in the elderly is thought to lead to more 
severe cognitive and pathological outcomes from similar injuries than in the young (Rothweiler, 
Temkin, and Dikmen 1998; Teo et al. 2018). Moreover, Simen and colleagues described a strong 
link between old age (>60 years old) and cognitive deficits including decline in episodic memory 
and executive functions (Simen et al., 2011).  
At the time, we had an appropriate cohort of mice aged 24-26 months old which (given 
the typical laboratory lifespan of 30 months) is thought to represent old age in humans (>64 
years old) (Dutta and Sengupta 2016). Following our 5r-mTBI or 5r-sham paradigm, we 
administered nilvadipine or vehicle for 21 days. Although our 5r-mTBI model does not 
demonstrate TBI-induced amyloid pathology in either wild type or hTau mice (Mouzon et al. 
2014, 2018, 2018 (1)), neuroinflammation is a consistent feature of this model, and TBI-
dependent effects on syk phosphorylation and tau have been reported within 15 days of injury in 
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both young and aged mice (Ferguson et al. 2017). These studies have also demonstrated that our 
models of r-mTBI induce deficits in spatial memory, motor functions, and disinhibition. Since 
such outcomes are representative of human r-mTBI and are often associated with an old age, we 
decided to measure cognitive functions in the current cohort. Moreover, understanding the 
correlation between the behavior and its underlying pathological changes is crucial to effectively 
assess the translational potential of nilvadipine.   
2.1.3 Hypothesis: 
1) Our model of 5r-mTBI will trigger neuroinflammation, tau pathology and cognitive 
deficits in the very aged (24-26 months old) hTau mice. 
2) Nilvadipine [2mg/kg] administered for 21 days will suppress TBI-induced 
pathological and neurological outcomes in the aged mice.  
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2.2 Materials and Methods 
2.2.1 Animals 
Male and female hTau mice (Jackson Laboratories (Bar Harbor, ME)) were aged at the 
Roskamp Institute until 82-106 weeks old (weight 19-32g). The animals were housed under 
standard laboratory conditions (14-hour light/10-hour dark cycle, 23±1˚C, 50±5% humidity) with 
free access to food and water. All procedures were carried out under Institutional Animal Care 
and Use Committee (IACUC) approval and in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. 
2.2.2 Experimental groups and study design 
A total of 39 mice were randomly assigned to 1 of 4 groups: sham-vehicle (n=9), sham-
nilvadipine (n=9), r-mTBI-vehicle (n=10), r-mTBI-nilvadipine (n=11). Each group included both 
male and female mice. All animals underwent anesthesia for the same duration and frequency. 
Sham animals were allowed to recover in their home cages after each anesthesia, while r-mTBI 
mice received 5 injuries over 9 days with a 48-hour inter-concussion interval, using our well-
established injury paradigm (Mouzon et al. 2012, 2014, 2017, Ojo et al. 2015; Tzekov et al. 
2014, 2016). Either nilvadipine or vehicle (PBS:PEG 1:1) were injected intraperitoneally (i.p.) 
daily for 21 days, with the first injection administered immediately following the last anesthesia 
(in 5r-sham) or the last injury (in 5r-mTBI). Behavior tests started on the second day of 
injections and included Rotarod, Barnes Maze, and Elevated Plus Maze, as shown in Figure 1. 
Euthanasia was performed on day 22 after the last injection. Brains were further analyzed by 
immunohistochemical and biochemical methods for inflammatory markers, tau, and 
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phosphorylated syk. Researchers were blind to animal group assignments during both 
neurobehavioral experiments and immunohistochemistry. 
 
 
                                                       Figure 1. Study design 
 
 
2.2.3 Injury Protocol 
R-mTBI injury was performed as previously described (Mouzon et al. 2012, 2014; 
Tzekov et al. 2014, 2016; Ojo et al. 2015). All animals were anesthetized with 1.5 L/min of 
oxygen and 3% isoflurane prior to r-mTBI or sham injury. The heads were shaved and mice were 
placed on a heating pad to maintain body temperature at 37˚C to prevent hypothermia. The head 
of each animal was fixed in a stereotaxic frame, and the blunt impactor tip (3 mm diameter) was 
positioned midway to the sagittal suture. The injury was triggered at 5 m/s velocity and 1.0 mm 
depth, with a dwell time of 200 milliseconds, using a myNeuroLab controller device (Impact 
OneTM Stereotaxic Impactor, Richmond, IL).  All mice experienced short-term apnea (<20 sec) 
and showed no skull fractures. All animals were allowed to recover from anesthesia on a heating 
pad and then returned to their cages with water and soft food access. Sham animals received 
anesthesia alone for the same duration of time as the r-mTBI mice, to control for the effects of 
repeated anesthesia. Mice were monitored daily for any abnormalities in behavior. 
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2.2.4 Treatment 
All mice received either nilvadipine or vehicle via i.p. injections for 21 days, starting 
immediately after the last injury (the first injection was administered while animals were still 
under anesthesia). The site for i.p. injection was sterilized with alcohol and was changed every 
day to avoid discomfort due to repeated injections at the same site. The treated groups received 
2mg/kg of nilvadipine dissolved in a 1:1 solution of PBS and PEG (polyethylene glycol) vehicle 
solution (Paris, Ait-Ghezala, et al. 2014). This dose is equivalent to the human dose of 8 mg that 
was prescribed in Europe conferring an antihypertensive activity. The animal equivalent dose 
(AED) was calculated using a conversion protocol based on the exponent of the body surface 
area (Km) with account for differences in metabolic rate: AED (mg/kg) = Human dose (mg/kg) x 
Km ratio = 8 mg/60kg x 12.3 ≈ 2 mg/kg (Nair and Jacob 2016). The injection volume (100µl) was 
calculated based on the average animal’s weight (0.028kg). Untreated animals underwent the 
same procedure, but received vehicle solution only (PBS:PEG/1:1). The nilvadipine and vehicle 
solutions were freshly prepared every day before the injections.  
2.2.5 Motor function assessment 
Motor function was assessed using the Rotarod apparatus, and the latency to fall from an 
accelerating rotating rod was measured. Baseline performance was recorded 1 day prior to the 
first injury/sham. Rotarod assessment started on the day after the last injury/sham procedure, and 
was carried out on days 1, 3, 5 and 7 post-last r-mTBI. An acclimation period involved 3 trials 
with a duration of 3 min each, and a 3 min rest interval in the animal’s home cage between the 
trials (velocity = 5rpm, no acceleration). The mice were placed back on the bar during the 
acclimation period if they fell. All experimental trials, including the baseline trials, lasted for 5 
min and were conducted with acceleration from 5 to 50 rpm over the 5 min period.  Each animal 
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underwent 3 trials per day, with a 3 min rest interval between each trial. The fall time of each 
mouse was recorded in seconds. To ensure that fall time would correlate with motor 
coordination, rather than purely grip strength, if a mouse clung to the bar for more than 5 
consecutive rotations on the accelerating rod without walking or making forward progress 
against the rotation of the bar, the time of the 5th rotation was considered to be the fall time and 
was recorded as such. 
2.2.6 Cognitive function assessment 
Barnes Maze (BM) was used to measure learning and short-term memory. BM was 
initiated on day 8 post-last mTBI/sham and lasted for 7 consecutive days to assess cognitive 
function. For 6 days, animals were trained to find the target hole which had a black escape box 
underneath. The walls in the room were equipped with visual cues and the brightness of the room 
was consistent throughout testing (7 days). The BM table was 1.2 meters in diameter and has 18 
equally spaced holes around the perimeter.  Every mouse had 4 acquisition trials per day, with a 
duration of 1.5 minutes each. The starting position for each trial during acquisition rotated, 
beginning at one of 4 cardinal directions of the maze and rotating, first clockwise (until reaching 
the initial position again) and then counterclockwise. If an animal did not find the target hole or 
did not go inside the box within the time limit, the mouse was guided to the target hole by hand. 
Regardless of their success, mice then spent 30 seconds in the box before returning to their cage. 
On the last day, 24 hours following the final acquisition trial, a probe trial was conducted during 
which the animals were placed in the middle of the maze and had 60 seconds to find the target 
hole, from which the escape box had been removed. The cumulative distance from the target 
hole, total distance travelled, time to find the target hole, and velocity were calculated using 
Noldus Ethovision XT software and analyzed to assess spatial memory and learning. Cumulative 
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distance is measured as the sum of the distance between the center point of the mouse and the 
center of the target hole over every sample from each trial at 30 samples per second.  This 
distance stops accumulating when the trial ends either when time has elapsed or when the mouse 
enters the target box. Data are presented as the raw values of the cumulative distance. 
2.2.7 Euthanasia  
Animals were euthanized on the day after the last injection (22 days post-last 
injury/sham). Mice were anesthetized with 3% isoflurane and perfused transcardially with 
phosphate-buffered saline (PBS), pH-7.4. After perfusion, the brains were post-fixed in a 
solution of 4% paraformaldehyde (PFA) at 4˚C for 48h and paraffin-embedded for 
immunohistochemistry.  
2.2.8 Tissue processing and immunohistochemistry 
Brain samples fixed in PFA were processed in paraffin using the Tissue-Tek VIP 
(Sakura, USA). Sagittal sections were cut at 8 µm using a Leica RM2235 microtome and 
mounted on positively charged glass slides. Prior to staining, sections were deparaffinized in 
xylene and rehydrated in ethanol solutions of decreasing concentrations. 
Non-fluorescent staining for GFAP: Following rehydration, slides were processed with 
hydrogen peroxide for 15 min and heated in the citric acid buffer (pH-6) for antigen retrieval. 
Slides were then blocked with normal goat serum, washed with PBS, and incubated in a primary 
antibody for GFAP overnight at 4˚C (GFAP7857983, Aves Labs, Inc., 1:10,000). On the next 
day, slides were processed using the anti-chicken VectaSTAIN ABC Kit and developed with 
3,3'-Diaminobenzidine (DAB) before mounting. 
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Non-fluorescent staining for Iba1: Reactive microglia were stained using an anti-Iba1 
antibody (ab107159, Abcam). After rehydration, slides were processed with hydrogen peroxide 
for 15 min followed by antigen retrieval using citric acid buffer (pH-6). Next, slides were 
blocked with rabbit serum for 1 h at room temperature and then incubated with the primary 
antibody (1:1000) overnight.  On the next day, samples were processed using the anti-goat 
VectaSTAIN ABC Kit and developed with DAB. 
Fluorescent staining for Iba1/p-tau/psyk: Fluorescent staining was performed with the 
antibodies for microglial marker Iba1 (ab107159, Abcam), phosphorylated tau at Thr231 (RZ3, 
Dr. Peter Davies) and at Ser202 (CP13, Dr. Peter Davies), and phosphorylated spleen tyrosine 
kinase psyk (Tyr525/526) (2710S, Cell Signaling). Following rehydration, antigen retrieval was 
performed by heating slides in citric acid buffer for 7 min in a microwave oven. Next, slides 
were washed with phosphate-buffered saline (PBS) and transferred to a Sudan Black solution for 
15 minutes to prevent autofluorescence. Slides were then blocked for 1 h with 10% donkey 
serum solution in PBS, and primary antibodies for Iba1 (1:300), RZ3 (1:400). CP13 (1:400) and 
psyk (1:200) were applied overnight. On the next day, secondary antibodies AlexaFluor488 
(A21202, Life Technologies), AlexaFluor568 (ab175477, Abcam), AlexaFluor 488 and 
AlexaFluor647 (A21449, Life Technologies) were applied for psyk, Iba1, RZ3 and CP13 
respectively. Slides were mounted with ProLong Gold Antifade 4',6-diamidino-2-phenylindole 
(DAPI) Mount. Each marker was stained separately except for the double staining for Iba1/psyk 
that was performed to evaluate colocalization of the two.  
 
2.2.9 Imaging 
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Imaging of non-fluorescent samples stained for GFAP/Iba1 was performed on an 
Olympus DP72 microscope at 10x magnification. Further analysis of the images included 
quantification of GFAP and Iba1 signal using ImageJ. Images were separated into individual 
color channels (hematoxylin counterstain and DAB chromogen) using the color deconvolution 
algorithm (Ruifrok and Johnston 2001). Three nonoverlapping regions of interest (ROI) of 100 
µm2 per image were then selected for the hippocampus, the body of the corpus callosum and the 
cortex (under the injury site). ROI were selected in the similar regions of the analyzed brain 
areas between the samples regardless of the obvious presence or absence of the pathological 
signal. A coverage area (%) per ROI was calculated and the mean value for each animal was 
used for further statistical analysis. 
Fluorescent imaging was carried out using a confocal microscope (LSM 800 Zeiss) at 
63x magnification. Cerebellum, hippocampus and cortex were screened to find areas of interest 
such as activated microglia, activated astroglia, p-tau and accumulation of psyk. Z-stacks were 
recorded for every image and orthogonal projections were obtained to enable a 3D representation 
of the picture.  
2.2.10 Statistical analysis 
All experimental data were analyzed using JMP 12 and GraphPad Prism 6 software. The 
data were checked for normality using Skewness-Kurtosis and Goodness of Fit. If normal, 
parametric method one-way ANOVA was applied to calculate the significance in the tested 
groups (p-values less than 0.05 were considered significant).  If significant, post-hoc analysis 
was applied using Turkey’s multiple comparison test/ Honest Significant Difference (HSD). The 
Turkey’s test compares all possible pairs of means between different treatment groups and is 
considered significant if p < 0.05. The Shapiro-Wilk test was used if data were not normally 
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distributed. All data were transformed to logarithm or square root, when required, to reach 
normality before further analysis. Repeated-measure analysis of variance (MANOVA) was used 
to analyze continuous performance of mice in the Barnes Maze and Rotarod (p<0.05 is 
significant). Error bars represent the standard error of the mean. 
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2.3 Results 
2.3.1 Behavior assessment 
 
All animals showed a decrease of the cumulative distance to the target hole over the 
course of the acquisition trials (Fig. 2A). The sham-vehicle group showed a 36% decrease from 
day 1 to day 6 while the r-mTBI-vehicle mice had a 28.5% decrease. R-mTBI-vehicle mice 
performed worse compared to the sham-vehicle over a 6-day period (p<0.05, MANOVA). 
Treatment with nilvadipine in r-mTBI mice induced a 41% decrease of the cumulative distance 
from day 1 to day 6. Nilvadipine treated r-mTBI mice had a significant decrease in cumulative 
distance compared to the vehicle-treated r-mTBI mice (p<0.001, MANOVA). The performance 
of sham-vehicle and sham-nilvadipine mice were not different from each other (p>0.5, 
MANOVA). Distance traveled was decreased in all groups for at least 21% between days 1-6, 
however there was no differences in the extent of this decrease between the groups (Fig.2 B).  
The mean latency to enter the target box was only significantly decreased (18.6%) in r-
mTBI-nilvadipine mice from day 1 to day 6 but not in the other groups (Fig.2 C).  This decrease 
was significantly different from the r-mTBI-vehicle mice (day 6 of acquisition: r-mTBI-
nilvadipine 69.7 sec vs r-mTBI-vehicle 87.3, p < 0.001, one-way ANOVA). Surprisingly, we did 
not see any difference in latency to enter target box between groups on day 4. Behavioral testing 
data is inherently noisy and typically requires large n numbers to achieve statistical significance, 
thus the lack of an effect on latency during an individual day should not be interpreted as a lack 
of an overall effect during testing. Unexpectedly, probe data showed no difference in spatial 
memory between sham-vehicle, sham-nilvadipine and 5r-mTBI-vehicle groups (p>0.05, one-way 
ANOVA) (Fig. 2D). However, 5r-mTBI-nilvadipine mice showed significant improvements in 
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finding the target hole compared to r-mTBI-vehicle animals (p<0.05, one-way ANOVA). Injured 
mice treated with nilvadipine required less time overall (mean = 13.75 ± 6.9 s) to locate the 
target hole within the trial compared to other groups: r-mTBI-vehicle = 38.27 ± 4.4 s, sham-
vehicle = 26.87 ± 5 s, sham-nilvadipine = 20.51 ± 8.4 s. There was no significant effect of 
nilvadipine treatment on motor function or anxiety level as measured by Rotarod and EPM 
(Fig.2E, F). 
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Figure 2. Behavior evaluation. Assessment of learning and spatial memory at 7 days post-last 
mTBI using Barnes Maze (A-D). Acquisition data shows a learning trend in mice by the mean 
cumulative distance to the target hole in cm (A) and the mean time spent to enter the target hole 
in seconds (C). There was no difference between the groups in the distance traveled (B). R-
mTBI-Nilvadipine mice performed better than r-mTBI-vehicle group (cumulative distance 
p<0.01, MANOVA; mean time: day 2 p<0.05, day 3 p<0.01, day 5 p<0.05, day 6 p<0.001, one-
way ANOVA). Probe data shows spatial memory by the mean time to locate the target hole (sec) 
after 6-day training (D). r-mTBI-Nilvadipine group also performed better than r-mTBI-vehicle 
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mice (p<0.05, one-way ANOVA). No significant differences were observed between r-mTBI-
vehicle and r-mTBI-Nilvadipine groups for motor functions (E) and disinhibition behavior (F).  
 
 2.3.2 Immunohistochemistry 
 
For mice subjected to r-mTBI, immunostaining for GFAP revealed evidence of a severe 
reactive astrogliosis in the corpus callosum (percent area: r-mTBI-vehicle 9.03% ± 1.05 vs sham-
vehicle 5.01% ± 1.2, p<0.05, one-way ANOVA with post-hoc Turkey’s test) and in the region of 
the cortex surrounding the injury site (percent area: r-mTBI-vehicle 4.02% ± 2.09 vs sham-
vehicle 0.08% ± 0.09, p<0.001, one-way ANOVA with post-hoc Turkey’s test) (Fig.3). After 21 
days, significantly decreased GFAP immunoreactivity was observed in the corpus callosum (r-
mTBI-nilvadipine 6.3% ± 1.3 vs r-mTBI-vehicle 9.03% ± 3.2; p<0.01, one-way ANOVA with 
post-hoc Turkey’s test) of nilvadipine r-mTBI versus vehicle r-mTBI mice. Treatment with 
nilvadipine also decreased GFAP immunoreactivity in cortex of r-mTBI mice (r-mTBI-
nilvadipine 1.75% ± 0.31 vs r-mTBI-vehicle 4.02% ± 2.09; p<0.05, one-way ANOVA with post-
hoc Turkey’s test). 
A similar response was detected with anti-Iba1 staining, which indicated excessive TBI-
dependent microgliosis in the corpus callosum (percent area: r-mTBI-vehicle 7.02% ± 2.2 vs 
sham-vehicle 3.06% ± 0.7, p<0.0001, one-way ANOVA with post-hoc Turkey’s test) and 
successful mitigation of this astrogliosis after treatment with nilvadipine (percent area: r-mTBI-
vehicle 7.02% ± 2.2 vs r-mTBI-nilvadipine 3.1% ± 2.5, p<0.05, one-way ANOVA with post-hoc 
Turkey’s test) (Fig. 4). No difference between the groups was observed for Iba1 in cortex (Fig. 4 
C). 
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Figure 3. Evaluation of the effect of nilvadipine after r-mTBI on astrocytes (GFAP) at 22 days 
post-r-mTBI in the corpus callosum (CC) and cortex. A – representative images (10x) of the 
GFAP staining in the CC in different treatment groups show excessive gliosis after r-mTBI 
which was reduced by nilvadipine. In cortex, r-mTBI caused an increase in GFAP 
immunoreactivity surrounding the injury site (p<0.001) which was attenuated by nilvadipine 
(p<0.05).  Quantitative analysis of GFAP staining in three 100µm2 fields of the CC (B) and 
cortex (C) at 22 days post-injury confirms injury-induced glial activation in the CC (p<0.05) and 
cortex (p<0.001) and a nilvadipine-dependent decrease of GFAP. Scale bars equal 100 µm for 
CC and 50 µm for cortex images. Data are presented as mean ± standard error of the mean; 
significance is calculated using one-way ANOVA with post-hoc Turkey’s test. 
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Figure 4. Evaluation of the effect of nilvadipine after r-mTBI on microglial population (Iba1) at 
22 days post-r-mTBI in CC and cortex: A - representative images (20x) of the Iba1 staining in 
the CC revealed increased microglial activation after r-mTBI and a reduction of Iba1 
immunoreactivity by nilvadipine. No difference in Iba1 was detected for cortex (p>0.05) (A, C). 
Quantitative analysis of Iba1 staining in three 100µm2 fields of the CC (B) at 22 days post-injury 
confirms the injury-induced (p<0.0001) and nilvadipine-induced (p<0.001) changes in glial 
response in CC. Scale bars equal 50 µm. Data are presented as mean ± standard error of the 
mean; significance is calculated using one-way ANOVA with post-hoc Turkey’s test. 
 
Tau phosphorylation at Thr231 and Ser202 is prominent in hTau mice and leads to an 
impaired tau-microtubules binding, which was shown to be increased in our r-mTBI model 
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(Mouzon et al. 2012, 2014, Ojo et al. 2013). Hence, the antibodies for these epitopes, RZ3 
(Thr231) and CP13 (Ser202), were chosen for IHC in the current study. Fluorescent IHC for 
phospho-tau Thr231 (RZ3) revealed no significant injury effect in the CA1 area of hippocampus 
(p>0.05, one-way ANOVA with post-hoc Turkey’s test) but there was an increase of RZ3 signal 
in cortex (p<0.05, one-way ANOVA with post-hoc Turkey’s test) (Fig. 5). Despite the lack of 
the injury effect in CA1, quantitative analysis of the signal intensity confirms the reduction of 
RZ3 by 50% in r-mTBI-nilvadipine (1,564% ± 107.6) vs r-mTBI-vehicle mice (3,715% ± 430) 
(Fig.5 B; p<0.05, one-way ANOVA with post-hoc Turkey’s test). Treatment with nilvadipine 
also decreased immunoreactivity for RZ3 in cortex (Fig. 5 C; p<0.05, one-way ANOVA with 
post-hoc Turkey’s test). However, no difference between the groups was detected for phospho-
tau Ser202 (CP13, by Dr. Peter Davis) in hippocampus or cortex (Fig.5D, E). 
 
94 
 
Figure 5. Evaluation of the effect of nilvadipine on RZ3 immunofluorescence in CA1 and cortex. 
A - IHC shows a trend of increased RZ3 immunoreactivity after r-mTBI in both CA1 and cortex. 
Quantitative analysis of the % intensity in the CA1 shows that RZ3 intensity is slightly increased 
in r-mTBI-vehicle vs sham-vehicle mice but not significant (p>0.05). C - In cortex, RZ3 is 
increased in the r-mTBI-vehicle mice compared to the sham-vehicle. Nilvadipine reduces RZ3 
fluorescent intensity in the CA1 by 50% (p<0.001) and in cortex by 30% (p<0.05). Scale bars 
equal 50 µm. No difference was shown between the groups for CP13 in CA1 (D) and cortex (E). 
Data are presented as mean ± standard error of the mean; significance is calculated using one-
way ANOVA with post-hoc Turkey’s test.  
 
Injured mice also demonstrated the presence of activated (phosphorylated) syk compared 
to the sham-vehicle group. Qualitative analysis revealed accumulation of psyk in certain sections 
of corpus callosum, but not uniformly across the brain. However, in these sections, psyk was 
colocalized with reactive microglia (Iba1), indicating a strong link with neuroinflammation (Fig. 
6). Treatment with nilvadipine ameliorated psyk and Iba1 in the r-mTBI mice. 
Figure 6. Evaluation of the effect of nilvadipine on psyk. A -Immunofluorescent staining of the 
corpus callosum with DAPI, Iba1 and psyk revealed an increased activity of psyk in the r-mTBI-
vehicle brains (white arrow). Upon treatment with nilvadipine, psyk signal was decreased to sham 
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levels (white arrow). B - Fluorescent immunohistochemistry for psyk/Iba1/DAPI revealed a 
colocalization of psyk and Iba1, indicating a strong link between activated syk and 
neuroinflammation. Mitigation of the psyk signal was correlated with decreased Iba1. Scale bars 
equal 10µm.  
 
2.4 DISCUSSION 
The effect of traumatic brain injury on aged animals and the ability of the aged brain to 
respond to the injury is remarkably understudied. Age is known to slow neurorehabilitation and 
prolong inflammation, which can worsen the pathogenesis of mTBI, exacerbate cognitive 
impairments, and increase the probability of developing dementia (Bartrés-Faz et al. 2001; 
Bernhardi et al. 2015; Hebert et al. 2003; Primiani et al. 2014). Our previous studies showed that 
the anti-hypertensive dihydropyridine, nilvadipine, is a syk inhibitor which can decrease 
neuroinflammation and amyloid pathology in the PSAPP transgenic mouse model of AD, and tau 
phosphorylation in the P301S mouse model of tauopathy (Paris et al. 2014). Here, we tested the 
effects of nilvadipine in hTau mice with r-mTBI to assess its effect on pathological and cognitive 
outcomes post-injury.  
With regard to the neuropathological findings, consistent with our previous work using 
this 5r-mTBI paradigm, we observed increased GFAP and Iba1 immunoreactivity in the corpus 
callosum and in the area of the cortex beneath the impact site, even in these significantly aged 
mice.  Our previous studies, wherein we have injured mice ranging from 3 to 18 months old,  
have demonstrated robust 5r-mTBI-dependent neuroinflammation regardless of the age of the 
mice at the time of injury (Ojo et al. 2013; Lynch et al. 2016; Mouzon et al. 2014, 2018; 
Ferguson et al. 2017). Both, young and aged groups of injured mice are characterized by reactive 
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astrogliosis and microgliosis in the corpus callosum, hippocampus and cortex. Our data confirm 
the persistence of TBI consequences over the lifespan of mice injured young, and despite the 
inherent age-dependent increases in neuroinflammation an injury effect is evident even in very 
aged mice. However, we did not observe any significant increase in tau phosphorylation 
following r-mTBI.  Previous findings showing that tau phosphorylation increases with age in 
hTau sham animals (Andorfer et al. 2003; Polydoro et al. 2009; Ojo et al. 2013) are corroborated 
by our recent study which showed an overall increase of phosphorylated tau in aged (12 months 
old) when compared to our previously-studied young (3 months old) hTau mice (Ferguson et al. 
2017). Thus, we hypothesize that the age-dependent increases in tau pathology may be obscuring 
any additional increases due to r-mTBI.  
Regarding behavioral data, we did not detect an injury effect on motor function or 
anxiety-like behavior, and only a minor effect on spatial memory, which is likely due to the 
much older age of the animals at the time of injury in this study compared to our previous work.  
Our previous studies with the same injury paradigm in younger animals, aged between 3 and 12 
months old at the time of injury, resulted in memory impairment after 5r-mTBI (Mouzon et al. 
2012, 2014; Ferguson et al. 2017). However, our previous data also show that in mice injured at 
a young age (2-3 months) cognitive deficits are less apparent over time, particularly when a year 
or more has elapsed post-injury (Mouzon et al. 2014, 2018; Ferguson et al. 2017). Thus, aging 
plays a confounding role in the baseline behavioral levels, so it obscures the effects of injury. 
Few studies have investigated the effects of r-mTBI on aged mice, and this study is the first to 
utilize this 5r-mTBI paradigm in such old mice. We propose that the advanced age of these 
animals causes detrimental deficits resulting in a “ceiling effect” that prevents a clear 
differentiation between age and injury-dependent deficits. In support of this hypothesis, studies 
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of hTau vs WT mice have shown that the hTau mice develop age-dependent memory deficits, 
not present at 4 months, but evident by 12 months of age (Polydoro et al. 2009; Yin et al. 2016). 
The characteristics of hTau mice aged 24 months have not previously been reported, but we 
would reasonably conclude that such mice would have dramatically impaired cognitive 
performance. Indeed, even in comparing sham mice across our studies we observed decreased 
performance in cognitive tasks with age; e.g. in our study of hTau mice aged 3 or 12 months, 
cognitive performance was diminished in the older versus young sham animals (Ferguson et al. 
2017); while in cohorts of wild type mice aged to 27 months, we saw a progressive worsening of 
memory throughout life (Mouzon et al. 2018). Thus, the age-dependent pathology underlying 
spatial memory (not specifically investigated here) appears sufficient to mask any additional 
effects of injury. 
Simen and colleagues reviewed a plethora of clinical and preclinical studies utilizing 
monkeys, rats and mice, and confirmed a decrease in episodic memory and other cognitive 
functions with age across species (Simen et al. 2011). These changes are believed to be 
associated with, but not limited to, age-dependent neuroinflammation (Barrientos et al. 2009; 
Gemma et al. 2005; Wan et al. 2007), demyelination (Vanguilder et al. 2012), impairment of 
synaptic receptors (Pagnussat et al. 2015), and increase of Ca2+ in the hippocampus (Foster 
2012). Such a diverse spectrum of age-related pathology will require much more work to 
understand any compounding effects of r-mTBI in the elderly.  Nevertheless, our model 
demonstrates a clear TBI-dependent neuroinflammatory response, and although we do not 
observe increased tau phosphorylation or increased cognitive deficits following TBI, nilvadipine 
treatment resulted in significant improvement in all three of these domains. Nilvadipine 
significantly decreased neuroinflammation in the corpus callosum and cortex, as shown by lower 
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levels of astrogliosis and microgliosis. Moreover, psyk accumulation was colocalized with 
activated microglia in the corpus callosum in the 5r-mTBI-vehicle mice, and nilvadipine 
treatment reduced both, psyk and Iba1 signals, to the sham levels.  The neurobehavioral deficits 
in the mice correlate with tau phosphorylation, but nilvadipine did not have a significant effect 
on cognitive performance in the sham mice, which exhibited similarly high levels of tau 
phosphorylation. Thus, it seems that the inflamed post-r-mTBI environment was necessary for 
nilvadipine to exhibit therapeutic properties.  As mentioned previously, the spleen tyrosine 
kinase regulates neuroinflammation through NFkB activity, and also phosphorylates tau directly 
at Tyr18 (Paris et al. 2014).  Nilvadipine inhibits syk, and this also activates PKA which 
phosphorylates Ser9 of GSK3β, thereby inactivating this potent tau kinase.  The syk inhibitory 
properties of nilvadipine have been previously demonstrated in mouse models of AD and 
tauopathies (Paris et al. 2014), but more work is required to confirm that this is the mechanism 
through which it elicits the favorable responses described in this study.  Nilvadipine is also an L-
type Ca2+ channel blocker (Peters et al.2015) and similar compounds have been investigated in 
TBI clinical trials (albeit these were more severe TBI cases) with very confounding results (G.-Z. 
Xu et al. 2013). We have previously shown efficacy of the non-blood-pressure-lowering 
enantiomer of nilvadipine ((-)-nilvadipine) in the controlled cortical impact mouse model of TBI 
(Ferguson, pers. comm).  Given the positive results from nilvadipine treatment in this study in 
aged mice, determining whether or not this enantiomer has potency in this mild TBI model was 
among the studies we next planned, in order to elucidate the mechanism of action and pursue 
nilvadipine’s potential as a therapeutic for repetitive mild traumatic brain injury. In addition, we 
of course wanted to repeat the study with younger hTau mice, not only to address another age 
group at significant risk for TBI in humans (young adults) but also to determine the role of aging 
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in r-mTBI pathology and treatment. Chapter 3 details the effects of both nilvadipine treatment 
and (-)-nilvadipine treatment in an identical study carried out in 2-3 month old hTau mice. 
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Chapter 3 – Investigation of the effect of treatment with nilvadipine and selective         
                     syk inhibitor in the young hTau mice following r-mTBI 
 
3.1 Introduction 
In the previous chapter we described a study in which 24-26-month old hTau mice were 
exposed to 5r-mTBI or 5r-sham, followed by a 3-week treatment with the drug nilvadipine (or 
vehicle control). Nilvadipine attenuated inflammation, tau phosphorylation and cognitive decline 
in aged hTau mice (Morin et al. 2018). Our data suggest that nilvadipine may represent a 
potential drug for TBI, however further work was required to address the effects of nilvadipine in 
young mice and to investigate the contributory role of the antihypertensive (calcium channel 
blocking) properties of nilvadipine. Below, we discuss the importance of these aspects and 
introduce an additional study to overcome these limitations. 
 
3.1.1 TBI in the aged and young brain 
Evidence of age effect on TBI outcomes in humans 
Multiple clinical and preclinical studies have shown that age influences TBI pathology 
and that the same severity of injury may lead to different outcomes in the young and the elderly. 
For example, one study in Taiwan analyzed medical records of 2081 adults (aged 20-64 or >65 
years old) diagnosed with moderate-severe TBI between 2009 and 2016, and found that older 
age was associated with higher GCS among individuals who received similar types of injuries 
(Rau et al. 2017). Several clinical studies (listed below) compared pathological markers of TBI, 
such as  S100β, GFAP and tau in populations of different ages and reported a stronger signal for 
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these markers in older individuals versus in comparably injured younger individuals. One such 
study conducted a gene profiling of blood in TBI victims younger than 35 or over 60 years old at 
the time of injury and showed an increase in calcium binding proteins and a decrease in growth 
factors, both linked to poor recovery, in the older but not younger individuals (Cho et al. 2016). 
Another study demonstrated a significant increase of S100β in plasma within 3 h after mTBI in 
individuals >65 years old but not in their younger counterparts <65 years old (Calcagnile et al. 
2013). These studies highlight that the aged brain appears to have a higher vulnerability to TBI 
which results in a more severe response than would occur for the same level of injury in a 
younger brain. However, a separate study by Gardner and colleagues recently suggested that 
strong age-related pathology in a healthy aged brain may mask TBI effects (Gardner et al. 2018). 
In this study, plasma levels of p-tau, total tau and GFAP were evaluated in mTBI patients and 
controls and stratified into three different age groups based on the age at injury (< 40, 40-60, >60 
years old). The results indicated that p-tau and GFAP were able to discriminate between mTBI 
and control in the young and middle-aged groups, but they had a decreasing accuracy in 
differentiating mTBI from control groups in the >60 cohort. The authors also reported that 
healthy individuals showed age-dependent increases in p-tau, but not in GFAP, which may be 
due to normal aging (patients with dementia were excluded from the enrollment, hence p-tau 
baseline signal was less likely to be associated with neurodegenerative conditions). This 
observation is supported by our previous study of 24-26-months old r-mTBI mice where baseline 
levels of p-tau were high enough to mask TBI effect (Morin et al. 2018). 
Evidence of an age effect in animal models of TBI 
Several animal models of mTBI have been developed to study the pathological and 
behavioral consequences of TBI, but only a few have addressed age-related variables such as 
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chronological age, age at injury and time since injury (Calcagnile et al.,  2013; Cheng et al., 
2018; Ferguson et al., 2016; Mouzon et al., 2018). To date, the preclinical studies that address 
how age at injury influences mTBI provide contradictory results. Cheng et al. compared mice 
(WT and PSAPP) that received two mTBI using CHIMERA at the age of 6 or 13 months (Cheng 
et al. 2018). Age at injury in both WT and PSAPP mice did not alter behavioral response 14 days 
post mTBI. Inflammation was increased in old WT mice after injury but decreased in old PSAPP 
mice compared to their young counterparts. Axonal injury was found in both strains of mice at 
young age but not in aged animals. Another study compared WT mice subjected to r-mTBI at 5 
weeks or 4 months of age and found that r-mTBI exacerbated cognitive functions and 
inflammation in a similar manner between the groups (Mannix et al. 2017). In our previous 
work, using the 5r-mTBI model, we explored the influence of age at injury (young [3 months] 
and aged [12 months]) on behavioral and pathological outcomes in hTau mice (Ferguson et al., 
2017; Mouzon et al., 2018). At 24h and 15d post injury, the TBI-dependent increases of Iba1, 
GFAP and p-tau (RZ3, CP13) were similar between the young and old mice. However, the 
younger animals showed greater APP signal in TBI vs controls at 24 h compared to aged mice, 
while the aged animals had a higher phospho-tau at Ser396/404 (PHF-1) at 15 days. 
Interestingly, young mice (both males and females) exhibited deficits in spatial memory but not 
in motor coordination. In the aged group, female, but not male, mice showed TBI-induced motor 
and memory impairments, indicating possible age-dependent effect of sex on outcomes in this 
model of TBI.  Most studies that have explored age as a variable have provided evidence that 
TBI induced detrimental changes in older rodents when compared to their young counterparts.  
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3.1.2 Hypotensive properties of nilvadipine 
 Previously, we did not account for the potential effect of the alternative mechanisms 
targeted by nilvadipine, namely its calcium channel blocking potential (hence its use as an 
antihypertensive drug) (Peters et al.2015). In one of our former studies, we treated 13-month old 
Tg APPsw mice, which mimic AD-like pathology including reduced cerebral blood flow (CBF), 
with nilvadipine (1mg/kg) daily for 15 days, and they demonstrated an increase in CBF 
compared to the vehicle treated mice (Paris et al. 2004). Thus, the positive effects of nilvadipine 
treatment could, at least in part, result from its cerebrovascular influence and resulting increased 
cerebral blood flow.  Interestingly, nilvadipine is a racemate, and the vasoactive properties are 
due to the (+) enantiomer, with the (-) enantiomer showing no vasoactivity (Tokuma and 
Noguchi 1995; Paris, Ait-Ghezala, et al. 2014).   In a previous study, (-)-nilvadipine 
administered to transgenic P301S mice for 4 consecutive days inhibited syk phosphorylation, 
decreased p-tau and Aβ pathology, and resolved cognitive deficits (Paris, Ait-Ghezala, et al. 
2014). Therefore, in these current studies, having seen the positive effects of the racemate in 
aged mice with TBI (Chapter 2), we also included treatment with the non-vasoactive (-)–
nilvadipine enantiomer (internal reference name ARC031) to investigate whether treatment 
effects on TBI outcomes required the vascular effects of racemic nilvadipine.  
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3.1.3 Hypothesis 
1) 5r-mTBI will cause more distinctive cognitive and pathological impairments in the 
young mice, compared to the aged mice described in chapter 2, due to the lack of age-
driven deteriorations which may have masked the response to injury. 
2) Nilvadipine administered in the young 5r-mTBI mice for 21 days (recapitulating the 
treatment paradigm in Chapter 2) will attenuate injury-dependent behavioral and 
pathological changes. 
3) Treatment with non-vasoactive (-)-nilvadipine will mitigate TBI-induced outcomes in 
a similar manner as the racemic nilvadipine due to the inhibition of syk. 
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 3.2 Methods and Materials 
  3.2.1 Animals 
Male and female hTau mice 12-14 weeks old (weight 19-25g) were sourced from Jackson 
Laboratories (Bar Harbor, ME). The animals were housed under standard laboratory conditions 
(14-hour light/10-hour dark cycle, 23±1˚C, 50±5% humidity) with free access to food and water. 
All procedures were carried out under Institutional Animal Care and Use Committee (IACUC) 
approval and in accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
3.2.2 Experimental groups and study design 
A total of 72 mice were randomly assigned to 1 of 6 groups (n=12 per group): repetitive 
sham/vehicle, repetitive sham/nilvadipine, repetitive sham/ARC031, repetitive injury/vehicle, 
repetitive injury/nilvadipine and repetitive injury/ARC031. The r-mTBI (total of 5 hits with an 
inter-concussion interval of 48h) was administrated to mice as previously described in Chapter 2. 
Sham injured animals (5 anesthesia, 48h apart) underwent the same procedures and were 
exposed to anesthesia for the same length of time as the mTBI animals. Either nilvadipine, 
ARC031 or vehicle (PBS:PEG 1:1) were injected intraperitoneally (100 µl, i.p.) daily for 21 
days, with the first injection administered immediately following the last injury. The behavior 
analysis began 24h after the last mTBI/anesthesia for each group, as shown in Figure 7. 
Euthanasia was performed 22 days after the last mTBI/sham procedure. Researchers were blind 
to animal group assignments during both neurobehavioral experiments and 
immunohistochemistry. Data from the previous study (Morin et al. 2018), where aged mice (24-
26 months old) underwent the same procedures, were used to compare the effect of age. 
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Figure 7. Study design 
 
3.2.3 Injury Protocol 
R-mTBI injury was performed as previously described (Mouzon et al. 2012, 2014; 
Tzekov et al. 2014, 2016; Ojo et al. 2015). All animals were anesthetized with 1.5 L/min of 
oxygen and 3% isoflurane prior to r-mTBI or sham injury. The heads were shaved and mice were 
placed on a heating pad to maintain body temperature at 37˚C to prevent hypothermia. The head 
of each animal was fixed in a stereotaxic frame, and the blunt impactor tip (3 mm diameter) was 
positioned midway to the sagittal suture. The injury was triggered at 5 m/s velocity and 1.0 mm 
depth, with a dwell time of 200 milliseconds, using a myNeuroLab controller device (Impact 
OneTM Stereotaxic Impactor, Richmond, IL).  All mice experienced short-term apnea (<20 sec) 
and showed no skull fractures. All animals were allowed to recover from anesthesia on a heating 
pad and then returned to their cages with water and soft food access. Sham animals received 
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anesthesia alone for the same duration of time as the r-mTBI mice, to control for the effects of 
repeated anesthesia. Mice were monitored daily for any abnormalities in behavior. 
3.2.4 Treatment 
All mice received either nilvadipine, ARC031 or vehicle via i.p. injections for 21 days, 
starting immediately after the last injury/sham (the first injection was administered while animals 
were still under anesthesia). The treated groups received 2mg/kg nilvadipine (equivalent to 
human dose 8 mg conferring antihypertensive activity) or 2mg/kg ARC031 dissolved in a 1:1 
solution of PBS and PEG (polyethylene glycol) vehicle solution (Paris, Ait-Ghezala, et al. 2014). 
The animal equivalent dose (AED) was calculated using a conversion protocol based on the 
exponent of the body surface area (Km) with account for differences in metabolic rate: AED 
(mg/kg) = Human dose (mg/kg) x Km ratio = 8 mg/60kg x 12.3 ≈ 2 mg/kg (Nair and Jacob 2016). 
The injection volume (100µl) was calculated based on the average animal’s weight (0.028kg). 
Untreated animals underwent the same procedure, but received vehicle solution only 
(PBS:PEG/1:1). All solutions were freshly prepared every day before the injections.  
3.2.5 Motor and cognitive functions assessment  
Motor function was assessed using the Rotarod apparatus by monitoring the time a mouse 
could remain on an accelerating rod in the same manner we described previously in Chapter 2. 
Learning and spatial memory were evaluated by monitoring the distance and time taken to find 
an escape hole over a period of 6 training day (learning) and a final probe trial (memory) in the 
same manner we described in Chapter 2.  
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3.2.6 Tissue collection and processing 
Twenty-two days after their last injury/anesthesia all animals were anesthetized with 3% 
isoflurane and perfused transcardially with phosphate-buffered saline (PBS), pH-7.4. For each 
mouse, after perfusion, one hemisphere was frozen and the other was blocked and processed as 
previously described in Chapter 2. 
3.2.7 Immunohistochemistry  
Immunohistochemistry for GFAP, Iba1 was carried out as described in Chapter 2. 
Imaging of non-fluorescent samples stained for GFAP/Iba1 was performed on an Olympus DP72 
microscope at 10x magnification. 
3.2.8 Fluorescent staining 
GFAP/Iba1/RZ3/psyk: Fluorescent staining was performed as described in Chapter 2 
using the following antibodies: Iba1 (ab107159, Abcam), GFAP (7857983, Aves Labs), 
phosphorylated tau at Thr231 (RZ3) (generously provided by Dr. Peter Davis, The Feinstein 
Institute for Medical Research, Bronx, NY) and phosphorylated spleen tyrosine kinase psyk 
(Tyr525/526) (2710S, Cell Signaling). Fluorescent imaging was performed using a confocal 
microscope (LSM 800 Zeiss) at 63x magnification. Z-stacks were recorded for every image and 
orthogonal projections were obtained to enable a 3D representation of the picture. (For 
immunofluorescent comparison between the young and aged mice, we used samples from the 
older animals described in Chapter 2). 
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3.2.9 Immunohistochemical quantification 
Immunoreactivity for cell markers was measured by quantitative optical segmentation as 
previously described in Chapter 2. Three nonoverlapping regions of interest (ROI) of 100 µm2 
per image were then selected for the hippocampus, the body of the corpus callosum and the 
cortex. ROI were selected in the similar regions of the analyzed brain areas between the samples 
regardless of the obvious presence or absence of the pathological signal. A coverage area (%) per 
ROI was calculated and the mean value for each animal was used for further statistical analysis. 
3.2.10 MesoScale Discovery (MSD) Multi-Spot Assay 
A cytokine profile was assessed in cortical mouse homogenates using the MSD 
Proinflammatory Panel 1 (mouse) kit (V-PLEX K15048D). Cortical homogenates were prepared 
by adding 500µl of M-PER solution which contained 1% EDTA and 1% of protease/phosphatase 
inhibitors cocktail. Then, samples were sonicated and centrifuged at 10,000 rpm (4˚C) for 10 min 
and the supernatant was separated for further analysis. First, the calibration solution Diluent41 
was prepared according to the kit protocol. Samples and controls were diluted 2-fold in 
Diluent41. Then, a combined detection antibody solution was prepared by mixing each antibody 
5-fold with Diluent45. The plate was thoroughly washed 3 times with Wash Buffer and loaded 
with samples (50 µL/well) followed by a 2 h incubation at the room temperature. Then, the plate 
was washed 3 times and detection antibody solution was added to samples at 25 µL/well. After a 
2 h incubation, the plate was washed again with Wash Buffer and 2X Read Buffer T was added 
at a concentration 150 µL/well followed by the plate analysis on the MSD instrument (MESO 
Quick Plex SQ120). 
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A Tau profile was assessed using a similar MSD protocol using the Phospho 
(Thr231)/Total Tau kit (V-PLEX K15121D) following manufacturer’s instructions. Briefly, the 
plate was blocked with Blocker A for 1h followed by adding the samples and calibrators into the 
wells. After 1h of incubation, the plate was incubated for 1h with detection antibodies and the 
Read Buffer T was added to analyze the plate. The plate was washed with the Wash Buffer after 
each step.  
(Both cytokine and tau analyses, performed by the MSD platform, included the cortical 
tissue from the aged mice (24-26 months old) from the previous study described in Chapter 2, on 
which MSD ELISA had not previously been performed. Samples from young and aged mice 
underwent MSD protocol manipulations at the same time). 
3.2.11 Statistical analysis 
All experimental data were analyzed using JMP 12 and PRISM Software. The data were 
checked for normality using Skewness-Kurtosis and Goodness of Fit. If normal, parametric 
methods (t-test and one-way ANOVA) were applied to calculate the significance between 
different experimental groups (p<0.05 were considered significant). The Shapiro-Wilk test was 
used if data were not normally distributed. All data were transformed to logarithm or square root, 
when required, to reach normality before further analysis. Repeated-measure analysis of variance 
(MANOVA) was used to analyze continuous performance of mice in the Barnes Maze and 
Rotarod (p<0.05 is significant). Error bars represent the standard error of the mean. 
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3.3 Results 
  3.3.1 Motor assessment 
Motor functions were assessed using Rotarod on days 1, 3, 5 and 7 post-last TBI. Overall, 
all mice except the r-mTBI-vehicle group exhibited at least 40% increase in latency to fall over a 
7-day period (Fig.8 A). R-mTBI-vehicle mice did not demonstrate improvement in their 
performance when compared to the baseline. Nilvadipine treatment in the injured mice 
ameliorated their motor deficits to levels not significantly different from sham mice, without 
affecting the behavior in healthy sham mice (r-mTBI-vehicle vs sham-vehicle p<0.0001, r-
mTBI-nilvadipine vs r-mTBI-vehicle p< 0.001, sham-nilvadipine vs sham-vehicle p>0.05, r-
mTBI-nilvadipine vs sham-vehicle p>0.05, MANOVA). Treatment with ARC031 did not show 
any therapeutic effect in the r-mTBI mice (Fig.8 B, p>0.05, MANOVA). 
 
Figure 8. Evaluation of the effect of nilvadipine or ARC031 on motor performance. (A,B) Mice 
in the r-mTBI-vehicle group showed a significant decrease in their performance compared to the 
sham-vehicle (p < 0.001, MANOVA). (A) Treatment with nilvadipine ameliorated motor deficits 
in the r-mTBI mice (r-mTBI-Nilvadipine vs r-mTBI-vehicle, p<0.001, MANOVA). (B) In r-
mTBI mice treated with ARC031, no differences were observed in the latencies compared to the 
r-mTBI-vehicle (p>0.05, MANOVA).  
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3.3.2 Memory assessment   
Short-term memory was assessed using Barnes Maze during days 8-14 post last TBI and 
the probe trial was recorded on day 15. Sham-vehicle mice demonstrated a 83% decrease of the 
cumulative distance and a 71% decrease in the distance traveled from day 1 to 6 (Fig.9 A, B). R-
mTBI vehicle mice exhibited a 25% reduction of the cumulative distance during days 1-3 which 
reached plateau on days 4-6 (r-mTBI-vehicle: day1 vs day 6 p<0.05, one-way ANOVA). R-
mTBI-vehicle mice had significantly higher cumulative distance (vs sham-vehicle p<0.001, 
MANOVA) and distance traveled (vs sham-vehicle p<p<0.0001, MANOVA) than controls. 
Travel distance in r-mTBI-vehicle mice stayed consistent with day 1 during an entire acquisition 
period (r-mTBI-vehicle: day 6 vs day 1 p>0.05, one-way ANOVA). On days 2-6, r-mTBI-
vehicle mice traveled longer time than sham-vehicle (r-mTBI-vehicle vs sham-vehicle: day2 
p<0.01, day3 p<0.01, day4 p<0.001, day5 p<0.001, day6 p<0.001, one-way ANOVA). 
Treatment with nilvadipine in r-mTBI mice lead to a 44% decrease in cumulative distance (r-
mTBI-nilvadipine vs r-mTBI-vehicle p< 0.01, r-mTBI-nilvadipine vs sham-vehicle p>0.05, 
MANOVA) and a 28.6% decrease in the distance traveled (r-mTBI-nilvadipine vs r-mTBI-
vehicle p< 0.0001, r-mTBI-nilvadipine vs sham-vehicle p<0.01, MANOVA). Similarly, a 
decrease in the latency to enter the target box from day 1 to day 6 was observed for sham-vehicle 
(44%) and sham-nilvadipine (25%) groups (Fig.9 C). After r-mTBI, mice spent 50% longer time 
to locate the box than sham-vehicle, with only transient improvements on days 3-5. A 35% 
increase was recorded for the r-mTBI-nilvadipine mice compared to sham-vehicle, although 
notably improved when compared to the injured controls (20%). During the probe trial, 5r-
mTBI-vehicle mice spent a significantly longer time locating the target hole indicating deficits in 
spatial memory (Fig. 10 D; r-mTBI-vehicle vs sham-vehicle p<0.05).  
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Figure 9. Evaluation of learning and memory. Compared to sham-vehicle, r-mTBI-vehicle mice 
exhibit learning deficits during the 6 days of acquisition. All injured groups travelled greater 
distance (A, p<0.001; B, p<0.001) and failed to enter the box (C, days 2-4, p<0.01, days 5-6 
p<0.001) compared to sham-vehicle mice. R-mTBI-Nilvadipine mice showed an improvement in 
all 3 parameters compared to the r-mTBI-vehicle (cumulative distance p<0.01, distance traveled 
p<0.0001, latency to target box p<0.05). (D) Probe data show that r-mTBI-vehicle mice spent 
more time to locate the target hole compared to the sham-vehicle controls (p<0.05, one-way 
ANOVA). Nilvadipine treatment in the r-mTBI ameliorated memory functions compared to r-
mTBI-vehicle (p<0.05, one-way ANOVA). (E) In the r-mTBI-ARC031 mice, mean time to 
target hole decreased compared to the r-mTBI-vehicle during the probe trial (p>0.05, one-way 
ANOVA).  
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Nilvadipine recovered these deficits back to the control levels with no effects on healthy 
sham mice (r-mTBI-nilvadipine vs r-mTBI-vehicle p< 0.01, r-mTBI-nilvadipine vs sham-vehicle 
p>0.05, one-way ANOVA). ARC031 also decreased r-mTBI-induced memory impairments 
during the probe trial (Fig.9; r-mTBI-ARC031 vs r-mTBI-vehicle p< 0.05, r-mTBI-ARC031 vs 
sham-vehicle p>0.05, one-way ANOVA). 
A comparison of the behavior between the young and old sham mice, presented in the 
previous chapter, revealed a significant difference in Rotarod and BM performance among 
healthy controls (Fig.10). Motor evaluation indicated an increased baseline level of latency to 
fall in the young mice compared to the old, which sustained during a 7-day testing (Fig.10A; 
young sham-vehicle vs old sham-vehicle p<0.0001, MANOVA).  Spatial memory assessment 
demonstrated no difference between the young and old sham mice on day 1 for distance traveled, 
cumulative distance, and latency to enter the box (Fig.10B-D). However, throughout days 2-6, 
younger mice showed a significant improvement in locating the target box compared to day 1, 
while older mice showed little change overtime. 
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Figure 10. Age-dependent behavior deficits in sham-vehicle mice. A – 24-26-month old 
sham-vehicle mice spent significantly less time on the rotarod compared to young sham-vehicle 
(p<0.0001). B-D – Barnes Maze acquisition data showed an increase in distance traveled 
(p<0.0001), cumulative distance (p<0.0001) and time to enter the box (days 2-6, p<0.0001 for 
each day) in the aged sham-vehicle mice vs young sham-vehicle. Data analyzed using 
MANOVA (A,B,C) and one-way ANOVA (D). 
 
3.3.3 Immunohistochemistry  
GFAP staining revealed no gliosis in the healthy tissue of sham-vehicle mice (Fig.11 A). 
An increased astroglial activity was prominent in the r-mTBI-vehicle mice in the corpus 
callosum (p<0.05, one-way ANOVA) and areas of cortex in surrounding injury site (p<0.001, 
one-way ANOVA) (Fig.11 A-D). This increase was reduced by the nilvadipine treatment in all 
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three analyzed brain areas (corpus callosum p<0.01, cortex p<0.05, one-way ANOVA). In the r-
mTBI-ARC031 mice, a significant decrease of astrogliosis was shown in corpus callosum 
(p<0.001, one-way ANOVA) but not in cortex (p>0.05, one-way ANOVA) (Fig.11 C-D). 
Immunofluorescent analysis demonstrated the extent of astroglial reaction in cortex of r-mTBI-
vehicle mice spreading from the superficial into the deeper cortical layers (Fig.12).  
Immunofluorescent analysis of GFAP in young and aged mice (samples from the mice 
described in Chapter 2, included to facilitate direct comparison) showed a TBI-induced increase 
in GFAP signal in hippocampus, corpus callosum and cortex across both age groups (Fig.13 
A,B). Quantification analysis of fluorescent intensity of GFAP showed > 50% increase in 
hippocampus (Fig. 13 C, F; young: r-mTBI-vehicle vs sham-vehicle p<0.05; aged: r-mTBI-
vehicle vs sham-vehicle p<0.05, one way ANOVA) and >60% in cortex in both young and aged 
mice (Fig.13 D, G; young: r-mTBI-vehicle vs sham-vehicle p<0.001; aged: r-mTBI-vehicle vs 
sham-vehicle p<0.01, one way ANOVA). In the r-mTBI-nilvadipine mice, GFAP signal was 
decreased compared to the r-mTBI-vehicle (young: hippocampus p<0.05, cortex p<0.05; aged: 
hippocampus p<0.05, cortex p<0.01, one-way ANOVA). Similarly, a greater area % of GFAP 
was detected in r-mTBI-vehicle mice in the corpus callosum of both young (p<0.05) and aged 
(p<0.001) groups compared to their retrospective sham-vehicle mice (Fig.13 E, H). Treatment 
with nilvadipine decreased TBI-induced GFAP signal in corpus callosum in both groups (young: 
p<0.01; aged: p<0.01, one-way ANOVA). 
IHC staining for Iba1 revealed a 50% increase in microgliosis in the r-mTBI-vehicle mice 
compared to sham-vehicle mice in the corpus callosum (p<0.01, one-way ANOVA) but not in 
cortex (p>0.05, one-way ANOVA) (Fig.14). In the r-mTBI-nilvadipine mice, Iba1 showed a 
50% decrease (to close to sham levels) compared to the r-mTBI-vehicle mice (p<0.05, one-way 
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ANOVA) (Fig.14 B). Similarly, treatment with ARC031 reduced Iba1 in corpus callosum of r-
mTBI-ARC031 mice compared to r-mTBI-vehicle (p<0.01, one-way ANOVA) (Fig.14 B). 
 
Figure 11. Evaluation of the effect of nilvadipine or ARC031 on astrocytes. (A-B) 
Representative images of GFAP in cortex. An increase in the area of GFAP staining was 
observed in the r-mTBI-vehicle mice compared to the sham-vehicle (p<0.001). This increase 
was suppressed in the r-mTBI-nilvadipine mice (p<0.05). (C-D) In the corpus callosum, r-
mTBI-vehicle mice also exhibited elevated levels of GFAP compared to the sham-vehicle 
mice (p<0.001). Treatment with nilvadipine and ARC031 in the r-mTBI mice reduced 
astrogliosis (p<0.0001, p<0.001, respectively) compared to respective TBI-vehicle. Data are 
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presented as mean ± standard error of the mean; significance was calculated using one-way 
ANOVA. Scale bars equal 100µm. 
  
 
Figure 12. Immunofluorescent staining of GFAP in cortex. In the r-mTBI-vehicle mice, GFAP 
signal was found spreading from the surface of the cortex into the deeper layers. Scale bars equal 
100 µm. 
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Figure 13. Immunofluorescence of GFAP and RZ3 in cortex, corpus callosum and hippocampus 
in the young (3 months) and aged (24 months) mice with r-mTBI. Representative images of 
cortex (A) show no differences in GFAP signal between the young and the old. In both groups 
(D,G), r-mTBI induced a significant increase in GFAP compared to the respective sham-vehicle 
(r-mTBI-vehicle vs sham-vehicle: young p<0.05, aged p<0.05). In the hippocampus (B), 
fluorescent intensity was increased after r-mTBI in both young (C, p<0.001) and old (F, 
p<0.0001) mice compared to sham-vehicle. Similarly, the area % was increased in the corpus 
callosum in the young (E, p<0.05) and aged (H, p<0.001) compared to their controls. Nilvadipine 
treatment decreased TBI-induced signal of GFAP in all areas for both young (cortex p<0.05, 
hippocampus p<0.05, CC p<0.01) and aged (cortex p<0.01, hippocampus p<0.05, CC p<0.01). 
No differences were found for RZ3 between the groups in all analyzed areas. All data were 
analyzed using one-way ANOVA. Scale bars equal 50µm (A) and 100µm (B). 
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Figure 14. Evaluation of the effect of nilvadipine on microglia in the aged r-mTBI mice. A,B - 
after r-mTBI, Iba1 signal was increased in the CC compared to sham-vehicle ( p<0.01). A 
significant decrease of Iba1 was shown in the r-mTBI mice after treatment with nilvadipine 
(p<0.05) and ARC031 (p<0.01). Data was analyzed using one-way ANOVA. Scale bars equal 
50µm. 
 
3.3.4 Inflammatory cytokines 
A panel of proinflammatory cytokines was assessed in the cortices of young mice and 
compared with the cortical levels of the same cytokines in the aged brains from the previous 
study (Morin et al. 2018). Overall, the analysis revealed no differences in baseline levels of 
cytokines between the sham young and sham old mice (Fig.15 A-E). TBI-induced increases in 
selective cytokines were observed in the old (aged r-mTBI-vehicle vs aged sham-vehicle: 
KCGRO p<0.05, TNFα p<0.05, one-way ANOVA) but not young mice when compared to their 
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respective sham mice. Aged r-mTBI-vehicle mice also exhibited higher levels of KCGRO 
(p<0.05), TNFα (p<0.01) and IL-1β (p<0.001) compared to young r-mTBI-vehicle (Fig.15 A-C). 
Accordingly, nilvadipine decreased abnormal cytokine levels in the r-mTBI aged mice to levels 
close to those observed in the age-matched sham mice (aged r-mTBI-nilvadipine vs aged r-
mTBI-vehicle: TNFα p<0.05, IL-1β p<0.01, IL-4 p<0.01, one-way ANOVA) but had no effect 
on the cytokine expression in young mice (Fig.15 A,C,D).  
 
Figure 15. Quantitative analysis (pg/mg of protein) of proinflammatory cytokines in cortex of 
young and aged hTau mice. (A-B) Aged r-mTBI-vehicle mice expressed higher levels of TNFα 
(p<0.001) and KCRGO (p<0.05) compared to their young counterparts. Within the age group, r-
mTBI-vehicle mice showed higher levels of TNFα (p<0.05) and KCGRO (p<0.05) vs sham-
vehicle. (C) IL-1β was overall increased in all aged mice compared to the young animals. Older 
r-mTBI-vehicle mice expressed higher levels of the cytokine compared to their young 
counterparts (p<0.001). For the aged mice, Nilvadipine decreased IL-1β when compared to r-
mTBI-vehicle group (p<0.01) (D) Nilvadipine had a stronger effect on the IL-4 reduction in the 
aged r-mTBI vs young r-mTBI mice (p<0.01). (E) IL-10 showed a trend in overall decrease for 
young mice compared to the aged. Data are presented as mean ± standard error of the mean; 
significance was calculated using one-way ANOVA.   
 
 
 
128 
 
3.3.5 Tau phosphorylation 
MSD ELISA analysis of cortical total tau and p-tau showed no TBI-induced changes in 
the young mice. The only significant difference observed was that sham-nilvadipine mice had 
significantly lower levels of p-tau compared to the r-mTBI vehicle mice (p<0.05, one-way 
ANOVA).  R-mTBI-nilvadipine were not significantly different from r-mTBI vehicle. A 
different trend was observed in the aged mice, where r-mTBI increased p-tau compared to sham 
mice (p<0.05, one-way ANOVA). Treatment with nilvadipine attenuated tau phosphorylation in 
the aged mice (p<0.05, one-way ANOVA). Total tau was slightly increased in all r-mTBI mice 
across different ages, however this increase was not significant for any comparisons of TBI vs 
respective sham (Fig.16). When normalized to total tau, p-tau did not differ between the groups 
within the same age (Fig.16 C). 
 
Figure 16. Quantitative analysis (pg/mg) of p-tau, total tau and p/tau/total tau in cortex of young 
and aged hTau mice. A - Quantitative analysis of cortical p-tau revealed no difference in sham-
vehicle mice between young and old groups. Tau phosphorylation was increased in the aged r-
mTBI-vehicle compared to the sham-vehicle mice (p<0.01), whereas no significant differences 
were observed in young mice (p>0.05). B - There was a trend in total tau increase in the young 
and aged r-mTBI-vehicle mice compared to their retrospective controls.  C - The ratio of p-tau to 
total tau was not significant between the sham-vehicle/r-mTBI-vehicle and r-mTBI-vehicle/r-
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mTBI-Nilvadipine mice in all age groups. In the young mice, tau ratio was significantly lower in 
the r-mTBI-vehicle mice compared to the sham-Nilvadipine (p<0.05) while in the aged mice 
there was no difference between the groups. Data are presented as mean ± standard error of the 
mean; significance is calculated using one-way ANOVA. 
 
3.3.6 Phosphorylated syk 
Fluorescent signal for psyk was detected in the young r-mTBI-vehicle mice but absent in 
the young sham-vehicle mice (Fig.17). Patchy psyk distribution was found in the corpus 
callosum but it was not easily detected and could not be quantified. All detected areas of psyk 
accumulation were localized in proximity to Iba1-immunoreactive microglia. In the r-mTBI-
nilvadipine and r-mTBI-ARC031 mice there was no evidence for psyk in the corpus callosum.  
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Figure 17. Evaluation of the effect of nilvadipine or ARC031 on psyk, GFAP and Iba1 in 
corpus callosum. No sham animals showed reactive astrocytes, microgliosis or signs of 
psyk. In the r-mTBI-vehicle mice, microglia appear to acquire amoeboid morphology and 
colocalize with psyk accumulations. Treatment with nilvadipine or ARC031 eliminated 
signs of psyk in corpus callosum in the areas near Iba1-reactive microglia. Scale bars equal 
20µm 
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3.4 Discussion 
The work described in this chapter attempted to determine whether age at injury 
influences recovery in a preclinical model of mTBI by comparing the efficacy of nilvadipine in 
aged animals (seen in Chapter 2) with young animals investigated here.  
We found that nilvadipine improved behavior and pathological impairments in young 
animals in a similar manner to the improvements observed in aged mice. Cognitive testing 
demonstrated a strong TBI-induced memory deficit in young vehicle-treated mice whereas none 
was seen in the aged r-mTBI-vehicle group during the probe trial on BM. When we compared 
the young and aged r-sham groups for both behavior tests, we found a decreased baseline in 
older mice versus the young. During motor assessment, healthy aged mice spent overall less time 
on the rotarod than young sham mice. In the BM, there was a decrease in short-term memory in 
older mice, suggesting that age adversely affects the baseline cognitive performance to such a 
degree as to mask any mTBI-induced cognitive deficits. Hence, in aged mice, Barnes maze 
testing could not differentiate whether r-mTBI exacerbated existing memory impairment.  
Pathological analysis has confirmed the detrimental effect of r-mTBI in all age groups of 
mice. In particular, both young and old animals exhibited TBI-induced astrogliosis in the 
hippocampus, corpus callosum and cortex. When compared to our previous data in aged mice 
(Morin et al. 2018), baseline levels of astroglial density in the hippocampus and corpus callosum 
were lower in the healthy young mice versus their aged counterparts. Increased signal of 
immunoreactive microglia was also shown in young TBI mice in corpus callosum but not in 
cortex or hippocampus. Similar data were reported in aged TBI mice in our prior study (Morin et 
al. 2018). Moreover, we observed an increase in cortical levels of pro-inflammatory cytokine IL-
1β and a decrease of anti-inflammatory IL-10 in the aged sham mice versus young sham mice. 
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This suggests a greater level of neuroinflammation in aged animals, which may indicate a higher 
level of vulnerability to physical insults.  Indeed, our r-mTBI model triggered a prominent 
inflammatory response in older animals as shown by the IHC analysis for GFAP.  A greater 
density of reactive astrocytes was recorded for the aged r-mTBI-vehicle mice versus young 
counterparts in cortex under the injury site, hippocampus and corpus callosum. Molecular 
analysis of inflammatory cytokines in the cortex showed an increase in pro-inflammatory 
cytokines TNFα and KCGRO after r-mTBI in the aged but not in the young mice. Taken 
together, these data support the concept of age-driven neuroinflammation and an increased 
vulnerability of the aged brain to r-mTBI.  
A significant effect of age on the ongoing pathology is supported by our findings of 
cortical and hippocampal age-specific tauopathy. When compared with our previous study in 
Chapter 2, aged sham mice had an increased expression of p-tau in the hippocampus and cortex 
when compared to their young sham counterparts. r-mTBI in young animals did not cause an 
increase in the cortical or hippocampal p-tau when compared to their respective sham. Molecular 
analysis of p-tau in the cortex also showed a lack of injury effect in the young mice, but a robust 
p-tau increase in old animals. In our earlier work, when we compared hTau mice that received 
5r-mTBI at 3 or 12 months of age, we found a pronounced p-tau pathology in the aged but not 
young mice (Mouzon et al., 2018; Ferguson et al., 2017). Growing evidence suggest that tau 
hyperphosphorylation plays a major role in the chronic consequences of TBI, especially in the 
development of age-associated disorders, such as CTE, ARTAG and AD (Kulbe and Hall 2017; 
Petraglia et al. 2014; Kovacs et al. 2018; Tateno et al. 2015). Tau pathology observed in the 
aging brain was shown to be exacerbated by brain injuries and may be linked to stronger 
inflammation and cognitive deficits.  
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Our data revealed therapeutic efficacy of nilvadipine on pathological and cognitive 
outcomes indicating its potency as treatment for r-mTBI. It attenuated motor deficits in young 
but not old mice, which may arise from a more severe underlying pathology in older animals due 
to possible higher vulnerability to brain traumas. Nilvadipine was able to mitigate the memory 
deficits induced by r-mTBI in both age groups as shown by the BM. In both young and old r-
mTBI mice, three-week treatment with nilvadipine reduced astrogliosis and microgliosis to the 
age-matched sham levels. This decrease was observed for all analyzed areas – cortex, 
hippocampus, corpus callosum (for astroglia) and corpus callosum only (for microglia). 
Molecular analysis of cortical levels of inflammatory cytokines showed a nilvadipine-induced 
decrease of TNFα and IL-1β in the aged mice. We have previously demonstrated that nilvadipine 
exhibits therapeutic properties by inhibiting syk phosphorylation (Paris et al., 2014). In our 
previous studies, we showed that psyk is linked to neuroinflammation, tau phosphorylation and 
cognitive deficits. We also showed that r-mTBI caused psyk accumulation in the corpus 
callosum of aged mice (Morin et al., 2018). Notably, psyk patches were always colocalized with 
amoeboid microglia indicating a strong link with neuroinflammation. Nilvadipine was able to 
reduce psyk in mouse models of AD and aged r-mTBI (Morin et al. 2018; Paris et al. 2014). In 
the current study, we observed a TBI-induced increase of psyk in the proximity to microglia in 
the corpus callosum but to a lesser extent than in the old mice. These data suggest an age-
dependent increase of psyk in the post-concussive brain. Nilvadipine inhibited syk 
phosphorylation in the young r-mTBI mice. 
Treatment with ARC031 showed a slightly different effect in the r-mTBI mice compared 
to nilvadipine. First, it did not attenuate motor deficits, but it did improve memory impairment in 
the young mice. Second, it reduced astrogliosis in the corpus callosum but, unlike nilvadipine, 
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had no effect on reactive astrocytes in the cortex. It did, however, decrease microgliosis in the 
corpus callosum of young r-mTBI mice. Third, it decreased syk phosphorylation in the corpus 
callosum in a similar manner to nilvadipine. The lack of effect of ARC031 (compared to 
nilvadipine) on motor outcomes may be linked to the effects of nilvadipine on cerebral blood 
flow; possibly the effects on cortical astrogliosis may also be related to vascular involvement of 
nilvadipine that are absent in ARC031. Further studies will require the use of other anti-
hypertensive calcium channel blockers in our 5r-mTBI model to validate this hypothesis.  
The advantage of this study is the ability to compare injuries with the same TBI severity 
across different age groups. Overall, our findings demonstrate an age-dependent response to r-
mTBI which is likely due to the age-driven pathological mechanisms in a healthy brain.  
Nilvadipine exhibited therapeutic efficacy in both young and aged mice and is proposed to act 
through the inhibition of psyk, a potential target for both TBI and AD. However, the diversity of 
pathological and cognitive analyses suggests complex nature of the “age-TBI-treatment” 
interaction and requires further investigation.  Our data provide valuable insights into the role of 
age of patients for treatment development and the necessity for considering different strategies to 
mitigate r-mTBI outcomes in young and old populations.  
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Chapter 4 – Investigation of delayed treatment with anatabine in two different injury  
                      paradigms of r-mTBI 
 
 4.1 Introduction 
In Chapter 1, we described the many faces of TBI pathobiology that vary from acute 
neuronal damage to long-lasting neurodegeneration. Of all aspects of TBI pathobiology, 
neuroinflammation is perhaps the most consistent, reported in most human studies and all 
preclinical models of TBI. In humans, markers of inflammation such as S100β (Cho et al. 2016; 
Zongo et al. 2012), GFAP (Bogoslovsky et al. 2017) and cytokines IL-6/IL-1β/TNFα (Devoto et 
al. 2017; Gill et al. 2018; Kanefsky et al. 2019) have been found in plasma in response to 
different types of TBI and at acute and chronic timepoints. Autopsy examination of brains with 
chronic TBI or CTE also confirm a profound role of long-lasting inflammation in 
neurodegeneration (Gentleman et al. 2004; Johnson et al. 2013; Kiernan et al. 2015; McKee et al. 
2016).  Nevertheless, existing drugs with anti-inflammatory action (e.g. progesterone (Stein 
2015), statins (Robertson et al. 2017), minocycline (J. Meythaler et al. 2019)) fail to resolve TBI-
associated neurological outcomes in clinical trials. Moreover, whether they actually have an 
effect on inflammation in the brain remains unclear, mainly due to the lack of effective real-time 
techniques that are able to measure neuroinflammation in a living person. A recent preclinical 
study has developed positron emission tomography (PET) markers to visualize microglia in 
mouse models of AD and EAE  and demonstrated high purity of the signal and biological safety 
(Horti et al. 2019), however, human microglial imaging is still experimental (Largeau et al. 
2017). Plasma biomarkers offer an alternative way to measure neuroinflammation, but they 
rather serve as surrogates and not a first-hand presentation of pathology. Here, we decided to test 
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a potent anti-inflammatory drug anatabine, which we previously showed to be effective in our 
models of AD (Verma et al. 2015; Paris et al. 2013) and EAE (Paris et al. 2013), and which 
showed promise for TBI treatment in an earlier study (S. Ferguson et al. 2016). 
4.1.1 Anatabine 
Anatabine is a natural alkaloid of the Solanaceae family which includes tobacco, 
potatoes, tomatoes and others. It was marketed in the United States by Rock Creek 
Pharmaceuticals as a dietary supplement and was used to treat joint pain and arthritis (Lanier et 
l., 2013). Later, anatabine was shown effective against thyroiditis, an inflammation of the 
thyroid, as assessed by the decrease of serum levels of thyroglobulin antibodies when 
administered 3 time daily for 3 months (Schmeltz et al. 2014). Preclinical models of thyroiditis 
in mice treated with anatabine also revealed a resolution of inflammation and a decrease of 
cytokines IL-1β and IL-12 (Caturegli et al. 2012). Anatabine is a natural agonist of nicotinic 
receptors that binds the α7 subtype of nicotinic acetylcholine receptors (nAChR) (Levin et al. 
2014). The large distribution of α7 nAChRs in the hippocampus makes it an attractive target for 
memory and learning deficits.  
Our team demonstrated the potent anti-inflammatory properties of anatabine through the 
inhibition of signal transducer and activation of transcription-3 (STAT3) and NFkB activation 
(Paris  et al. 2013) (Fig.18). Similar to NFkB, phosphorylated STAT3 translocates to the nucleus 
where it acts as a transcriptional factor increasing the expression of GFAP and pro-inflammatory 
cytokines (Oliva et al. 2012; Dawn et al. 2004; Yi et al. 2007). Increased levels of P-STAT3 and 
associated cytokines production were shown in rodent models of AD (Wan et al. 2010), ischemia 
(De Butte-Smith et al. 2012) and TBI (Oliva et al. 2012). Anatabine was able to not only reduce 
phosphorylation of STAT3 and suppress pro-inflammatory cytokines but also to decrease 
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phosphorylation of tau at multiple epitopes (RZ3, PHF-1, CP13) in Tg APPsw and P301S mouse 
models of AD (Paris et al. 2013; Verma et al. 2015).  In the PSAPP mice, treatment with 
anatabine for 6 months also reduced amyloid burden in the hippocampus and cortex (Verma et 
al. 2015). Similar therapeutic properties of anatabine were shown in mice with experimental 
autoimmune encephalomyelitis (EAE) modeling Multiple Sclerosis (MS), where a 16-day 
treatment decreased microgliosis and astrogliosis, suppressed STAT3 and NFkB phosphorylation 
and prevented demyelination in the spinal cord (Paris et al. 2013). In in vivo models of LPS-
induced inflammation, anatabine reduced production of inflammatory cytokines IL-6, IL-1β and 
TNFα. Due to the powerful anti-inflammatory properties of anatabine, and the very strong 
neuroinflammatory presentation in our 5-hit mTBI mouse model (Mouzon et al. 2012, 2018) we 
explored the therapeutic potential of anatabine treatment in this model (5r-mTBI; 48 hours inter-
injury interval).  Wild type mice were treated with anatabine in their drinking water for 9 
months, starting either immediately after the last injury/sham procedure or at 9 months after the 
last TBI/sham injury in a crossover design (Ferguson et al. 2016). Anatabine improved cognitive 
deficits at 6 months and decreased inflammation at 9 months post injury. Interestingly, following 
the crossover in this study, we found that delayed treatment of anatabine showed positive effects 
by 18 months post-injury in injured mice that did not begin to receive anatabine until 9 months 
post TBI, specifically reduced Iba1 in corpus callosum. These data demonstrate that late 
administration of anatabine can be effective, which is encouraging for mTBI patients who 
typically do not seek medical attention at acute or subacute timepoints after injury  
Overall, the ability of anatabine to suppress astrogliosis/microgliosis, reduce STAT3 and NFkB 
phosphorylation, mitigate amyloid burden and tau pathology across several neuropathological 
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models makes it another promising candidate to treat individuals who have been exposed to 
multiple TBI through their life.   
 
Figure 18. Proposed mechanism of action of anatabine 
 
  4.1.2 Rationale of using two models of r-mTBI 
One of the proposed reasons of translational failures in drug discovery for TBI is the lack 
of sufficient interrogation of potential treatments at the preclinical stage (DeWitt et al. 2018; 
Mohamadpour et al. 2019) including the inadequacy of laboratory approaches to replicate the 
heterogeneity of the human patient population and the heterogeneity of human brain injuries. In 
cases of repetitive TBI, additional limitations, such as injury repetitiveness, time interval 
between the impacts and recovery conditions between the injuries, appear. Therefore, to begin to 
address these deficiencies we have adopted an overarching mantra that any treatments showing 
potential in preclinical models of TBI should be explored in multiple different injury paradigms, 
in order to identify treatments that work in many different scenarios. We therefore decided to test 
anatabine in two of our well-characterized models of r-mTBI – the 5r-mTBI (previously 
described in chapters 2 and 3, (Mouzon et al. 2012)) and a chronic repetitive mTBI (cr-mTBI) 
model in which mice receive 2 hits per week for 3 months (24 hits total) (Ojo et al. 2016). The 
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two models use the same impact characteristics (depth - 1.0 mm depth, velocity - 5 m/s) but vary 
in the frequency, length of exposure and inter-concussive interval.  In hTau mice, both models 
trigger neuroinflammation and cognitive deficits (Mouzon et al. 2018; Ojo et al. 2013, 2016). 
 
 4.1.3 Rationale for using delayed treatment 
 More than 80% of individuals with a single mTBI fully recover within days and months; 
and clinical studies confirm that at 6 and 12 months post mTBI individuals do not differ in 
cognitive performance from healthy controls (Barker-Collo et al. 2015; Losoi et al. 2016).  
However, when cognitive deficits persist, especially in cases of repeated concussions, they may 
lead to memory impairments, mood disorder, anxiety and other problems that manifest years 
after the impact. Therefore, there is a need for developing delayed treatment that will be effective 
when administered at later time points after the injury. Unfortunately, this approach is greatly 
understudied in experimental models of TBI since most studies focus on acute treatment. For 
example, in a recent review, Bergold summarized treatment studies involving more than 40 anti-
inflammatory drugs used in rodents with mild to moderate TBI (Bergold 2016). Almost all 
studies administered treatment within 5-30 min after TBI with only few extending the window 
up to 4-6 hours.  None of the studies were designed to administer the first dose at times longer 
than 6 hours. Here, we aim to conduct a more translationally relevant study where r-mTBI mice 
will be treated with the anti-inflammatory drug anatabine at a delayed timepoint, 3 months after 
the last injury.  
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 4.1.4 Hypothesis 
1) Treatment with anatabine will ameliorate TBI-induced deficits in both models of r-
mTBI and, thus, prove to be effective across different models, demonstrating the ability to target 
heterogeneous nature of TBI and having greater potential to successfully translate to the 
heterogeneous TBI patient population. 
2) Delayed treatment with anatabine will suppress TBI-induced inflammation and related 
cognitive deficits, again, holding greater translational potential for the human patient population 
and indicating a wider therapeutic window for TBI than might previously have been anticipated.   
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4.2 Materials and Methods 
4.2.1 Animals 
Male and female hTau mice 12-14 weeks old (weight 19-25g) were sourced from Jackson 
Laboratories (Bar Harbor, ME). The animals were housed under standard laboratory conditions 
(14-hour light/10-hour dark cycle, 23±1˚C, 50±5% humidity) with free access to food and water. 
All   procedures were carried out under Institutional Animal Care and Use Committee (IACUC) 
approval and in accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
4.2.2 Experimental groups and study design 
The study was comprised of 2 cohorts of mice that received either 5 r-mTBI (n=34) or 
chronic-r-mTBI (cr-mTBI, n= 38). In the 5r-mTBI cohort, TBI mice received 5 injuries over 9 
days with a 48-hour inter-concussion interval (Mouzon et al. 2012, 2014, 2017, Ojo et al. 2015; 
Tzekov et al. 2014, 2016). In the cr-mTBI cohort, mice received a total of 24 injuries - 2 injuries 
each week (with a 3-4 day inter-concussion interval) for the duration of 3 months (Fig.19). Each 
cohort included four groups: Sham-Vehicle, r-mTBI-Vehicle, Sham-Anatabine, r-mTBI-
Anatabine. The distribution of mice between the groups in each cohort is shown in Table 2.  
Each group included both male and female mice evenly distributed among the groups.  
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Table 2. Distribution of mice in the groups (M-males, F-females) 
For sham/mTBI procedures, all animals underwent anesthesia with 1,5 mL/min of oxygen 
and 3% isoflurane for 3 min on the heating platform to prevent hypothermia. TBI mice were placed 
on a heating pad to prevent hypothermia during the injury procedure. The head of each animal was 
fixed in a stereotaxic frame, and a 5 mm blunt metal impactor was positioned midway to the sagittal 
suture. The injury was triggered at 5 m/s velocity and 1.0 mm depth, with a dwell time of 200 
milliseconds, using a myNeuroLab controller device (Impact OneTM Stereotaxic Impactor, 
Richmond, IL).  All TBI mice experienced short-term apnea (<20 sec) and showed no skull 
fractures. All animals (sham and TBI) were allowed to recover from anesthesia on a heating pad 
and then returned to their cages with water and soft food access. 
  Regardless of the paradigm to which mice were assigned, after the last injury/sham 
procedure, mice were kept under normal housing conditions for 3 months. One week prior to the 
initiation of treatment, acclimation and baseline levels for Rotarod were recorded. No other 
manipulations on mice were conducted.  After a 3-month period, anatabine was administered to 
mice of Sham-Anatabine and TBI-Anatabine groups with drinking water in concentration 
20mg/kg/day. The volume was calculated based on the average weight of mice prior to treatment 
(25.5g) and a previously calculated water consumption volume for C57BL/6 mice of 7.4ml/30g 
(Bachmanov et al. 2002). The solution was changed weekly for 3 months. Placebo mice received 
regular water. Behavior tests started on day 61 after the initiation of anatabine and included 
 5r-mTBI cr-mTBI 
Sham-Vehicle 8 (4M,4F) 9 (5M, 4F) 
r-mTBI-Vehicle 10 (5M, 5F) 11 (5M, 6F) 
Sham-Anatabine 7 (4M, 3F) 8 (5M, 3F) 
r-mTBI-Anatabine 9 (6M, 3F) 10 (6M, 4F) 
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Rotarod, Barnes Maze, and Elevated Plus Maze as shown in Figure 19. Euthanasia was performed 
on the 91st day, after the last day of treatment. Behavioral and histological assessments were done 
by researchers blinded to the experimental groups.   
 
 
Figure 19. Study design. 
 
Note: The timelines chosen for these two groups were designed in order to match TBI 
mice by age at first injury (3 months old). This resulted in the mismatch of animals’ age at 
euthanasia (5r-mTBI - 9 months; cr-mTBI – 12 months). 
 
4.2.3 Behavior  
Behavior was assessed during the last month of treatment and included Rotarod, Barnes 
Maze (BM) and Elevated Plus maze (EPM). A detailed procedure for each testing is described in 
the Methods section of the second Chapter. Briefly, Rotarod acclimation and baseline levels 
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were recorded during a delay period before the initiation of treatment. Acclimation included 3 
trials for 5 min without acceleration while baseline trial was performed using acceleration mode 
5 to 50 rpm. Rotarod assessment started on day 61 after the beginning of Anatabine treatment 
and was performed every other day during a 7-day trial. Each animal underwent 3 trials for 3 min 
with 5 min interval rest. After the final day of rotarod testing, cognitive function was evaluated 
using the BM. For a period of 6 days, four trials were given per day, with mice starting from one 
of four cardinal points on each trial. On the 7th day, a single probe trial lasting 60 sec was 
performed with the mouse starting from the center of the maze and the target box removed. 
Disinhibition behavior was assessed using the EPM day prior to euthanasia. Mice were placed in 
the middle of the plus-shaped maze elevated 80 cm above the ground with 2 open and 2 closed 
arms perpendicular to each other in a brightly lit room. Animal movement was recorded during a 
5 min trial. Each animal underwent only one trial. The center point of the mouse determined by 
Ethovision XT14 tracking was used to decide the current arm of maze the mouse occupied. The 
time spent in open vs closed arms was calculated.  
 
4.2.4 Tissue processing and immunofluorescence 
At 6 months post last mTBI/sham injury, mice were anesthetized with isoflurane and 
perfused transcardially with phosphate‐buffered saline (PBS) with heparinized PBS, pH-7.4. 
Brains were removed and post fixed in a solution of 4% paraformaldehyde at 4ºC for 48 h, 
dehydrated in graded ethanol solutions, cleared in histoclear, and embedded in paraffin. Serial 
sections (6 µm thick) were cut onto positively charged glass slides and boiled in citrate buffer 
(10mM pH 6.0) for antigen retrieval, followed by incubation with the following antibodies: 
GFAP/NFkB/RZ3. Fluorescent staining was performed with the antibodies for astroglial marker 
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GFAP (7857983, Aves Labs), NFkB (3034, Cell Signaling) and phosphorylated tau at Thr231 
(RZ3). Following rehydration, antigen retrieval was performed by heating slides in citric acid 
buffer for 7 min in a microwave oven. Next, slides were washed with PBS and transferred to a 
Sudan Black solution for 15 minutes to prevent autofluorescence. Slides were then blocked for 1 
h with 10% donkey serum solution in PBS, and primary antibodies for GFAP (1:500), NFkB 
(1:500) and RZ3 (1:500) were applied overnight. On the next day, secondary antibodies 
AlexaFluor488 (A21202, Life Technologies) and AlexaFluor647 (ab175477, Abcam) were 
applied. Slides were mounted with ProLong Gold Antifade 4',6-diamidino-2-phenylindole 
(DAPI) Mount. Imaging was performed using a confocal microscope (LSM 800 Zeiss) at 20x 
magnification. Quantification of the fluorescent images was performed using LSM 800 Zeiss and 
the intensity of fluorescence was measured for each antibody. The same area of interest was 
applied to each image and the background signal was subtracted from the obtained values.   
 
4.2.5 Statistical analysis 
All experimental data were analyzed using JMP 12 and PRISM Software. The data were 
checked for normality using Skewness-Kurtosis and Goodness of Fit. If normal, parametric 
methods (t-test and one-way ANOVA) were applied to calculate the significance between 
different experimental groups (p<0.05 were considered significant). The Shapiro-Wilk test was 
used if data were not normally distributed. All data were transformed to logarithm or square root, 
when required, to reach normality before further analysis. Repeated-measure analysis of variance 
(MANOVA) was used to analyze continuous performance of mice in the Barnes Maze and 
Rotarod (p<0.05 is significant). Error bars represent the standard error of the mean. 
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4.3 Results 
4.3.1 Motor assessment 
Rotarod assessment showed a 37.5% TBI-induced decrease in sensorimotor performance 
of cr-mTBI-vehicle compared to cr-sham-vehicle group (Fig.20). No TBI effect was observed in 
5r-mTBI-vehicle vs 5r-sham-vehicle mice (Fig.20 B). The cr-mTBI-vehicle mice had a 
significantly lower latency to fall compared to their controls during a 7-day trial (Fig.20 A; cr-
mTBI-vehicle vs cr-sham-vehicle: 128± 3 sec vs 206±17sec; p<0.0001, MANOVA). In the 5r-
mTBI mice, an overall motor performance was lower in the 5r-mTBI-vehicle mice vs 5r-sham-
vehicle, however, when normalized to each group baseline, this significance disappeared 
(p>0.05, MANOVA). Treatment with anatabine in the cr-mTBI mice increased latency to fall 
compared to vehicle treated cr-mTBI mice (cr-mTBI-anatabine vs cr-mTBI-vehicle: 206±23sec 
vs 128± 3 sec; p<0.0001, MANOVA). In the 5r-mTBI animals, no anatabine-dependent response 
was observed in the TBI mice. 
 
Figure 20. Evaluation of the effect of anatabine on motor performance Anatabine 
treatment improved motor function outcomes in the cr-mTBI (A) but nor 5r-mTBI (B). Mice in 
the cr-mTBI-vehicle group showed a significant decrease in their performance compared to the 
cr-sham-vehicle (A; p < 0.0001). This effect was not observed in the 5r-mTBI-vehicle mice (B). 
Treatment with anatabine ameliorated motor deficits in the cr-mTBI mice (cr-mTBI-anatabine vs 
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cr-mTBI-vehicle, p<0.0001). (B) In 5r-mTBI mice treated with anatabine, no differences were 
observed in the latencies compared to the 5r-mTBI-vehicle (p>0.05). All data were analyzed 
using MANOVA. 
 
4.3.2 Memory assessment  
cr-mTBI: The acquisition trial showed an overall decrease in cumulative distance, 
distance traveled and latency to enter the box in all groups. cr-mTBI-vehicle mice showed a 68% 
increase in the cumulative distance compared to the cr-sham-vehicle by the end of a 6-day 
acquisition trial (Fig.21 A; p<0.05, MANOVA). For distance traveled, cr-mTBI-vehicle mice 
showed a 33% increase compared to cr-sham-vehicle mice (Fig.21 B; p<0.05, MANOVA). In 
the cr-mTBI-vehicle mice, latency to enter the box was 43% increased compared to cr-sham-
vehicle (Fig. 21 C; day 6 p<0.01, one-way ANOVA). Latency was not different between cr-
sham-vehicle and cr-mTBI-vehicle until day 4 (day 4 p<0.001, day 5 p<0.001, day 6 p<0.01, 
one-way ANOVA). cr-mTBI-anatabine mice had a 65% decrease in cumulative distance 
compared to cr-mTBI-vehicle group (p<0.05, MANOVA). For distance traveled, cr-mTBI-
anatabine mice exhibited a 30% decrease compared to cr-mTBI-vehicle. Treatment with 
anatabine significantly reduced latency to enter the box in the injured mice starting on day 2 of 
the acquisition trial (cr-mTBI-anatabine vs cr-mTBI-vehicle: day 2 p<0.01, day 3 p<0.01, day 4 
p<0.001, day 5 p<0.01, day 6 p<0.01, one-way ANOVA). During the probe trial, cr-mTBI-
vehicle mice spent 90% longer time to locate the target hole compared to the cr-sham-vehicle 
(Fig. 22 A; cr-mTBI-vehicle vs sham-vehicle: 28.3± 21sec vs 2.6± 1.2sec; p<0.05, one-way 
ANOVA). In the cr-mTBI-anatabine mice, mean time was 82.3% decreased compared to cr-
mTBI-vehicle (cr-mTBI-anatabine vs cr-mTBI-vehicle: 4.9± 4.2sec vs 28.3± 21sec; p<0.05, one-
way ANOVA).  
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Figure 21. Evaluation of learning and memory in cr-mTBI and 5r-mTBI mice. Anatabine 
treatment improved spatial memory deficits in the cr-mTBI but not 5r-mTBI mice. In the cr-
mTBI cohort, cr-mTBI-vehicle mice exhibited longer cumulative distance (A; p<0.05), distance 
traveled (B; p<0.05), and latency to enter the box on days 4-6 (C) compared to cr-sham vehicle. 
Similarly, in the 5r-mTBI cohort, 5r-mTBI-vehicle mice exhibited longer cumulative distance 
(D; p<0.05), distance traveled (C; p<0.001), and latency to enter the box on days 3-6 (F) 
compared to 5r-sham vehicle. cr-mTBI-anatabine mice showed a decrese in cumulative distance 
(A; p<0.05), distance traveled (B; p<0.05) and latency (C) compared to cr-mTBI-vehicle mice. 
Anatabine did not attenuate memory deficits in 5r-TBI-anatabine group. Statistical significance 
for the cumulative distance and distance traveled were analyzed using MANOVA; the latency 
for each day were analyzed using one-way ANOVA. 
 
5r-mTBI: The acquisition trial showed an overall decrease in the cumulative distance, 
distance traveled, and latency to enter the target box for all experimental groups over a 6 day 
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period. 5r-mTBI-vehicle mice showed a 67% increase in the cumulative distance compared to 
the 5r-sham-vehicle by the end of a 6-day acquisition trial (Fig. 21 D; p<0.05, MANOVA). 
Similarly, in the 5r-mTBI-vehicle mice, distance traveled was 52% increased (Fig. 21 E; 
p<0.001, MANOVA) and latency to enter the box was 57.8% increased, compared to 5r-sham-
vehicle (Fig. 21 F; day 6 p<0.001, one-way ANOVA). Latency to enter the box was increased in 
the 5r-mTBI-vehicle mice compared to 5r-sham-vehicle starting day 3 after the initiation of the 
trial (days 3 p<0.05, day 4 p<0.01, day 5-6 p<0.001, one-way ANOVA). No anatabine-induced 
improvements were shown for any of these parameters in the 5r-mTBI group (5r-mTBI-
anatabine vs 5r-mTBI-vehicle: cumulative distance p>0.05, distance traveled p>0.05, latency 
p>0.05). In the probe trial, latency to locate the target hole was increased in the 5r-mTBI-vehicle 
mice vs 5r-sham-vehicle (Fig. 22 B; p<0.05, one-way ANOVA) but no anatabine-induced 
decrease in the 5r-TBI mice was shown compared to 5r-mTBI-vehicle (p>0.05, one-way 
ANOVA).    
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Figure 22. Probe trial in the cr-mTBI and 5r-mTBI mice. Mean time to enter the target 
zone was decreased in the cr-mTBI but not 5r-mTBI after anatabine treatment. A – In the cr-
mTBI group, TBI induced a significant increase in mean time compared to sham-vehicle 
(p<0.05), which was decreased in the cr-mTBI-anatabine mice vs cr-mTBI-vehicle (p<0.05). B – 
In the 5r-mTBI group, 5r-mTBI-vehicle mice had an increase in the mean time compared to 5r-
sham-vehicle (p<0.05) but no anatabine induced decrease was detected in the 5r-mTBI-anatabine 
mice. Statistical significance was analyzed using one-way ANOVA. 
 
4.3.3 Disinhibition assessment  
EPM was used in both models of r-mTBI to measure disinhibition, which reflects a 
spectrum of human behavior including aggression, impulsivity, poor social interaction and risk 
assessment skills, all or some of which are often reported post injury.  EPM analysis showed a 
significant TBI effect in the 5r-mTBI but not cr-mTBI mice. In the 5r-mTBI group, 5 r-mTBI-
vehicle mice spent significantly more time in the open arm compared to the 5r-sham-vehicle 
indicating disinhibition behavior (Fig. 23; p<0.05, one-way ANOVA). Treatment with Anatabine 
significantly reduced time spent in open arms in the 5r-mTBI mice (p<0.01, one-way ANOVA). 
In the cr-mTBI mice, no differences were observed between the groups. 
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Figure 23. Evaluation of disinhibition in the cr-mTBI and 5r-mTBi mice. Disinhibition 
was suppressed by anatabine in the 5r-mTBI but not cr-mTBI mice. A – in the cr-mTBI cohort, 
TBI did not produce disinhibition behavior compared to sham mice. There was no difference 
between cr-mTBI-vehicle and cr-mTBI-anatabine groups. B – in the 5r-mTBI cohort, TBI 
increased time spent in the open arm compared to sham-vehicle (p<0.05). Treatment with 
anatabine increased time spent in the closed arm in the 5r-mTBI mice compared to 5r-mTBI-
vehicle (p<0.01). Statistical significance was analyzed using one-way ANOVA. 
 
4.3.4 Immunohistochemistry   
In the cr-mTBI but not 5r-mTBI mice, Iba1 signal was increased in the corpus callosum 
in the injured mice compared to their respective controls (Fig. 24 ; 5r-mTBI-vehicle vs 5r-sham-
vehicle p> 0.05, cr-mTBI-vehicle vs cr-sham-vehicle p<0.05, one-way ANOVA). In the cr-
mTBI mice, anatabine resolved microglia activation close to cr-sham-vehicle levels (Fig. 24 B,C; 
cr-mTBI-anatabine vs cr-mTBI-vehicle p<0.05, cr-mTBI-anatabine vs cr-sham-vehicle p>0.05, 
one-way ANOVA). 
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Figure 24. Evaluation of the effect of anatabine on microglia. A – representative images of Iba1 
in corpus callosum in the 5r-mTBI and cr-mTBI mice. B – cr-mTBI-vehicle mice had an increase 
in Iba1 signal compared to cr-sham-vehicle (p<0.05). C – in 5r-mTBI-vehicle mice, no signs of 
increased Iba1 were found. Anatabine decreased Iba1 in cr-mTBI mice (cr-mTBI-anatabine vs 
cr-mTBI-vehicle  p<0.05) but not in 5r-mTBI. Data analyzed using one-way ANOVA. Scale bars 
equal 20µm. 
 
Immunofluorescent assessment for the astroglial marker GFAP revealed an increase in 
astrogliosis in the injured mice compared to the sham (Fig. 25 A). In both 5r-mTBI and cr-mTBI 
groups, a strong glial response was detected in the hippocampus and corpus callosum but not in 
the cortex. Quantitative analysis showed a significant increase in the area % of GFAP cells in the 
corpus callosum of the r-mTBI mice compared to sham-vehicle mice (Fig. 25 D: 5r-mTBI-
vehicle vs 5r-sham-vehicle p<0.001; Fig. 25 B: cr-mTBI-vehicle vs cr-sham-vehicle p<0.001). 
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After treatment with anatabine, both 5r-mTBI and cr-mTBI showed a significant reduction in 
GFAP immunoreactivity in corpus callosum (5r-mTBI-anatabine vs 5r-mTBI-vehicle p<0.01; cr-
mTBI-anatabine vs cr-mTBI-vehicle p<0.01, one-way ANOVA). Immunoreactivity for NFkB 
was detected in the cortex and hippocampal areas CA1, CA3, and DG. In the cortex, quantitative 
analysis for NFkB revealed an increase in both cohorts in the r-mTBI groups compared to their 
respective controls: 5r-mTBI (Fig. 25 E: 5r-mTBI-vehicle vs 5r-sham-vehicle p<0.0001, one-
way ANOVA) and cr-mTBI (Fig. 25 C: cr-mTBI-vehicle vs cr-sham-vehicle p<0.0001, one-way 
ANOVA).  Images at higher magnification (20X) revealed a NFkB/DAPI colocalization in the r-
mTBI mice in the CA1 area of hippocampus and throughout cortex (Fig. 26). Their increase was 
attenuated after treatment with anatabine in all areas (quantitative analysis for cortex: 5r-mTBI-
anatabine vs 5r-mTBI-vehicle p<0.0001; cr-mTBI-anatabine vs cr-mTBI-vehicle p<0.001).  
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Figure 25. Immunofluorescent analysis of GFAP and NFkB. A – representative images of 
NFkB/GFAP in cortex, corpus callosum and hippocampus. In the cr-mTBI group, TBI produced 
a significant increase of GFAP in corpus callosum (B, p<0.001) and of NFkB in cortex (C, 
p<0.0001) compared to cr-sham-vehicle. Similarly, in the 5r-mTBI group, TBI induced GFAP 
(D, p<0.001) and NFkB (E, p<0.0001) immunoreactivity compared to 5r-sham-vehicle mice. 
Treatment with anatabine decreased GFAP (cr-mTBI p<0.01; 5r-mTBI p<0.01) and NFkB (cr-
mTBI p<0.001; 5r-mTBI p<0.0001) in r-mTBI mice compared to the respective r-mTBI-vehicle 
mice. Data analyzed using one-way ANOVA. Scale bar equal 200 µm. 
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Figure 26. Representative images of NFkB in cortex and CA1 area of hippocampus in 5r-mTBI 
and cr-mTBI mice. Arrows indicate nuclear localization of NFkB. Scale bars equal 20µm. 
 
Immunofluorescent analysis for phosphorylated tau showed a significant increase of RZ3 
signal in cortex (Fig.27 A) of both 5r-mTBI and cr-mTBI mice compared to their respective 
sham-vehicle mice (Fig. 27 B: 5r-mTBI-vehicle vs 5r-sham-vehicle: p<0.05; Fig. 27 C: cr-
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mTBI-vehicle vs cr-sham-vehicle p<0.001, one-way ANOVA).  Anatabine treatment decreased 
RZ3 fluorescent intensity in the 5r-mTBI (vs 5r-mTBI-vehicle p<0.05, one-way ANOVA)) and 
cr-mTBI (vs cr-mTBI-vehicle p<0.001, one-way ANOVA). 
 
Figure 27. Evaluation of the effect of anatabine on RZ3 in cortex. A – representative images of 
RZ3 in cortex. TBI induced an increase of RZ3 in 5r-mTBI (B, p<0.05) and cr-mTBI (C, 
p<0.001) mice compared to the respective sham-vehicle. In the r-mTBI-anatabine mice, RZ3 was 
decreased in both 5r-mTBI (p<0.05) and cr-mTBI (p<0.001) mice compared to the respective r-
mTBI-vehicle. Data analyzed using one-way ANOVA. Scale bars equal 20µm. 
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4.4 Discussion 
This chapter focused on the delayed treatment with anatabine in hTau mice in two 
different models of r-mTBI. We found that anatabine decreased GFAP, Iba1, NFkB and p-tau in 
both models, however its effect on behavior was mostly demonstrated in the cr-mTBI model, but 
not in the 5r-mTBI mice. 
 Both 5-rmTBI and cr-mTBI mice (vehicle treated) exhibited strong injury-dependent 
astrogliosis in the corpus callosum and hippocampus 6-months post last injury/sham. However, 
no reactive astrocytes were observed in cortex within the injury site, a pathology commonly 
found at sub-acute phase in our models (Mouzon et al., 2012). Such temporal alterations 
probably indicate that accumulation of astrocytes in the cortex shortly after TBI is associated 
with mechanical deformation of tissue, and it quickly resolves after the termination of 
mechanical stress. On the contrary, white matter has been shown to be more vulnerable to TBI 
leading to long-lasting pathology (Braun et al. 2017). White matter is comprised of 
interconnected axon tracts that are especially susceptible to stretch forces at the grey-white 
matter junctions. In fact, most axonal injury in white matter is caused not by shear and stress 
forces but as a result of white matter atrophy, demyelination and other secondary injury events 
(Büki and Povlishock 2006). These processes have been shown to sustain for over one year in 
different rodent models of TBI (Bramlett and Dietrich 2002) and TBI patients (Johnson et al. 
2013), and to be linked to cognitive deficits (Alhilali et al. 2015; Bramlett and Dietrich 2015; 
Kinnunen et al. 2011). We also observed an increased phosphorylation of NFkB in both our 
models at 6 months post-injury. NFkB is a transcription factor that is involved in the regulation 
of immune response and inflammation. Under baseline conditions, NFkB is found in cytosol but 
upon activation, it translocates into nucleus where it binds specific DNA sequences and promotes 
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the expression of inflammatory cytokines (Nennig and Schank 2017). Our data confirm a TBI-
induced nuclear localization of NFkB in both groups – 5r-mTBI and cr-mTBI. As we expected, 
tau phosphorylation was also upregulated in the cortex and the CA1 area of the hippocampus at 6 
months post injury. We have previously shown an increase in total and p-tau (Thr 231) in cr-
mTBI hTau mice at 3 months post-injury (Ojo et al. 2016) but these data represent our first time 
reporting a similarly persistent p-tau signal in the 5r-mTBI hTau mice. Our data suggest that 5 
mild hits are sufficient to increase phosphorylation of tau to a degree shown in the model with 24 
hits.  
Treatment with anatabine for 3 months after a delay of 3 months post-last injury 
attenuated TBI-induced pathology in both models of r-mTBI. We observed a decrease of GFAP, 
Iba1, NFkB and p-tau, markers that were increased in response to TBI but not in sham mice. 
These data are supported by our previous findings where at 9 months post 5r-mTBI, anatabine 
reduced inflammation and improved cognitive functions in wild-type mice (S. Ferguson et al. 
2016). Interestingly, in our previous study, we observed that following an initial 9 months of 
treatment, a 9-month cessation of anatabine resulted in a return of the injury-dependent Iba1 
signal indicating that microgliosis was suppressed but not completely removed by anatabine. 
Thus, anatabine does not target the underlying causes of inflammation but exhibits a modulating 
effect for the period of treatment. However, a 9-month delayed treatment with anatabine 
successfully reduced Iba1 to sham levels at the 18-month time points, which gave incentive for 
our study described in this chapter. 
At 6 months post TBI, both models exhibited injury-induced memory and learning 
deficits whereas, unexpectedly, only the 5r-mTBI, but not the cr-mTBI mice, showed 
disinhibition behavior. A long-lasting disinhibition (time spent in the open arm) was found in 
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other models of 5-hit mTBI in WT mice (Gold et al. 2018) but no study has addressed the effect 
of >20 hits on such behavior. The lack of disinhibitory behavior in the cr-mTBI, a more severe 
model than 5r-mTBI, requires further investigation. The effect of anatabine on motor and 
cognitive outcomes showed inconsistent results between the two models. In the cr-mTBI mice, 
anatabine mitigated both sensorimotor decline and memory loss, whereas in the 5r-mTBI group 
anatabine did not exhibit therapeutic effect on the same parameters. However, in 5r-mTBI but 
not cr-mTBI mice, anatabine decreased disinhibition, the only TBI-induced behavior changes 
that were detected in this model. So far, we are unable to elaborate on the diverse effect of 
anatabine on cognitive improvements, especially when ameliorated pathology was shown in both 
models. A possible explanation may be that anatabine acts through the alternative mechanisms 
which differ between the models due to the final age of mice and the injury model. Anatabine is 
an agonist of α7 subunit of nAChR which is involved in the regulation of calcium signaling 
(Shen and Yakel 2009). Calcium dysregulation has been shown a key feature of secondary injury 
involved in cellular apoptosis an oxidative stress. Further investigation of its response to 
anatabine in TBI may provide explanation for the dual effect of the drug seen in our models.  
The largest platform so far that was designed to compare the efficacy of potential 
treatments across different injury models in order to enhance the translation of therapies from 
rodents to men is Operation Brain Trauma Therapy (OBTT) consortium (Kochanek et al. 2018). 
Through the extensive literature review, they identified 10 therapies that were further tested 
across rat models of FPI, CCI and penetrating ballistic-like brain injury (PBBI). To assess 
therapeutic efficacy, they developed a scoring matrix (max. 22 points) based on the primary 
outcome metrics including sensorimotor, cognition, neuropathology and biomarkers (GFAP and 
UCHL-1). To date, the results of the first 5 treatments – nicotinamide, erythropoietin, 
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cyclosporine, simvastatin, and levetiracetam – showed that 4 of them underperformed relative to 
initial studies in individual models of TBI and only levetiracetam reached 10 (out of 22) points 
across different models (Kochanek et al. 2016). The follow-up testing of levetiracetam and the 
remaining 5 treatments (glibenclamide, minocycline, AER-271, amantadine, VA64) are ongoing. 
Overall, this study demonstrated that the most promising preclinical therapeutic candidates fail to 
reproduce similar results across various models. Despite these findings, OBTT approach has 
several limitations that may undermine its translational potential. First, the TBI models used 
represent very different mechanisms ranging from diffuse (FPI) to focal (CCI, PBBI), each of 
them causing distinct pathology meaning that successful treatment for one type receives a score 
which does not properly reflect its translational potential within that category of injury. Second, 
all treatments were administered at the very acute time points ranging from 15 minutes to 24 
hours post-TBI. This time window may have missed treatments that require chronic 
administration relevant for cases of human mild and sometimes even moderate TBI.  
We would like to acknowledge that our study described in this chapter also has several 
limitations and the comparison between two models of r-mTBI should be performed carefully. 
First, the age of mice at the time of treatment and euthanasia was different between the cohorts. 
Due to the longer duration of cr-mTBI paradigm (12 weeks) than 5r-mTBI (9 days), mice that 
entered the study at 3 months of age, were older in the cr-mTBI group (12 months) than 5r-mTBI 
(9 months) by the end of the study (Table 3). The age difference at each step (i.e. end of injury, 
beginning of treatment, behavior assessment, euthanasia and tissue collection) might have 
contributed to the variations of treatment outcomes. 
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Age 5r-mTBI cr-mTBI 
at first injury 3 months/12 weeks 3 months/12 weeks 
at last injury >3 months/13 weeks 6 months/24 weeks 
at first dose of anatabine 6 months/ 25 weeks 9 months/36 weeks 
at behavior assessment 8 months/33 weeks 11 months/44 weeks 
at last dose of anatabine 9 months/41 weeks 12 months/52 weeks 
at euthanasia 9 months/41 weeks 12 months/52 weeks 
Table 3. Age of mice across the major intervention steps 
 
Second, our study was limited to a single treatment time-point and, thus, does not provide 
a clear picture of the time-dependent treatment effect. Administration of additional time points of 
treatment with anatabine post-injury may provide a better picture of its effect on chronic 
outcomes. 
Overall, our study provides evidence that certain drugs can vary therapeutically between 
different models of TBI, and it may account for the failures in clinical translation. To better 
investigate heterogeneity of different models and treatment paradigms, we plan to conduct a 
proteomic analysis of mice across different studies described in Chapter 3 and Chapter 4. 
Identification of TBI- and treatment-related variations on molecular level is an important 
undertaking. 
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Chapter 5 - Proteomic approach to the identification of phosphorylated proteins   
across different models of r-mTBI and treatment paradigms in order to determine                      
common therapeutic targets. 
 
5.1 Introduction 
Proteomics is a technique that allows the identification of a large number of proteins, 
across a wide dynamic range, in tissue extracts or biofluids. Mass spectrometry (MS)-based 
proteome analysis of TBI brain tissue may identify novel biomarkers, pathways, protein-protein 
interactions and potential targets associated with brain injury (Denslow et al. 2003). MS 
proteomics requires no prior knowledge of the proteins being identified and thus provides an 
unbiased approach to finding TBI-associated changes. So far, only a few preclinical studies have 
conducted proteomic analysis in models of TBI, and even fewer after mild TBI; moreover, to the 
best of our knowledge, none has assessed TBI proteomics in response to treatment (Sowers et al. 
2018;  Chen et al. 2018; Song et al. 2018). These studies reported that mechanisms dysregulated 
acutely after a single mTBI (3-24 hours) included microtubule organization, axon guidance and 
myelination, synaptic functions and calcium signaling (Chen et al. 2018; Song et al. 2018). 
Meanwhile, at 30 days and 15 weeks, pathways involving neurogenesis and neuronal 
development and differentiation were altered (Chen et al. 2018). Moreover, we have previously 
shown 13 different proteins that were changing over multiple time points post injury (24 hour, 3, 
6, 9, 12 months) in the 5r-mTBI WT mice (Joseph O. Ojo et al. 2018). These proteins included 
serine protease and metalloproteinase enzymes, immunoglobulins, and inflammatory ptoteins. 
The associated canonical pathways modulated after r-mTBI in our model involved complement 
system, production of nitric oxide and oxygen species, and LXL/LXR pathway, which is linked 
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to inflammation, oxidative stress and lipid biogenesis. The direction of changes involved an 
acute trend (24 hours) in the TBI vs sham mice toward a decrease at 3 month and a gradual 
increase at 6, 9, and 12 months post-injury, indicating non-linear progression of pathology. 
Significant differences have also been shown between single and r-mTBI, where mechanisms 
unchanged after single mTBI, such as cell adhesion or cAMP signaling pathways, were 
significantly downregulated after r-mTBI (Song et al. 2018). Another factor that may contribute 
to proteomic variations in the models of TBI is age at the time of injury. However, one study that 
measured the effect of moderate TBI on proteomic profile in old (21 months) or young/juvenile 
(5 weeks/16 weeks) rats showed limited age-induced variations  (Mehan and Strauss 2012).  
Mehan and Strauss identified a total 19 proteins (e.g. heat shock proteins (HSP), ApoE, 
vimentin, etc) that were equally upregulated after TBI across all age groups relative to the age-
matched controls with only one protein - serum albumin protein (SAP) – that appeared to be 
increased only after TBI in the young but not old rats due to higher baseline levels of this protein 
in the aged sham rats. These data don’t support strong proteomic variations in the age-dependent 
TBI reponse, however their study was limited to a very small number (19) of the analyzed 
proteins and might not be representative of real proteome changes. Overall, there are limited data 
on TBI proteomics, and inter-laboratory variations in the MS-based protocols, animal strains, 
euthanasia procedures and other factors confounds any collective interpretation.  Nonetheless, 
such studies clearly have the potential to provide important information about protein changes 
across different ages, injury models and time points, which could reveal therapeutic targets and 
biomarkers for diagnosis and theragnosis.  
 In this chapter, we present our first attempt our proteomic profiling from the two 
different injury paradigms and two treatments described in Chapters 3 and 4.  In addition to 
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investigating the response to injury, these studies provided us with the opportunity to identify the 
influence of treatment on the response to injury, in settings where therapeutic benefits were 
demonstrated.  As previously discussed, for effective clinical translation from preclinical studies 
investigation of different models is needed, and identification of molecular level responses that 
correlate with beneficial treatments in different models may help us to hone the therapeutic 
targets.  Given limited time, we began with a phosphoproteomic approach, which will be 
complemented by a total proteomics analysis in future studies.  Given the possible confounder of 
age at injury, at this time we focused on our studies of young mice receiving injury.  Samples 
were included from the following studies: 5r-mTBI/Nilvadipine (chapter 3), 5r-mTBI/Anatabine, 
and cr-mTBI/Anatabine (chapter 4).  These studies varied by several parameters: 1) injury model 
(5r-mTBI or cr-mTBI); 2) drug (nilvadipine or anatabine); 3) time at the beginning of treatment 
(acute vs chronic/delayed); 4) age of mice at the time of treatment and euthanasia.  Previously, 
we showed that such factors as age, injury model and treatment paradigm contribute to variations 
in the pathological outcomes and neurorecovery. Identification of any common 
phosphoproteomic responses, despite all these variables, could reveal possible therapeutic targets 
that can be efficient across TBI heterogeneity.  
Hypothesis: 
1) We hypothesized that unbiased proteomic analysis of the influence of different treatments 
on response to TBI across multiple paradigms might reveal common pathways of 
repair/regeneration.  Such pathways would then become a focus for identification of 
therapeutic targets of relevance to the heterogeneous human TBI patient population. 
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5.2 Methods 
 
5.2.1 Study groups 
Given the complications that could ensue from the discussion of the multiple different 
study cohorts under discussion in this chapter, for the sake of simplicity we have adopted the 
following abbreviations (Table 4). 
 
Table 4. Abbreviations of the study cohort and treatment groups. 
   
5.2.2 Tissue extraction and homogenization  
Phosphoproteomic analysis was performed using cortex homogenates from the 
previously described studies with the time points as described in Table 5. Cortex tissue was 
homogenized using 500 µl Mammalian Protein Extraction Reagent (MPER) per sample 
containing 1% EDTA and 1% protease/phosphatase inhibitors cocktail. Samples were sonicated 
3 x 10 min and centrifuged at 10,000 rpm at 4˚C for 10 min. Supernatants were separated and 
used for further analysis.  
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Study cohort Cortex extraction Age at death 
Young 5r-mTBI Nilvadipine 21 days post last TBI 4 months 
5r-mTBI Anatabine 6 months post last TBI 9 months 
Cr-mTBI Anatabine 6 months post last TBI 12 months 
                                                                 Table 5. Time points 
 
 5.2.3 Sample Preparation  
Frozen tissue homogenates were thawed and their protein content was determined using a 
bicinchoninic acid (BCA) assay. Samples were immediately aliquoted to avoid variation in the 
protein concentrations due to freeze/thaw cycles. A control sample was created by pooling an 
aliquot containing 60 µg of protein from each of the 48 samples into one Eppendorf tube. Next, 
six 150 µg aliquots of this control sample were transferred to separate 2 mL Eppendorf tubes. A 
10 µL aliquot of a protein standard mixture was added to each control replicate and 100 mM 
triethylammonium bicarbonate buffer (TEAB) was added appropriately to adjust the final 
volume to 100 µL. For the 5r-mTBI/A and 5r-mTBI/N cohorts, 150 µg of protein was aliquoted 
per sample into 2 mL Eppendorf tubes. The protein standard mixture addition and the final 
volume adjusted were repeated as per the control sample replicates. Due to the limited amount of 
the samples, 50 µg of protein per sample of the cr-mTBI/A cohort was aliquoted. Samples were 
randomized and divided into six batches with one overlapping repeat sample per batch for 
between batch quality control validation. At this stage all batches were frozen at -20oC. 
Further sample processing was performed in batches and was guided by Thermo Scientific’s 
instructions for TMT 10-plex Mass Tag Labeling Kits and Reagents, although not strictly 
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followed. Each batch consisted of one control replicate, eight true samples and one repeat 
sample. Processing of one or two batches of samples was started every two days. 
Protein reduction and alkylation were accomplished by the addition of 5 µL of 200 mM 
tris(2-carboxyethil) phosphine (TCEP) per sample, incubated for 1 hour at 55°C, followed by 5 
µL of 375 mM iodoacetamide, incubated for 30 min at room temperature in the dark. The protein 
was then precipitated with 600 µL of cold acetone, and the process proceeded overnight at -
20°C. The next day, samples were pelleted by centrifugation at 8000 x g for 15 min at 4°C. The 
supernatant was aspirated, and pellets were allowed to dry for approximately 20 minutes. The 
protein was then resuspended in 100 µL of 50 mM TEAB via a 1-hr incubation in a thermocycler 
at 37°C followed by a 1.5-hour bath sonication with intermittent vortexing.  
 
5.2.4 Protein Digestion 
 Protein was digested first with Lys-C, incubated in a thermocycler at 37°C for 1 hour, 
and then with Trypsin, incubated in the thermocycler at 37°C overnight. Samples originally 
containing 150 µg of protein received 3 µL of (0.25 µg/µL) Lys-C, and those originally 
containing only 50 µg of protein received 1 µL. (0.5 µg/µL) Trypsin was added in the same 
manner. Samples were then stored at -20°C until ready for peptide labeling. 
5.2.5 Peptide Labeling 
 TMT10plex labeling reagents were brought to room temperature and dissolved in 
anhydrous isopropanol. For each batch, the combined sample was labeled with TMT-126 and the 
repeat sample was labeled with TMT-131. Labeling of true samples were randomized. Each 
sample was combined with one mass-tagging reagent and incubated at room temperature for 1 
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hr. Subsequently, 8 µL of 5% hydroxylamine was added to each sample and incubated for 15 
minutes to quench the reaction. The total volume foreach labeled sample was combined into one 
new Eppendorf tube and stored at -20°C. Once all batches reached this stage, the six samples 
were desalted using Pierce C18 spin columns per product instructions. The instructions include 
an optional wash step for the removal of excess TMT reagent. The samples were then 
concentrated on a SpeedVac until sample volumes had been reduced to approximately 25 µL and 
then stored at -20°C. 
5.2.6 Phosphopeptide-enrichment 
 Phosphopeptide enrichment was performed using TiO2 beads using steps modified from 
Huang et al. (Huang et al. 2015). Various acidic acetonitrile solutions were used for the sample 
buffer, and for peptide binding and washing.  Ammonia hydrate solutions were used for the 
elution phase. Sample buffer was added to the samples and the resulting solution was transfer 
pipetted into an Eppendorf tube containing conditioned TiO2 beads. Sample tubes were placed on 
a shaker for 1 hour to facilitate binding of the phosphopeptides. TiO2 beads were collected after 
a brief spin on a tabletop mini-centrifuge and the supernatant representing the unbound peptide 
fraction was removed and saved. The beads were washed with a three-step procedure. The 
supernatants were discarded after these steps. Bound analytes, enriched in phosphopeptides, were 
eluted in two steps with the addition of ammonia hydrate solutions. The supernatants were saved 
after each elution step and combined. The phosphopeptide enriched fractions were then 
concentrated on a SpeedVac until volumes had been reduced to 25-50 µL. Next, an aliquot of 
0.1% TFA (aq.) was added to each in preparation for clean-up on Pierce C18 spin columns per 
product instructions.  
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5.2.7 LC/MS/MS Analysis  
Samples were analyzed on a LC/MS system comprised of an Easy nLC 1000 (Thermo) 
coupled to a Q Exactive hybrid quadrupole-Orbitrap mass spectrometer with a NanoFlex source 
(Thermo Scientific). Peptides were trapped on an Acclaim PepMap 100 (75 µm X 20 mm, 
Thermo Scientific) and desalted. Chromatography was performed on an analytical column (75 
µm X 150 mm, Thermo Scientific) packed with C18, 2 µm particles using a 115 minute 
water/acetonitrile reversed-phase gradient method.  
The Q Exactive was operated in data-dependent acquisition (DDA) mode. Full scan MS 
spectra (m/z 400-1800) were acquired in the orbitrap analyzer with a resolving power of 70000 
(at m/z 200). The fifteen most intense multiply charged ions (z ≥ 2) were sequentially isolated 
with a 1.0 Da isolation width and fragmented in the collision cell by higher-energy collisional 
dissociation (HCD). Fragment ions were mass analyzed to a 35000 resolving power (at m/z 200). 
 
5.2.8 Peptide and Protein Identification and Quantification 
 Raw data were processed using Proteome Discoverer software (version 2.1, Thermo 
Scientific). The MS/MS spectra were searched against a Uniprot mouse protein database 
(downloaded February 2018) using a target-decoy strategy. Reporter ion intensities were 
extracted from nonredundant peptide spectral matches (PSMs) and the ratios were determined 
relative to the combined sample. 
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5.2.9 Data Analysis  
 Results were obtained for a total of 12 groups (sham-vehicle, TBI-vehicle, sham-
treatment, TBI-treatment) across 3 cohorts (5r-mTBI/nilvadipine, 5r-mTBI/anatabine, cr-
mTBI/anatabine). Data were presented as the abundance ratio (fold changes) of protein for each 
group and were further normalized to the cohort-specific sham-vehicle values. The changes in 
protein levels were considered significant if the abundance ratio was >1.5 (upregulated) or <0.5 
(downregulated).  
The interaction analysis of the dysregulated phosphoproteins was performed using 
STRING platform (Szklarczyk et al. 2019). Accession numbers were uploaded into an online 
platform where the background values for species Mus Musculus were applied. The platform 
automatically identifies proteins according to the uploaded accession numbers and shows 
possible interactions based on the experimental data from existing studies. 
 
 
Note: The actual MS-based procedures were performed by our MS core staff. 
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5.3 Results 
Overall, 861 phosphoproteins were identified across all cortex extracts from the three 
studies.   
5.3.1 Proteome profiles in different models of r-mTBI  
First, TBI response was determined by calculating the fold change of TBI-V to SH-V for 
each cohort. The lowest number of significantly regulated phosphoproteins in the [TBI-V/SH-V] 
groups was detected for the cr-mTBI/A: with 69 phosphoproteins upregulated (↑) and 33 
downregulated (↓) (Fig. 28). In the 5r-mTBI/A group, [TBI-V/SH-V] showed 203 (↑) and 52 (↓) 
phosphoproteins (Fig. 29). In the 5r-mTBI/N, there were 57 (↑) and 447 (↓) phosphoproteins 
(Fig. 30).  
In the (TBI-N/SH-N)/(TBI-V/SH-V) groups, the number of the altered phosphoproteins 
was oppositely dysregulated compared to cohort-matched TBI-V/SH-V groups: in the cr-
mTBI/A - 45 (↑) and 189 (↓) (Fig. 28); in the 5r-mTBI/A group - 88 (↑) and 221 (↓) (Fig. 29); in 
the 5r-mTBI/N - there were 73 (↑) and 478 (↓) phosphoproteins (Fig. 30). 
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                       Figure 28.  Protein-protein interactions in the cr-mTBI/A cohort 
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Figure 29. Protein-protein interactions in the 5r-mTBI/A cohort 
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Figure 30. Protein-protein interactions in the 5r-mTBI/N cohort 
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5.3.2 Phosphoprotein changes across different models 
The comparison of the [TBI-V /SH-V] across three different studies revealed only one 
upregulated phosphoprotein (neurofascin (NFASC)) common to response to injury in all three 
models, and no common downregulated phosphoproteins (Fig. 31).  Between different pairings 
of the gropus the number of common upregulated or downregulated phosphoproteins was as 
follows: 5r-mTBI/N & 5r-mTBI/A – 35 (↑), 3 (↓); 5r-mTBI/N & cr-mTBI/A – 9 (↑), 2 (↓); 5r-
mTBI/A & cr-mTBI/A – 6 (↑), 2 (↓). 
 
  
Figure 31. Venn diagrams of the dysregulated phosphoproteins in response to TBI-V (A,C) and 
TBI-T (B,D). 
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The comparison of the altered phosphoproteins in terms of the influence of treatment on 
response to injury [(TBI-T/SH-T)/(TBI-V/SH-V)] between all 3 studies revealed 2 common 
phosphoproteins that were upregulated - cAMP-regulated phosphoprotein 21 (ARPP21) and 
hepatoma-derived growth factor-related protein 3 (HRP-3) - and 2 downregulated - 
synaptotagmin 1 (Syt-1) and vacuolar protein sorting-associated protein 13C (VSP13C). The 
distribution of the dysregulated phosphoproteins between any two studies showed the maximum 
overlap to be in the number of downregulated phosphoproteins in the two anatabine treatment 
studies (5r-mTBI/anatabine & cr-mTBI/anatabine) – 94. 
Further analysis of these 94 phosphoproteins, which were downregulated in response to 
treatment, demonstrated that 6 of them were upregulated after TBI in both groups (Fig. 32) 
 
 
Figure 32.  Heatmap of selected phosphoproteins that were upregulated in the TBI-V/SH-
V and downregulated in the (TBI-T/SH-T)/(TBI-V/SH-V) groups in for both 5r-mTBI/A and cr-
mTBI/A cohorts. 
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Figure 33. Variability in the analysis outcome demonstrated for the upregulated 
phosphoproteins in the 5r-mTBI/A [(TBI-T/SH-T)/(TBI-V/SH-V)] cohort. A – previously 
utilized analysis that applied high confidence interaction score. B – alternative analysis that 
applied medium confidence interaction score reveals a greater number of protein-protein 
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interactions. Selected section represents phosphoproteins associated with several TBI-related 
pathways: red – cAMP signaling pathway, blue – inflammation, yellow – Parkinson’s Disease 
related pathways, green – Alzheimer’s Disease related pathways. C – pathway analysis 
demonstrates a large number of altered processes associated with upregulated phosphoproteins. 
Selected areas show the affected TBI-related processes such as behavior (cognitive and 
locomotor), neurogenesis, and synaptic organization.  
 
5.4 Discussion 
  The goal of this chapter was to conduct a preliminary proteomic investigation of response 
to treatment in our different mouse models, and specifically to identify phosphoproteins that 
were similarly affected by treatments across the three cohorts. These cohorts differ in the type of 
drug administered, therapeutic time window, time at first administration, age and injury model. 
We proposed that phosphoproteins that were similarly altered in response to treatment may 
represent potential targets that would be common across heterogeneous human TBI populations.  
Overall, a total of 861 phosphoproteins were identified. It is important to note that a full 
interpretation of these data will require the pending Total proteome analysis from the same 
samples, so that the significance of protein phosphorylation (i.e. the phospho:total) can be 
assessed.   
First, we assessed the effect of TBI on these phosphoproteins for each model. The lowest 
number of dysregulated phosphoproteins was found in the cr-mTBI/A cohort when compared to 
5r-mTBI/A and 5r-mTBI/N. Interestingly, the cr-mTBI/A treated cohort received a greater 
number of hits when compared to the other groups (24 vs 5 hits) and were significantly older by 
the end of the study (12 months vs 9 months and 4 months), and might thus have been expected 
to show a larger number of significantly modulated phosphoproteins. As we discussed in Chapter 
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2, one of the possible reasons for a lower TBI signal in the aged mice may be a masking effect of 
age-related pathology. Our proteomic data appear to support this concept, however further 
analysis is warranted.  
 Interesting findings were observed when we compared the TBI effect in 5r-mTBI/A and 
the 5r-mTBI/N groups. Both models used the same injury paradigm (5 hits) administered in 3 
months old mice, but the tissue extraction was performed at different time points post injury - 3 
weeks (5r-mTBI/N) or 6 months (5r-mTBI/A) – allowing the analysis of temporal proteome 
changes within the same model. We found that a higher number of phosphoproteins were 
downregulated at 3 weeks post-TBI (447) vs 3 months (52), whereas upregulated 
phosphoproteins were less prevalent at acute (57) versus chronic (203) time points. These data 
suggest very distinct molecular profiles of acute vs chronic phases supporting our expectation 
that the efficacy of therapeutic targets will likely be dependent on time post-injury. For example, 
in the chronic but not acute phase, we observed an upregulation of several serine/threonine 
kinases including glycogen synthase kinase beta (GSK3β). GSK3β is involved in tau 
phosphorylation and amyloid beta production, and was marked as a key element in the AD 
pathogenesis (Hernandez et al. 2012). Previously, the enzyme’s activity was shown to be 
dysregulated after TBI, while its inhibition was linked to reduced cell death and improved 
cognitive functions (Dash et al. 2011). Chronic upregulation of GSK3β may underly tau 
phosphorylation found in our 5r-mTBI-V mice at 3 months post-injury (Chapter 4) but not at 3 
weeks post-injury (Chapter 3). Such temporal heterogeneity of pathological markers warrants 
investigation of different therapeutic time windows for potential target candidates. 
When we compared the phosphoproteome profile for the 5r-mTBI/N cohort in response 
to injury or treatment, we found that TBI caused a downregulation of 442 unique 
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phosphoproteins and the same number of unique upregulated phosphoproteins in response to 
nilvadipine. There is a considerable overlap (93%) in the proteins being downregulated in 
response to injury and upregulated following treatment, suggesting that the 5r-mTI model 
triggered an acute decrease in the phosphorylation of a large number of proteins, all of which 
were restored by nilvadipine.  This apparent recovery of the “normal” phenotype may be a 
feature of the much shorter timeframe of this particular study, and the fact that treatment was 
administered acutely after injury. 
Further, to identify common therapeutic targets across treatments, we found 4 proteins 
that were either up- or downregulated in response to all of the treatments in the TBI mice. One of 
the upregulated proteins between all TBI-T groups was cAMP-regulated phosphoprotein 21 
(ARPP21). The primary function of cAMP signaling is the activation of protein kinase A (PKA) 
and phosphorylation of transcription factors that are involved in cell survival and the suppression 
of the expression of pro-inflammatory cytokines (Titus et al. 2013). Phosphorylation of cAMP is 
regulated by calcium ions, and, due to a significant Ca²⁺ influx after TBI, cAMP is expected to 
be upregulated, as it had been shown in models of stroke and epilepsy (Tanaka 2001). However, 
multiple studies have demonstrated a downregulation of cAMP across different models of TBI 
(Atkins et al. 2007; Titus et al. 2013). Pre-clinical studies also showed that downregulation of 
cAMP is linked to memory worsening, and treatment with agonists of cAMP restores normal 
cognitive functions (Titus et al. 2013). An increased amount of phosphorylated ARPP21 was 
demonstrated in all our models after treatment with either anatabine or nilvadipine.  ARPP21 
was previously shown to be a positive regulator of dendritic growth, and the knockdown of 
ARPP21 gene was correlated with a decrease in dendritic complexity (Rehfeld et al. 2018). 
Upregulation of ARPP21 appears to have crucial role in neurorecovery, but whether it can be a 
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primary target for TBI is still unclear. The second upregulated protein was hepatoma-derived 
growth factor-related protein 3 (HRP-3). To our knowledge, there are no studies addressing the 
effect of TBI on HRP-3. While members of HRP family are expressed in various tissues, HRP-3 
is unique to neurons (El-Tahir et al. 2006). A significant role of HRP-3 was demonstrated for 
neurite growth suggesting its potential role in neurorecovery (El-Tahir et al. 2009).  
Surprisingly, TBI-T mice showed a significant decrease in phosphorylated synaptotagmin 
1 (Syt-1), a calcium-binding protein located in the membranes of the synaptic vesicles which 
contributes to the docking mechanism required for exocytosis (Wen et al. 2017). Proteolysis of 
Syt-1 prevents docking of the vesicles to presynaptic membrane affecting mediators release and 
disrupting synaptic functions. Studies showed that Syt-1 is usually decreased after subarachnoid 
hemorrhage (Chen et al. 2013) and TBI (M. C. Liu et al. 2006), which may lead to poor 
neurorecovery and worsened synaptic plasticity. Surprisingly, our study showed that treatment 
with nilvadipine or anatabine decreased Syt-1 in spite of expected upregulation. Again, this may 
be explained by our current focus on analysis of phosphoproteins. In the case of Syt-1, its 
phosphorylation is regulated by Ca²⁺-calmodulin complex (Popoli 1993) which was 
downregulated in some of our models (5r-mTBI/N and 5r-mTBI/A) and may potentially affect 
the functioning of Syt-1. The second downregulated phosphoprotein was vacuolar sorting 
associated protein 13 C (VSP13C). Several studies proposed that mutations in VSP13C gene lead 
to mitochondrial stress, mitophagy and cognitive impairments associated with the early onset of 
PD (Lesage et al. 2016; Schormair et al. 2018). However, due to the lack of data on VSP13C in 
TBI, its role remains unclear. 
We then focused on comparison of the influence of anatabine across two different models 
(5r-mTBI and cr-mTBI). We expected to observe a greater number of overlapping 
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phosphoproteins by excluding mice treated with nilvadipine. Indeed, we identified a total of 2 
upregulated and 94 downregulated phosphoproteins common to the response to treatment in both 
models, which included S100β, GSK3β, and protein phosphatases, all of which were originally 
upregulated in at least one of the TBI-V groups. As we mentioned earlier, GSK3β has been 
linked to tau phosphorylation and amyloid accumulation in the AD models (Hernandez et al. 
2012). Additional studies also showed a TBI-induced upregulated of GSK3β  which was 
prevented by treatment with the enzyme inhibitors (Shim and Stutzmann 2016). The protein 
S100β is widely used as a marker of astrocytic activation, hence a decreased phosphorylation of 
this protein may be an indicator of reduced inflammation in our models (Braun et al. 2017). We 
also revealed 6 phosphoproteins from this dataset that were upregulated after TBI in the absence 
of treatment. They included serine/threonine phosphatase, synaptic proteins (Neurofascin, 
syntaxin-binding protein) and proteins associated with plasma membrane functioning.  
We would like to acknowledge that, owing to the limited time, our study at this time has 
analyzed only phosphoproteins and not total proteins, which are required for a complete picture 
of protein changes. This limitation will be addressed in our future studies where we plan to map 
protein phosphorylation against total changes in the same tissue we used here.  We also plan to 
conduct a more detailed analysis of the identified peptides by modeling the interaction of known 
proteins with compounds outside of our dataset.  Moreover, applying less stringent criteria 
during the interaction analysis may reveal a greater number of protein-protein connections that 
have been missed in the current data analysis. Overall, this study presents valuable data 
demonstrating high heterogeneity of TBI and possible therapeutic targets that may be effective 
across different models. 
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Chapter 6 - Summary 
The overarching goal of this dissertation was to address several of the current gaps in the TBI 
preclinical field by building on our previous work on characterization and development of 
preclinical models of r-mTBI to investigate the effects of different potential treatments and 
include clinically relevant administration paradigms.  In the course of this work we developed 
the following aims:  1) To replicate heterogeneity of human concussions by using two mouse 
models of r-mTBI; 2) To test two potential TBI therapeutics - nilvadipine and anatabine - that 
have demonstrated safety in humans; 3) To address the long-term consequences of mTBI by 
exploring delayed and chronic treatment paradigms; and 4) To investigate common therapeutic 
responses across these multiple approaches in order to identify viable, translational targets for 
further investigation. 
 
         6.1 Addressing Aim 1 
To address Aim 1 and to mimic the clinical TBI heterogeneity, we used two injury paradigms 
- 5r-mTBI and cr-mTBI - that use the same mTBI injury but involve 5 versus 24 hits, 
respectively, and thus mimic different injury frequency and chronicity. We found that both 
models replicably induced chronic astrogliosis and tau phosphorylation and increased nuclear 
NFkB activation.  We also demonstrated TBI-dependent cognitive impairment with both models.   
However, only the cr-mTBI model was associated with significant motor deficits, whereas only 
the 5r-mTBI triggered disinhibition behavior. We have previously observed motor deficits with 
the 5r-mTBI model acutely after injury (B. Mouzon et al. 2012), but these have not persisted.  
The persisting motor deterioration in the cr-mTBI mice thus appears to be associated with a 
greater number of hits and may also be related to the older age of mice at the time of testing.  
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The inconsistent presentation with disinhibition is difficult to interpret at this time and will 
require further investigation.  Despite these neurobehavioral variations, our study demonstrated 
that, assessed at 6 months post-last injury, 5 mild hits over a short period of time (9 days) can 
trigger equally severe long-term pathological outcomes and memory deficits as 24 hits over 3 
months.   
The high heterogeneity of human concussions has been suggested as a possible reason behind 
the failures of all the drugs introduced into clinical development for TBI (DeWitt et al., 2018; 
Mohamadpour et al. 2019).  As we find strong evidence for neuroinflammation in all of our 
preclinical models, and to the best of our knowledge this is a feature of all laboratory models and 
human patient samples (Pearn et al. 2017; V. E. Johnson et al. 2013; Pavlovic et al. 2019; McKee 
et al. 2014), we exposed both models of r-mTBI to the same anti-inflammatory treatment, 
anatabine. We observed that anatabine attenuated TBI pathology equally in both models but had 
inconsistent effects on memory deficits. In the cr-mTBI, anatabine improved spatial memory, but 
this effect was not detected in the 5r-mTBI mice. Intriguingly, cr-mTBI mice were 3 months 
older than 5r-mTBI at the time of behavior assessment (11-12 months vs 8-9 months old, 
respectively), and 12 months, but not before, is the age when cognitive impairments appear in 
healthy hTau mice (M. Polydoro et al. 2009). Hence, memory impairments in the cr-mTBI might 
have been triggered by both TBI and old age, whereas behavioral problems in the 5r-mTBI mice 
were driven solely by TBI.  It is surprising to see that anatabine was more effective in mice with, 
supposedly, greater extent of cognitive deficits, but, perhaps, the level of severity of the 
pathological environment is crucial for a drug to reach its therapeutic peak.  Interestingly, in our 
previous work with anatabine treatment in wild type mice subjected to the 5r-mTBI, delayed 
treatment with anatabine at 9 months post-last injury also did not result in significant cognitive 
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improvement, despite a positive effect on inflammation (S. Ferguson et al. 2016). However, in 
that study the mice were 21 months old at the time of assessment and we deduced that the 
advanced age of the mice had confounded detection of any improvement in cognitive 
performance.  Interpretation of these findings is difficult at the moment and requires further 
analysis before drawing final conclusions regarding the effect of anatabine on cognition. This 
highlights the need to understand both the treatment time window and the length of treatment 
needed to produce beneficial results. The discrepant data in terms of functional/behavioral 
outcomes, particularly when considering the same treatment across different injury paradigms, 
might certainly be considered to reflect the complexities of translation to human clinical trials 
and supports the need for much more thorough preclinical characterization of any proposed 
treatments. 
Implications: 
We suggest that preclinical testing of potential therapeutics should be performed in different 
models of mTBI to account for heterogeneity and to provide more accurate conclusions 
regarding the likely effects of treatment in human patients.  
 
  6.2 Addressing Aim 2 
To address Aim 2, we explored 2 treatments – nilvadipine and anatabine.  Ideally, we intend 
to investigate nilvadipine in the delayed treatment 5r-mTBI and cr-mTBI paradigms, to provide a 
direct comparison with our anatabine data.   For now, nilvadipine was administered acutely for 
the duration of 21 days post-TBI whereas anatabine was tested as a delayed treatment starting at 
3 months post last injury. These drugs have different mechanisms of action: nilvadipine is syk 
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inhibitor and anatabine is a nAChR agonist. Nevertheless, both drugs attenuated TBI-induced 
pathology including neuroinflammation and tau phosphorylation and caused model-specific 
improvements of behavior performance.  
Nilvadipine has been associated with robust positive effects in animal models of AD and 
with clinical benefits for patients with early stage AD in a phase III randomized, controlled trial 
(Abdullah et al. 2019; Lawlor et al., 2018). Post mortem studies indicate that there is a biological 
link between TBI and AD pathology (e.g. inflammation, tauopathy, more rarely - 
amyloidopathy), suggesting that treatments that are effective in AD might also be effective in 
TBI. In the AD models, nilvadipine attenuates neuroinflammation, tau phosphorylation and 
amyloid accumulation (Paris, Ait-Ghezala, et al. 2014). Although we do not see amyloid 
pathology in our r-mTBI model, considering post-injury neuroinflammation and tau as malleable 
responses common between TBI and AD, our positive results in AD thereby support the use of 
nilvadipine as potential therapeutic agent for the chronic effects of TBI. Indeed, we showed that 
nilvadipine exhibited similar therapeutic effect on TBI-induced inflammation and tau 
phosphorylation in young and aged mice.  
A nAChR agonist anatabine has been previously shown to decrease inflammation in the 
models of AD, EAE, and LPS-induced inflammation (Paris, Beaulieu-Abdelahad, Abdullah, et 
al. 2013; Verma et al. 2015), and given a featured role of neuroinflammation in TBI pathology, 
anatabine might be effective in TBI. Together, our previous (S. Ferguson et al. 2016) and current 
findings support the ability of anatabine to decrease TBI-induced inflammation but they also 
indicate  its role in reducing tau phosphorylation and improving motor and cognitive functions 
(in the cr-mTBI mice). 
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Implications: 
Both nilvadipine and anatabine demonstrate efficacy in our preclinical models of r-mTBI.  
Given that both have previously demonstrated safe use in humans, their further investigation as 
potential treatments for mTBI is warranted.   
 
  6.3 Addressing Aim 3 
A likely scenario for treatment of r-mTBI patients is that they will not begin treatment until 
some time has elapsed since the injuries, once clinical symptomatology emerges.  We therefore 
sought to address Aim 3 by investigating the effects of delayed treatment in our models, and for 
this we used the anti-inflammatory anatabine, administered at 3 months post-last injury. 
Anatabine attenuated TBI-induced pathological outcomes in both models (cr-mTBI and 5r-
mTBI) and improved behavior functions (in the cr-mTBI mice). These data confirm the 
possibility of a chronic therapeutic time window for TBI and warrants further investigation. Our 
approach highlights the importance of broadening the preclinical approaches to drug discovery to 
address the problems that have become apparent with clinical translation. 
Implications: 
Our data suggest that delayed treatment with an anti-inflammatory drug was an effective 
approach with which to target chronic outcomes of r-mTBI. More preclinical studies should 
implement a delayed treatment approach to mimic relevant human conditions as it may reveal 
novel properties of the existing treatment candidates and introduce new therapeutics. 
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6.4 Addressing Aim 4 
To address Aim 4 and to identify common therapeutic targets across different models, we 
conducted a phosphoproteomic analysis of cortex extracts from the mice treated with nilvadipine 
or anatabine (Chapter 3-4). Despite a highly heterogeneous phosphoproteome profile between 
the groups, we identified 4 proteins that were dysregulated in all the models in response to 
treatment. These proteins were associated with synaptic functions, neuronal growth and dendritic 
complexity, and may indicate treatment-induced increases in synaptic plasticity. Multiple studies 
have linked dendritic branching and the number of synapses with cognitive performance 
indicating its importance in neurorecovery. However, whether they represent an effective target 
requires further investigation.  We have not yet conducted the total proteome analyses for these 
samples which are needed in order to fully understand the protein responses to TBI and to 
treatment in these models.  Overall, we have data to suggest a complex protein response to 
various models of TBI, which underlie pathological heterogeneity and may contribute to the 
failures of clinical trials.  
Implications: 
The demonstrated heterogeneity of the phosphoproteomic profiles in our r-mTBI models 
underlines the likelihood that different therapeutics will have efficacy in different injury 
paradigms, and at different times of administration post injury.   
 
6.5 Future directions 
Throughout the studies we presented in this dissertation, we collected an extensive 
number of samples that represent a very heterogeneous dataset of r-mTBI conditions from which 
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we evaluated cognitive and pathological outcomes in response to injury and treatment. At the 
final stage we attempted to combine these samples for the MS-based proteomics analysis to 
identify molecular targets that are similarly dysregulated across the models and may represent 
possible therapeutic targets. We plan to proceed with the investigation of proteomic profiling of 
the existing data by conducting a total proteome analysis and mapping it against our current 
dataset. Once we are able to analyze the disturbed phosphoproteome in relation to the total 
proteome we plan to conduct a more thorough investigation of all the phosphoproteins identified 
to be significantly regulated, and cluster them according to their signaling pathways. Moreover, 
our next step will involve the analysis of the phosphorylated sites of the detected proteins 
followed by the identification of predicted protein interactions outside our dataset.   
 
6.6 Conclusion 
Overall our data support the fact that the therapeutic window for intervention in the 
negative sequelae of r-mTBI may be quite large, which is very encouraging for the patient 
population who may not seek treatment until many months or even years after they sustained the 
injuries.  However, our data also clearly demonstrate similarities and differences across different 
injury paradigms (even with the same injury impact), addressing, at a very small scale, the 
problem of the heterogeneity of the human TBI patient population.  Our data continue to support 
the contention that much more rigorous testing of potential therapeutics in different models of 
TBI is required before drawing strong conclusions regarding the efficacy of the treatment, and 
prior to attempting their clinical translation.  
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